

Pd-Catalyzed Enantioselective Reductive Heck Reaction of *mono-Fluoro*, *gem*-Difluoro, and Trifluoromethyl tethered-Alkenes

Naveen Sihag,^a Hemaang Bhartiya,^a Swati Jain,^a Jitendra Singh,^b S. Rajagopala Reddy^{b,*} and M Ramu Yadav^{a*}

^aDepartment of Chemistry, Indian Institute of Technology Delhi, Hauz Khas, New Delhi, 110016, India. Phone number: (+91) 11-2659-1506; e-mail address: ramuyadav@chemistry.iitd.ac.in.

^bDepartment of Chemistry, School of Chemical Sciences and Pharmacy, Central University of Rajasthan, NH-8, Bandarsindri, Ajmer, Rajasthan 305817, India; e-mail address: rajagopala.seelam@curaj.ac.in.

Table of Contents

1. General Information	S3
2. Synthesis of Substrates	S4
Synthesis of <i>o</i> -Halo Trifluoromethyl Acrylamides	
Synthesis of <i>o</i> -Halo β -Phenyl Trifluoromethyl Acrylamides	
Synthesis of <i>o</i> -Halo <i>gem</i> -Difluoro and Monofluoro Acrylamides	
3. Experimental Procedures:	S25
Reductive Heck Cyclization of <i>o</i> -Halo Trifluoromethyl Acrylamide	
Enantioselective Reductive Heck Cyclization of <i>o</i> -Halo Trifluoromethyl Acrylamide	
Reductive Heck Cyclization of <i>o</i> -Halo β -Phenyl Trifluoromethyl Acrylamides	
Enantioselective Reductive Heck Cyclization of <i>o</i> -Halo β -Phenyl Trifluoromethyl Acrylamides	
Reductive Heck Cyclization of <i>o</i> -Halo <i>gem</i> -Difluoromethyl Acrylamide	
Enantioselective Reductive Heck Cyclization of <i>o</i> -Halo <i>gem</i> -Difluoromethyl Acrylamide	
Reductive Heck Cyclization of <i>o</i> -Halo Monofluoromethyl Acrylamide	
Enantioselective Reductive Heck Cyclization of <i>o</i> -Halo Monofluoromethyl Acrylamide	
4. Optimization of Reaction Conditions	S31
5. Characterization data and HPLC Spectra of Enantioenriched Products.....	S36
6. Synthetic Applications.....	S77
7. Stereo-divergent Reactions.....	S79
8. Mechanistic Studies.....	S82
9. Computational Studies.....	S85
10. X-Ray Structural Analysis.....	S100
11. References.....	S104
12. NMR Spectra.....	S106

1. General Information

Experimental: All the inert condition reactions were performed in a nitrogen atmosphere using Glove box and Schlenk line techniques. All glassware was oven-dried overnight at 100 °C before use. Catalytic reactions were performed in commercially available 7.0 mL screw cap vials fitted with PTFE/silicone septa purchased from Sigma-Aldrich.

Chromatography: Analytical Thin Layer Chromatography (TLC) was performed on Merck and GLR precoated silica gel 60 F₂₅₄ plates, using UV light as the visualization agent. Chromatographic purification of products was accomplished by column chromatography on Finar silica gel (100-200 mesh). The solvents were removed under reduced pressure using a rotary evaporator to obtain the desired compounds.

Characterization: All proton nuclear magnetic resonance spectra (¹H NMR), proton decoupled carbon nuclear magnetic resonance spectra [¹³C{¹H} NMR], and fluorine nuclear magnetic resonance spectra (¹⁹F NMR) were collected on Bruker Ascend 500 MHz and JEOL 400 MHz (the respective frequencies are for ¹H (500 MHz and 400 MHz), ¹³C (126 MHz and 101 MHz), and ¹⁹F (471 MHz and 377 MHz). Chemical shifts are reported in parts per million (ppm) downfield relative to tetramethylsilane (TMS, 0.0 ppm), all ¹H NMR and ¹³C NMR spectra referenced to residual solvent signal (¹H, CDCl₃ = 7.26 ppm) and (¹³C, CDCl₃ = 77.00 ppm). Coupling constants (*J*) are reported in Hz. The following abbreviations are used to indicate the multiplicity: s, singlet; d, doublet; t, triplet; q, quartet; sept, septet; m, multiplet; dd, doublet of doublets; ddd, doublet of doublet of doublets; dq, doublet of quartet; dp, doublet of pentet; bs, broad singlet; bd, broad doublet; bt, broad triplet; bq, broad quartet; tq, triplet of quartet. High-resolution mass spectra (HRMS) were obtained using Waters Xevo-G2XQTOF instruments with the electrospray ionization (ESI) method. The gas chromatography-mass spectrometry (GC-MS) analysis was performed using an Agilent 5977B GC/MSD spectrometer. Single crystal X-ray diffractions were recorded using Bruker AXS Smart Apex CCD diffractometer and Rigaku XtaLab Synergy Custom X-Ray Diffractometer. Optical rotations were recorded on Rudolph, AUTOPOL V digital polarimeter using a 10 cm sample cell, and [α]_D values are given in deg.dm⁻¹.g⁻¹.mL; concentration *c* is listed in g.mL⁻¹ and all data are reported as follows: [α]_D^{temp} (*c* = g.mL⁻¹, solvent). Enantiomeric excesses (*ee*) were determined by chiral HPLC analysis (Shimadzu) LC-20AD using Chiralcel OJ-H, AD-H, and OD-H columns with *n*-Hexane and ⁱPrOH as solvents. Retention times are reported

using the following abbreviation: *t_r*. Preparative HPLC (Shimadzu) LC-20AP having a C18 column with acetonitrile (CH₃CN) and H₂O as solvents have been used in purification. The melting points of compounds were recorded using DIGITAL MELTING POINT APP. by UNITECH SALES.


Materials: Unless specified otherwise, all reagents, chiral ligands, and metal salts were obtained from commercial suppliers (BLD Pharma, Spectrochem, GLR, TCI, Sigma-Aldrich, SRL chemical) and used without further purification. Acrylamide derivatives were synthesized according to the literature. Anhydrous solvents were dried using CaH₂ pre-drying followed by vacuum distillation, and solvents like tetrahydrofuran (THF), and toluene (PhMe) were dried via sodium wire/benzophenone conventional drying agents. Oxalyl chloride was purchased from Spectrochem and distilled under N₂. Triethylamine was distilled and stored over KOH pellets for usage.

2. Synthesis of Substrates

All disubstituted acrylamides were prepared according to the previous reports.^{1,2} The known substrates (**1a**, **1a'**, **1b–1j**, **1l–1p**) characterization data were consistent with the reported literature. Further, the general procedure and characterization data for unreported substrates are given.

2.1 General Procedure for the Synthesis of *o*-Halo Trifluoromethyl Acrylamides and *o*-Iodo β -Phenyl Trifluoromethyl Acrylamides.

General procedure-I (GP-I):



Scheme S1. Synthesis of trifluoromethyl acrylamides from di- and trisubstituted olefins.

Step 1. Round Bottom Flask I (RB-I): A two-necked round bottom flask equipped with a magnetic stir bar was charged with acrylic acid (1.2 equiv) and dry DCM (0.2 M) was added under

nitrogen atmosphere. The flask was then cooled to 0 °C using an ice bath and 4–6 drops of dry DMF were added. Afterward, freshly distilled oxalyl chloride (1.5 equiv) was added dropwise to the solution. Then, the solution was slowly allowed to attain room temperature and stirred for 5 to 7 hours with nitrogen (N₂) balloon until the solution turned yellow-orange. The acyl chloride was directly used for the next step without further purification.

Round Bottom Flask II (RB–II): In a separate two-necked round-bottom flask equipped with a magnetic stir bar, *o*-halo aniline derivatives (1.0 equiv), triethylamine (3.0 equiv), and dry DCM (0.2 M) were added and stirred for 3-6 h at room temperature to activate anilines.

Step 2. Then, freshly prepared acryloyl chloride **RB–I** was added dropwise to **RB–II** for 10 to 15 min at 0 °C under a nitrogen atmosphere. The resultant mixture was allowed to warm up to room temperature and stirred overnight with nitrogen (N₂) balloon until the aniline derivative was consumed completely (monitored by TLC). The reaction mixture was washed with water and extracted with DCM (3.0 times). The organic layer was sequentially washed with 1.0 N HCl solution, 1.0 N NaOH solution, and brine. The final organic solution was dried over anhydrous Na₂SO₄, filtered, and concentrated using a rotary evaporator. The residue was purified by SiO₂ column chromatography (100–200 mesh) using a mixture of hexane, DCM, and ethyl acetate to afford the desired acrylamides.




Figure S1. *N*-(2-Haloaryl)-trifluoromethyl acrylamides.





Figure S2. *N*-(2-Iodoaryl)-trifluoromethyl acrylamides.




Org. Lett. **2012**, *14*, 3858–3861

Chem. Commun. **2015**, *51*, 4587–4590

Figure S3. *N*-(2-Haloaryl)-*N*-substituted β -phenyl trifluoromethyl acrylamides.

Characterization data of starting materials:


Methyl 3-bromo-4- (*N*-methyl-2-(trifluoromethyl)acrylamido)benzoate (**1k**):



According to **GP-I**, amide coupling of 2-(trifluoromethyl)acrylic acid (420 mg, 3.0 mmol) with methyl 3-bromo-4-(methylamino)benzoate (610 mg, 2.5 mmol) afforded the desired amide **1k** (130 mg) in 14% yield as a white solid; R_f = 0.35 (3% EtOAc, 30% DCM in hexane); Melting point: 94–96 °C.

^1H NMR (500 MHz, CDCl_3) δ 8.33 (s, 1H), 8.01 (d, J = 7.9 Hz, 1H), 7.30–7.24 (m, 1H), 5.80 (s, 1H), 5.63 (s, 1H), 3.95 (s, 3H), 3.32 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 164.7, 163.4, 146.2, 135.2, 133.9 (q, J = 31.9 Hz), 131.7, 130.04, 129.98, 124.9 (q, J = 5.0 Hz), 122.5, 121.2 (q, J = 274.0 Hz), 52.7, 36.3; ^{19}F NMR (377 MHz, CDCl_3) δ -64.4 ppm; HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{13}\text{H}_{12}\text{BrF}_3\text{NO}_3$: 365.9947, found 365.9953.

2-(*N*-(2-Bromophenyl)-2-(trifluoromethyl)acrylamido)ethyl-3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate (**1q**):




According to **GP-I**, amide coupling of 2-(trifluoromethyl)acrylic acid (336 mg, 2.4 mmol) with 2-((2-bromophenyl)amino)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate (957 mg, 2.0 mmol) afforded the desired amide **1q** (302 mg) in 25% yield as a yellow solid; R_f = 0.08 (3% EtOAc, 30% DCM in hexane); Melting point: 78–80 °C.

^1H NMR (500 MHz, CDCl_3) δ 8.46 (dd, J = 7.9, 1.5 Hz, 1H), 8.11 (dd, J = 7.4, 1.2 Hz, 1H), 7.79–7.74 (m, 2H), 7.62–7.49 (m, 4H), 7.41 (t, J = 7.7 Hz, 1H), 7.15 (d, J = 3.3 Hz, 3H), 5.75 (s, 1H),

5.58 (s, 1H), 4.76–4.67 (m, 1H), 4.65–4.57 (m, 1H), 4.50–4.43 (m, 1H), 3.69–3.61 (m, 1H), 2.25 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 178.2, 163.8, 163.6, 160.9, 154.5, 140.3, 136.2, 134.1, 133.9 (q, $J = 32.3$ Hz), 132.9, 131.4, 131.0, 130.6, 130.1, 129.3, 128.6, 128.5, 124.4 (q, $J = 5.8$ Hz), 124.0, 123.2, 122.8, 121.2 (q, $J = 274.0$ Hz, one of the quartet peak merged with other peaks), 119.8, 117.6, 61.9, 46.9, 11.8; $^{19}\text{F}\{^1\text{H}\}$ NMR (471 MHz, CDCl_3) δ -64.4 ppm; HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ calcd. for $\text{C}_{29}\text{H}_{21}\text{BrF}_3\text{NO}_5\text{Na}$: 622.0447, found 622.0466.

2-(*N*-(2-Bromophenyl)-2-(trifluoromethyl)acrylamido)ethyl 2-(4-isobutylphenyl)propanoate (1r):




According to GP-I, amide coupling of 2-(trifluoromethyl)acrylic acid (504 mg, 3.6 mmol) with 2-((2-Bromophenyl)amino)ethyl 2-(4-isobutylphenyl)propanoate (1.2 g, 3.0 mmol) afforded the desired amide **1r** (364 mg) in

23% yield as a yellow liquid; $R_f = 0.46$ (3% EtOAc, 30% DCM in hexane).

^1H NMR (500 MHz, CDCl_3) δ 7.65–7.56 (m, 1H), 7.24–7.16 (m, 2H), 7.16–7.11 (m, 2H), 7.11–7.06 (m, 2H), 7.05–6.96 (m, 1H), 5.72 (s, 1H), 5.53 (d, $J = 10.7$ Hz, 1H), 4.73–4.63 (m, 0.5H), 4.56–4.48 (m, 0.5H), 4.37–4.30 (m, 0.5H), 4.29–4.22 (m, 1H), 4.02–3.95 (m, 0.5H), 3.65–3.54 (m, 1H), 3.52–3.38 (m, 1H), 2.44 (d, $J = 7.2$ Hz, 2H), 1.84 (sept, $J = 6.8$ Hz, 1H), 1.41 (dd, $J = 20.5$, 7.1 Hz, 3H), 0.89 (bd, $J = 6.6$ Hz, 6H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 174.40, 174.38, 163.7, 163.6, 140.59, 140.55, 139.8, 137.52, 137.49, 134.2, 134.1, 133.9, 133.8, 131.6, 130.12, 130.07, 129.34, 129.31, 128.63, 128.61, 127.14, 127.10, 124.3 (dq, $J = 10.8$, 5.5 Hz, this due to two quartet merging), 122.9, 122.8, 121.23 (q, $J = 274.1$ Hz), 121.21 (q, $J = 274.2$ Hz), 61.6, 60.9, 47.5, 46.2, 45.0, 44.9, 30.14, 30.13, 22.4, 22.3, 18.5, 18.3; $^{19}\text{F}\{^1\text{H}\}$ NMR (471 MHz, CDCl_3) δ -64.2 ppm; HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ calcd. for $\text{C}_{25}\text{H}_{27}\text{BrF}_3\text{NO}_3\text{Na}$: 548.1019, found 548.1031.

2-(*N*-(2-Bromophenyl)-2-(trifluoromethyl)acrylamido)ethyl-2-(4-chlorophenoxy)-2-methylpropanoate (1s):




According to GP-I, amide coupling of 2-(trifluoromethyl)acrylic acid (840 mg, 6.0 mmol) with 2-((2-Bromophenyl)amino)ethyl 2-(4-chlorophenoxy)-2-

methylpropanoate (2.1 g, 5.0 mmol) afforded the desired amide **1s** (1.06 g) in 40% yield as a yellow liquid; $R_f = 0.42$ (3% EtOAc, 30% DCM in hexane).

^1H NMR (500 MHz, CDCl_3) δ 7.64 (dd, $J = 7.9, 1.3$ Hz, 1H), 7.28 (td, $J = 7.5, 1.2$ Hz, 1H), 7.22 (td, $J = 7.7, 1.7$ Hz, 1H), 7.20–7.14 (m, 3H), 6.78–6.72 (m, 2H), 5.76 (s, 1H), 5.56 (s, 1H), 4.64 (ddd, $J = 14.6, 7.4, 4.1$ Hz, 1H), 4.43 (ddd, $J = 11.4, 5.6, 4.3$ Hz, 1H), 4.26 (ddd, $J = 11.6, 7.4, 3.9$ Hz, 1H), 3.48 (ddd, $J = 14.6, 5.6, 4.1$ Hz, 1H), 1.52 (s, 6H); **$^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3)** δ 173.5, 163.6, 153.8, 140.0, 134.0, 133.7 (q, $J = 32.0$ Hz), 131.4, 130.2, 129.0, 128.7, 127.2, 124.5 (q, $J = 5.2$ Hz), 122.6, 121.1 (q, $J = 274.0$ Hz), 120.6, 79.3, 61.9, 46.8, 25.2, 24.8; **^{19}F NMR (377 MHz, CDCl_3)** δ -64.2 ppm; **HRMS (ESI-TOF) m/z :** $[\text{M}+\text{Na}]^+$ calcd. for $\text{C}_{22}\text{H}_{20}\text{BrClF}_3\text{NO}_4\text{Na}$: 556.0109, found 556.0103.

***N*-Ethyl-*N*-(2-iodophenyl)-2-(trifluoromethyl)acrylamide (**1b'**):**




According to **GP-I**, amide coupling of *N*-ethyl-2-iodoaniline (1.6 mL, 10 mmol) with 2-(trifluoromethyl)acrylic acid (1.68 g, 12 mmol) afforded **1b'** (1.18 g) in 32% yield as a white solid; $R_f = 0.21$ (5% EtOAc in hexane);

Melting point: 70–72 °C.

^1H NMR (500 MHz, CDCl_3) δ 7.91 (d, $J = 5.5$ Hz, 1H), 7.37 (t, $J = 6.8$ Hz, 1H), 7.11 (bd, $J = 7.0$ Hz, 1H), 7.05 (t, $J = 7.1$ Hz, 1H), 5.74 (s, 1H), 5.65 (s, 1H), 4.40–4.39 (m, 1H), 3.30–3.17 (m, 1H), 1.20–1.11 (m, 3H); **$^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3)** δ 163.1, 143.6, 140.5, 134.3 (q, $J = 31.3$ Hz), 131.0, 129.9, 129.4, 124.1 (q, $J = 5.0$ Hz), 121.4 (q, $J = 273.9$ Hz), 99.6, 43.9, 11.9; **^{19}F NMR (377 MHz, CDCl_3)** δ -64.2 ppm; **HRMS (ESI-TOF) m/z :** $[\text{M}+\text{Na}]^+$ calcd. for $\text{C}_{12}\text{H}_{11}\text{F}_3\text{INNaO}$: 391.9730, found 391.9727.

***N*-Benzyl-*N*-(2-iodophenyl)-2-(trifluoromethyl)acrylamide (**1c'**):¹**




According to **GP-I**, amide coupling of *N*-benzyl-2-iodoaniline (1.3 mL, 7 mmol) with 2-(trifluoromethyl)acrylic acid (1.18 g, 8.4 mmol) afforded **1c'** (875 mg) in 29% yield as a white solid; $R_f = 0.26$ (5% EtOAc in hexane);

Melting point: 53–55 °C.

^1H NMR (500 MHz, CDCl_3) δ 7.91 (d, $J = 7.9$ Hz, 1H), 7.27–7.23 (m, 3H), 7.21–7.12 (m, 3H), 6.99 (td, $J = 7.9, 1.0$ Hz, 1H), 6.60 (d, $J = 7.5$ Hz, 1H), 5.83–5.69 (m, 3H), 4.14 (d, $J = 14.3$ Hz, 1H); **$^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3)** δ 163.4, 142.9, 140.3, 135.7, 134.2 (q, $J = 31.5$ Hz), 131.7,

130.0, 129.4, 129.1, 128.5, 127.9, 124.2 (bq, $J = 5.0$ Hz), 121.4 (q, $J = 274.7$ Hz), 99.3, 51.8; ^{19}F NMR (377 MHz, CDCl_3) δ -64.0 ppm.


***N*-(2-Iodo-4-methylphenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (1d')**



According to **GP-I**, amide coupling of 2-iodo-*N*,4-dimethylaniline (2.4 mL, 15 mmol) with 2-(trifluoromethyl)acrylic acid (2.52 g, 18 mmol) afforded **1d'** (2.0 g) in 36% yield as a yellow liquid; $R_f = 0.26$ (5% EtOAc in hexane).

^1H NMR (500 MHz, CDCl_3) δ 7.71 (s, 1H), 7.16 (bd, $J = 7.8$ Hz, 1H), 7.03 (bd, $J = 8.0$ Hz, 1H), 5.78 (s, 1H), 5.68 (s, 1H), 3.26 (s, 3H), 2.32 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 163.7, 143.0, 140.7, 140.4, 134.0 (q, $J = 31.5$ Hz), 130.6, 128.9, 124.6 (q, $J = 5.2$ Hz), 121.4 (q, $J = 274.0$ Hz, one of quartet peak merged with other peaks), 98.3, 36.9, 20.4; ^{19}F NMR (377 MHz, CDCl_3) δ -64.2 ppm; HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{12}\text{H}_{12}\text{F}_3\text{INO}$: 369.9910, found 369.9906.


***N*-(4-Fluoro-2-iodophenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (1e')**



According to **GP-I**, amide coupling of 4-fluoro-2-iodo-*N*-methylaniline (2.1 mL, 15 mmol) with 2-(trifluoromethyl)acrylic acid (2.52 g, 18 mmol) afforded **1e'** (3.14 g) in 56% yield as a white solid; $R_f = 0.18$ (5% EtOAc in hexane); Melting point: 59–61 °C. (Due to rotamers of **1e'**, we obtained the product as a mixture with minor isomer).

^1H NMR (500 MHz, CDCl_3) δ 7.60–7.54 (m, 1H), 7.17–7.04 (m, 2H), 5.78 (s, 1H), 5.67 (s, 1H), 3.241 (s, 1.67H), 3.235 (s, 1.32H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 163.5, 161.1 (d, $J = 254.5$ Hz), 141.9 (d, $J = 3.2$ Hz), 133.9 (q, $J = 32.2$ Hz), 130.1 (d, $J = 8.7$ Hz), 127.1 (d, $J = 24.7$ Hz), 124.6 (bq, $J = 5.0$ Hz), 121.2 (q, $J = 273.9$ Hz), 116.8 (d, $J = 22.2$ Hz), 98.5 (d, $J = 8.6$ Hz), 36.9; ^{19}F NMR (377 MHz, CDCl_3) δ -64.1, -64.8 (minor isomer), -(110.6–110.7) ppm; HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{11}\text{H}_9\text{F}_4\text{INO}$: 373.9659, found 373.9661.


***N*-(4-Chloro-2-iodophenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (1f')**



According to **GP-I**, amide coupling of 4-chloro-2-iodo-*N*-methylaniline (2.82 mL, 20 mmol) with 2-(trifluoromethyl)acrylic acid (3.36 g, 24 mmol) afforded **1f** (2.89 g) in 37% yield as a yellow liquid; $R_f = 0.21$ (5% EtOAc in hexane). (Due to rotamers of **1f**, we obtained the product as a mixture with minor isomer).

^1H NMR (500 MHz, CDCl_3) δ 7.88 (bs, 1H), 7.36 (d, $J = 8.2$ Hz, 1H), 7.09 (bd, $J = 8.3$ Hz, 1H), 5.82 (s, 1H), 5.69 (s, 1H), 3.26 (s, 3H); **$^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3)** δ 163.5, 144.4, 139.7, 134.8, 134.0 (q, $J = 31.8$ Hz), 130.04, 129.96, 124.88 (q, $J = 5.0$ Hz), 121.3 (q, $J = 274.0$ Hz), 98.9, 36.9; **^{19}F NMR (377 MHz, CDCl_3)** δ -64.1, -64.7 (minor isomer) ppm; **HRMS (ESI-TOF) m/z :** $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{11}\text{H}_9\text{ClF}_3\text{INO}$: 389.9364, found 389.9360.


***N*-(4-Bromo-2-iodophenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1g'**):**



According to **GP-I**, amide coupling of 4-bromo-2-iodo-*N*-methylaniline (4.0 g 15.1 mmol) with 2-(trifluoromethyl)acrylic acid (2.54 g, 18.12 mmol) afforded **1g'** (3.22 g) in 49% yield as a white solid; $R_f = 0.39$ (10% EtOAc in hexane); Melting point: 45–47 °C. (Due to rotamers of **1g'**, we obtained the product as a mixture with minor isomer).

^1H NMR (500 MHz, CDCl_3) δ 8.04 (d, $J = 2.0$ Hz, 1H), 7.51 (d, $J = 8.2$ Hz, 1H), 7.03 (d, $J = 8.3$, 1H), 5.83 (s, 1H), 5.69 (s, 1H), 3.26 (s, 3H); **$^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3)** δ 163.5, 144.9, 142.5, 133.9 (q, $J = 32.8$ Hz), 133.1, 130.4, 124.9 (q, $J = 5.0$ Hz), 122.8, 121.3 (q, $J = 274.0$ Hz), 99.4, 36.8; **^{19}F NMR (377 MHz, CDCl_3)** δ -64.2, -64.7 (minor isomer) ppm; **HRMS (ESI-TOF) m/z :** $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{11}\text{H}_9\text{BrF}_3\text{INO}$: 433.8859, found 433.8858.

***N*-(4-Cyano-2-iodophenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1h'**):**




According to **GP-I**, amide coupling of 3-iodo-4-(methylamino)benzonitrile (2.64 g, 10.23 mmol) with 2-(trifluoromethyl)acrylic acid (1.72 g, 12.27 mmol) afforded **1h'** (1.5 g) in

39% yield as a white solid; $R_f = 0.17$ (10% EtOAc in hexane); Melting point: 84–86 °C. (Due to rotamers of **1h'**, we obtained the product as a mixture with minor isomer).

^1H NMR (500 MHz, CDCl_3) δ 8.19 (bs, 1H), 7.69 (d, $J = 7.7$ Hz, 1H), 7.33–7.23 (m, 1H), 5.85 (s, 1H), 5.67 (s, 1H), 3.29 (s, 3H); **$^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3)** δ 163.2, 149.8, 143.7, 133.9 (q, $J = 31.5$ Hz, one quartet peak is merged with other peak), 133.4, 130.0, 125.4 (bq, $J = 2.1$ Hz,

quartet splitting is not clear), 121.1 (q, $J = 273.9$ Hz), 116.0, 113.9, 98.8, 36.8; ^{19}F NMR (377 MHz, CDCl_3) δ -64.2, -64.7 (minor isomer) ppm; HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{12}\text{H}_9\text{F}_3\text{IN}_2\text{O}$: 380.9706, found 380.9698.


***N*-(2-Iodo-4-(trifluoromethyl)phenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1i'**):**



According to **GP-I**, amide coupling of 2-iodo-*N*-methyl-4-(trifluoromethyl)aniline (2.48 mL, 15 mmol) with 2-(trifluoromethyl)acrylic acid (2.52 g, 18 mmol) afforded **1i'** (3.0 g) in 47% yield as a yellow liquid; $R_f = 0.50$ (10% EtOAc in hexane). (Due to rotamers of **1i'**, we obtained the product as a mixture with minor isomer).

^1H NMR (500 MHz, CDCl_3) δ 8.13 (s, 1H), 7.65 (d, $J = 7.9$ Hz, 1H), 7.28 (bd, $J = 7.8$ Hz, 1H), 5.83 (s, 1H), 5.68 (s, 1H), 3.28 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 163.3, 149.0, 137.4, 133.8 (q, $J = 32.4$ Hz), 131.8 (q, $J = 33.5$ Hz), 129.8, 127.0 (q, $J = 3.5$ Hz), 125.3 (bq, $J = 4.6$ Hz, quartet splitting is not clear), 122.3 (q, $J = 273.4$ Hz), 121.2 (q, $J = 273.9$ Hz), 98.6, 36.7; ^{19}F NMR (377 MHz, CDCl_3) δ -62.6, -64.2, -64.7 (minor isomer) ppm; HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{12}\text{H}_9\text{F}_6\text{INO}$: 423.9628, found 423.9622.


***N*-(2-Iodo-5-methylphenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1j'**):**



According to **GP-I**, amide coupling of 2-iodo-*N*,5-dimethylaniline (2.94 g, 14.67 mmol) with 2-(trifluoromethyl)acrylic acid (2.46 g, 17.6 mmol) afforded **1j'** (3.07 g) in 57% yield as a white solid; $R_f = 0.17$ (5% EtOAc in hexane); Melting point: 81–83 °C. (Due to rotamers of **1j'**, we obtained the product as a mixture with minor isomer).

^1H NMR (500 MHz, CDCl_3) δ 7.73 (d, $J = 8.1$ Hz, 1H), 6.99 (s, 1H), 6.87 (d, $J = 8.0$ Hz, 1H), 5.78 (s, 1H), 5.68 (s, 1H), 3.27 (s, 3H), 2.29 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 163.7, 145.5, 140.4, 139.9, 134.0 (q, $J = 31.7$ Hz), 130.9, 130.2, 124.6 (q, $J = 5.0$ Hz), 121.4 (q, $J = 277.2$ Hz), 94.2, 36.8, 20.7; ^{19}F NMR (377 MHz, CDCl_3) δ -64.2, -64.8 (minor isomer) ppm; HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{12}\text{H}_{12}\text{F}_3\text{INO}$: 369.9910, found 369.9906.


***N*-(5-Fluoro-2-iodophenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1k'**):**



According to **GP-I**, amide coupling of 5-fluoro-2-iodo-*N*-methylaniline (2.41 g, 11.8 mmol) with 2-(trifluoromethyl)acrylic acid (1.98 g, 14.2 mmol) afforded **1k'** (1.18 g) in 27% yield as a white solid; $R_f = 0.14$ (5% EtOAc in hexane); Melting point: 50–52 °C. (Due to rotamers of **1k'**, we obtained the product as a mixture with minor isomer).

¹H NMR (500 MHz, CDCl₃) δ 7.84 (dd, $J = 8.7, 5.9$, Hz, 1H), 6.94 (d, $J = 7.5$ Hz, 1H), 6.85 (td, $J = 8.3, 2.7$ Hz, 1H), 5.83 (s, 1H), 5.71 (s, 1H), 3.28 (s, 3H); **¹³C{¹H} NMR (126 MHz, CDCl₃)** δ 163.5, 163.2 (d, $J = 252.3$ Hz), 146.9 (d, $J = 8.8$ Hz), 141.2 (d, $J = 8.3$ Hz), 133.9 (q, $J = 31.9$ Hz), 125.0 (bq, $J = 4.6$ Hz), 121.2 (q, $J = 273.8$ Hz), 117.7 (d, $J = 21.5$ Hz), 117.2 (d, $J = 22.8$ Hz), 91.9 (d, $J = 2.9$ Hz), 36.8; **¹⁹F NMR (377 MHz, CDCl₃)** δ -64.2, -64.8 (minor isomer) -110.3 (dd, $J = 13.4, 6.8$ Hz) ppm; **HRMS (ESI-TOF) m/z** : [M+H]⁺ calcd. for C₁₁H₉F₄INO: 373.9659, found 373.9655.


***N*-(5-Chloro-2-iodophenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1l'**):**



According to **GP-I**, amide coupling of 5-chloro-2-iodo-*N*-methylaniline (4.01 g, 15 mmol) with 2-(trifluoromethyl)acrylic acid (2.52 g, 18 mmol) afforded **1l'** (3.0 g) in 51% yield as a white solid; $R_f = 0.19$ (5% EtOAc in hexane); Melting point: 85–87 °C. (Due to rotamers of **1l'**, we obtained the product as a mixture with minor isomer).

¹H NMR (500 MHz, CDCl₃) δ 7.81 (d, $J = 8.5$ Hz, 1H), 7.18 (bs, 1H), 7.06 (dd, $J = 8.5, 2.1$ Hz, 1H), 5.84 (s, 1H), 5.69 (s, 1H), 3.28 (s, 3H); **¹³C{¹H} NMR (126 MHz, CDCl₃)** δ 163.4, 146.7, 141.0, 135.6, 134.0 (q, $J = 31.9$ Hz), 130.2, 129.8, 125.0 (bq, $J = 4.5$ Hz), 121.3 (q, $J = 276.4$ Hz), 96.0, 36.8; **¹⁹F NMR (377 MHz, CDCl₃)** δ -64.2, -64.7 (minor isomer) ppm; **HRMS (ESI-TOF) m/z** : [M+H]⁺ calcd. for C₁₁H₉ClF₃INO: 389.9364, found 389.9366.

(*Z*)-*N*-(2-Iodophenyl)-*N*-methyl-3-phenyl-2-(trifluoromethyl)acrylamide (3a**):**




According to **GP-I**, amide coupling of 3-phenyl-2-(trifluoromethyl)acrylic acid³ (864 mg, 4.0 mmol, used ~30:70 to ~40:60 ratio of *Z/E* isomer compound) with 2-iodo-*N*-methylaniline (769 mg, 3.3 mmol) afforded the desired amide **3a** (714 mg) in 50% yield as a white solid; $R_f = 0.22$ (3% EtOAc, 30% DCM in hexane); Melting point: 83–85 °C.

¹H NMR (500 MHz, CDCl₃) δ 7.97 (d, J = 7.9 Hz, 1H), 7.40 (t, J = 7.6 Hz, 1H), 7.31–7.21 (m, 4H), 7.15 (s, 1H), 7.10–7.04 (m, 3H), 3.35 (s, 3H); **¹³C{¹H} NMR (126 MHz, CDCl₃)** δ 165.4 (q, J = 2.7 Hz), 145.8, 140.4, 140.0 (q, J = 3.7 Hz), 132.3, 129.95, 129.94, 129.8, 129.4, 128.7 (q, J = 2.6 Hz), 128.2, 126.1 (q, J = 32.4 Hz), 121.6 (q, J = 274.9 Hz), 98.4, 36.7; **¹⁹F{¹H} NMR (471 MHz, CDCl₃)** δ -56.7 ppm; **HRMS (ESI-TOF) m/z :** [M+Na]⁺ calcd. for C₁₇H₁₃IF₃NONa: 453.9886, found 453.9892.

Note: The independent amide coupling with *E*-isomer resulted in the *E/Z* isomerization. Therefore, the overall yield of *Z*-amide is higher.

Note: Compounds **3a'** and **3a''** are prepared according to the reported procedure.²


(*Z*)-*N*-Benzyl-*N*-(2-iodophenyl)-3-phenyl-2-(trifluoromethyl)acrylamide (3b**):**



According to **GP-I**, amide coupling of 3-phenyl-2-(trifluoromethyl)acrylic acid³ (864 mg, 4.0 mmol, used ~30:70 to ~40:60 ratio of *Z/E* isomer compound) with *N*-benzyl-2-iodoaniline (1.0 g, 3.3 mmol) afforded the desired amide **3b** (949 mg) in 47% yield as a white solid; R_f = 0.38 (3% EtOAc, 30% DCM in hexane); Melting point: 74–76 °C.

¹H NMR (500 MHz, CDCl₃) δ 7.96 (d, J = 7.9 Hz, 1H), 7.30–7.20 (m, 8H), 7.18 (s, 1H), 7.14 (t, J = 7.6 Hz, 1H), 7.10–7.03 (m, 2H), 6.99 (t, J = 7.7 Hz, 1H), 6.66 (d, J = 7.8 Hz, 1H), 5.82 (d, J = 14.3 Hz, 1H), 4.21 (d, J = 14.3 Hz, 1H); **¹³C{¹H} NMR (126 MHz, CDCl₃)** δ 165.0 (q, J = 2.4 Hz), 142.9, 140.2, 139.4 (q, J = 4.0 Hz), 135.8, 132.2, 131.8, 129.9, 129.34, 129.32, 129.2, 128.7 (bq, J = 2.4 Hz), 128.4, 128.2, 127.8, 126.1 (q, J = 32.5 Hz), 121.6 (q, J = 274.9 Hz), 99.1, 51.6; **¹⁹F NMR (377 MHz, CDCl₃)** δ -56.5 ppm; **HRMS (ESI-TOF) m/z :** [M+Na]⁺ calcd. for C₂₃H₁₇IF₃NONa: 530.0199, found 530.0215.


(*Z*)-*N*-(2-Iodo-4-methylphenyl)-*N*-methyl-3-phenyl-2-(trifluoromethyl)acrylamide (3c**):**



According to **GP-I**, amide coupling of 3-phenyl-2-(trifluoromethyl)acrylic acid³ (1.3 g, 6.0 mmol, used ~30:70 to ~40:60 ratio of *Z/E* isomer compound) with 2-iodo-*N*,4-dimethylaniline (1.2 g, 5.0 mmol) afforded the desired amide **3c** (796 mg) in 36% yield as a yellow solid; R_f = 0.22 (3% EtOAc, 30% DCM in hexane); Melting point: 61–63 °C.

¹H NMR (500 MHz, CDCl₃) δ 7.78 (s, 1H), 7.32–7.27 (m, 3H), 7.20–7.14 (m, 2H), 7.14–7.08 (m, 3H), 3.32 (s, 3H), 2.33 (s, 3H); **¹³C{¹H} NMR (126 MHz, CDCl₃)** δ 165.6 (bq, J = 2.7 Hz), 143.1, 140.7, 140.3, 139.8 (q, J = 3.7 Hz), 132.4, 130.6, 129.4, 129.2, 128.9 (bq, J = 2.6 Hz), 128.3, 126.2 (q, J = 32.5 Hz), 121.6 (q, J = 275.0 Hz), 98.2, 36.8, 20.5; **¹⁹F NMR (377 MHz, CDCl₃)** δ -56.6 ppm; **HRMS (ESI–TOF) m/z** : [M+Na]⁺ calcd. for C₁₈H₁₅IF₃NONa: 468.0043, found 468.0045.


(Z)-N-(4-Fluoro-2-iodophenyl)-N-methyl-3-phenyl-2-(trifluoromethyl)acrylamide (3d):



The above method **GP–I**, amide coupling of 3-phenyl-2-(trifluoromethyl)acrylic acid³ (259 mg, 1.2 mmol, used ~30:70 to ~40:60 ratio of *Z/E* isomer compound) with 4-fluoro-2-iodo-*N*-methylaniline (251 mg, 1.0 mmol) afforded the desired amide **3d** (145 mg) in 32% yield as a yellow solid; R_f = 0.22 (3% EtOAc, 30% DCM in hexane); Melting point: 65–67 °C.

¹H NMR (500 MHz, CDCl₃) δ 7.67 (dd, J = 7.5, 2.7 Hz, 1H), 7.34–7.27 (m, 3H), 7.22 (dd, J = 8.6, 5.3 Hz, 1H), 7.17 (s, 1H), 7.15–7.08 (m, 3H), 3.32 (s, 3H); **¹³C{¹H} NMR (126 MHz, CDCl₃)** δ 165.4 (bq, J = 2.0 Hz), 161.2 (d, J = 254.7 Hz), 142.1 (d, J = 3.3 Hz), 140.1 (q, J = 3.7 Hz), 132.1, 130.5 (d, J = 8.6 Hz), 129.6, 128.9 (q, J = 2.3 Hz), 128.4, 127.2 (d, J = 24.6 Hz), 126.2 (q, J = 32.5 Hz), 121.5 (q, J = 274.8 Hz), 116.9 (d, J = 22.1 Hz), 98.5 (d, J = 8.8 Hz), 36.9; **¹⁹F NMR (377 MHz, CDCl₃)** δ -56.5, -110.5 (q, J = 7.0 Hz); **HRMS (ESI–TOF) m/z** : [M+Na]⁺ calcd. for C₁₇H₁₂IF₄NONa: 471.9792, found 471.9792.

(Z)-N-(2-Iodophenyl)-N-methyl-2-(trifluoromethyl)-3-(4-trifluoromethyl)phenyl acrylamide (3e):




The above method **GP–I**, amide coupling of 2-(trifluoromethyl)-3-(4-(trifluoromethyl)phenyl)acrylic acid³ (444 mg, 1.2 mmol, used ~30:70 to ~40:60 ratio of *Z/E* isomer compound) with 2-iodo-*N*-methylaniline (303 mg, 1.3 mmol) afforded the desired amide **3e** (306 mg) in 47% yield as a white solid; R_f = 0.28 (3% EtOAc, 30% DCM in hexane); Melting point: 45–47 °C.

¹H NMR (500 MHz, CDCl₃) δ 7.99 (d, J = 7.9 Hz, 1H), 7.53 (d, J = 8.2 Hz, 2H), 7.43 (t, J = 7.6 Hz, 1H), 7.26 (d, J = 7.4 Hz, 1H), 7.19 (s, 1H), 7.16–7.08 (m, 3H), 3.36 (s, 3H); **¹³C{¹H} NMR (126 MHz, CDCl₃)** δ 164.7 (bq, J = 2.5 Hz), 145.5, 140.5, 138.2 (q, J = 3.8 Hz), 135.9, 131.1 (q,

$J = 32.8$ Hz), 130.2, 130.1, 129.8, 128.7 (bq, $J = 2.4$ Hz), 128.4 (q, $J = 32.6$ Hz), 125.3 (q, $J = 3.7$ Hz), 123.7 (q, $J = 272.3$ Hz), 121.2 (q, $J = 275.1$ Hz), 98.5, 36.7; ^{19}F NMR (377 MHz, CDCl_3) δ -56.5, -62.9 ppm; HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{18}\text{H}_{13}\text{IF}_6\text{NO}$: 499.9941, found 499.9954.

2.2 General Procedure for the Synthesis of *o*-Iodoaryl *gem*-Difluoro and Monofluoro Acrylamides (GP-II & III):



Scheme S2. Synthesis of *o*-iodoaryl *gem*-difluoro and monofluoromethyl acrylamides.

General Procedure-II (GP-II): A round bottom flask equipped with a magnetic stir bar was charged with *o*-iodo trifluoromethyl acrylamide **1'** (1.0 equiv) and sodium borohydride (0.4 equiv). Later, the RB was introduced into the glove box to add THF (0.5 M). Then, the reaction was stirred inside the glove box at room temperature for 2 hours. After completion of the reaction (monitored by TLC), the reaction mixture was washed with water and extracted with DCM (3 times). The combined organic solution was dried over anhydrous Na_2SO_4 , filtered, and concentrated in a rotary evaporator. The residue was purified by SiO_2 column chromatography (100–200 mesh) using a mixture of hexane, DCM, and ethyl acetate to afford the desired acrylamides (**5a-5l**).

A similar procedure has been followed to prepare monofluoromethyl acrylamides (**7a-7e**) from *gem*-difluoro methyl acrylamides (GP-III).





Figure S4. *N*-(2-Haloaryl) *gem*-difluoro and monofluoro methyl acrylamides.

Characterization Data of *o*-Iodoaryl *gem*-Difluoro and Monofluoro Acrylamides:


3,3-Difluoro-*N*-(2-iodophenyl)-*N*, 2-dimethyl acrylamide (**5a**)⁴:



According to **GP-II**, the reaction of *N*-(2-iodophenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1a'**, 178 mg, 0.5 mmol) with NaBH₄ (7.5 mg, 0.2 mmol) afforded the desired amide **5a** (115 mg) in 68% yield as a white solid; *R*_f = 0.28 (3% EtOAc, 30% DCM in hexane); Melting point: 71–73 °C (89:11 mixture of isomers based on ¹⁹F NMR ratio, the minor isomer highlighted with star mark).

¹H NMR (500 MHz, CDCl₃) δ 7.90 (d, *J* = 7.9 Hz, 1H), 7.39 (t, *J* = 7.5 Hz, 1H), 7.28–7.23 (m, 1H), 7.06 (t, *J* = 7.5 Hz, 1H), 3.30 (s, 0.3H), 3.27–3.22 (m, 2.7H), 1.65 (bq, *J* = 3.2 Hz, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 166.0 (dd, *J* = 9.2, 3.5 Hz), 153.2 (t, *J* = 290.6 Hz), 145.4, 144.9*, 140.2, 140.0*, 129.8, 129.6*, 129.4, 129.1 (d, *J* = 2.7 Hz), 128.5*, 98.3, 97.6*, 86.0 (dd, *J* = 22.0, 17.8 Hz), 38.5*, 36.9, 11.2, 10.7*; ¹⁹F NMR (377 MHz, CDCl₃) δ -(78.95–79.35) (m, 1F), -81.7* (d, *J* = 37.0 Hz, 0.13F), -(89.36–89.60) (m, 1F), -90.3* (d, *J* = 36.6 Hz, 0.13F) ppm; HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. for C₁₁H₁₁IF₂NO: 337.9848, found 337.9843.


***N*-Ethyl-3,3-difluoro-*N*-(2-iodophenyl)-2-methylacrylamide (**5b**):**



According to **GP-II**, the reaction of *N*-(2-iodophenyl)-*N*-ethyl-2-(trifluoromethyl)acrylamide (**1b'**, 369 mg, 1.0 mmol) with NaBH₄ (15 mg, 0.4 mmol) afforded the desired amide **5b** (147 mg) in 42% yield as a yellow liquid along with (*E*)-*N*-ethyl-3-fluoro-*N*-(2-iodophenyl)-2-methylacrylamide (85 mg, 25% yield); R_f = 0.32 (3% EtOAc, 30% DCM in hexane). (89:11 mixture of isomers based on ¹⁹F NMR ratio, the minor isomer highlighted with star mark).

¹H NMR (500 MHz, CDCl₃) δ 7.92 (d, *J* = 8.0 Hz, 1H), 7.38 (t, *J* = 7.6 Hz, 1H), 7.20 (bd, *J* = 7.8 Hz, 1H), 7.07 (t, *J* = 7.6 Hz, 1H), 4.22 (dq, *J* = 14.2, 7.2 Hz, 1H), 3.80 (td, *J* = 13.9, 6.8 Hz, 0.16H), 3.56 (dt, *J* = 21.3, 7.0 Hz, 0.16H), 3.28 (dq, *J* = 14.2, 7.1 Hz, 1H), 1.95 (s, 0.31H), 1.71 (s, 0.29H), 1.62 (bt, *J* = 3.0 Hz, 3H), 1.16 (t, *J* = 7.2 Hz, 3H); **¹³C{¹H} NMR (126 MHz, CDCl₃)** δ 165.5 (dd, *J* = 9.2, 3.1 Hz), 153.1 (dd, *J* = 291.2, 289.6 Hz), 143.5, 140.2, 130.3 (d, *J* = 2.8 Hz), 129.8, 128.9, 99.4, 86.3 (dd, *J* = 21.6, 18.2 Hz), 43.9, 12.5, 11.1; **¹⁹F NMR (377 MHz, CDCl₃)** δ -79.9 (dp, *J* = 33.8, 3.8 Hz, 1F), -82.7* (d, *J* = 39.4 Hz, 0.11F), -90.2 (dq, *J* = 33.2, 3.0 Hz, 1F), -91.2* (d, *J* = 37.4 Hz, 0.11F) ppm; **HRMS (ESI-TOF) *m/z***: [M+H]⁺ calcd. for C₁₂H₁₃IF₂NO: 352.0004, found 351.9995.


***N*-Benzyl-3,3-difluoro-*N*-(2-iodophenyl)-2-methylacrylamide (**5c**):**



According to **GP-II**, the reaction of *N*-(2-iodophenyl)-*N*-benzyl-2-(trifluoromethyl)acrylamide (**1c'**, 790 mg, 1.5 mmol) with NaBH₄ (23 mg, 0.6 mmol) afforded the desired amide **5c** (304 mg) in 49% yield as a white solid; R_f = 0.46 (3% EtOAc, 30% DCM in hexane); Melting point: 47–49 °C. (91:09 mixture of isomers based on ¹⁹F NMR ratio, the minor isomer highlighted with star mark).

¹H NMR (500 MHz, CDCl₃) δ 7.90 (d, *J* = 7.9 Hz, 1H), 7.30–7.23 (m, 3H), 7.22–7.13 (m, 3H), 7.01 (t, *J* = 7.6 Hz, 1H), 6.77 (d, *J* = 7.8 Hz, 1H), 5.68 (d, *J* = 14.4 Hz, 1H), 4.11 (d, *J* = 14.4 Hz, 1H), 1.67 (bt, *J* = 2.9 Hz, 3H); **¹³C{¹H} NMR (126 MHz, CDCl₃)** δ 165.9 (dd, *J* = 9.1, 3.2 Hz), 153.0 (dd, *J* = 291.6, 289.5 Hz), 143.0, 140.0, 136.2, 130.7 (d, *J* = 3.0 Hz), 129.9, 129.1, 128.6, 128.4, 127.6, 99.2, 86.1 (dd, *J* = 21.9, 18.2 Hz), 52.0, 11.2; **¹⁹F NMR (377 MHz, CDCl₃)** δ - (79.30–79.65) (m, 1F), -80.8* (d, *J* = 36.0 Hz, 0.07F), -(89.85–90.10) (m, 1F), -90.3* (d, *J* = 35.1 Hz, 0.09F) ppm; **HRMS (ESI-TOF) *m/z***: [M+H]⁺ calcd. for C₁₇H₁₅IF₂NO: 414.0161, found 414.0160.


3,3-Difluoro-*N*-(2-iodo-4-methylphenyl)-*N*, 2-dimethylacrylamide (**5d**):



According to **GP-II**, the reaction of *N*-(2-iodo-4-methylphenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1d'**, 369 mg, 1.0 mmol) with NaBH₄ (15 mg, 0.4 mmol) afforded the desired amide **5d** (202 mg) in 57% yield as a yellow liquid; *R*_f = 0.31 (3% EtOAc, 30% DCM in hexane). (88:12 mixture of isomers based on ¹⁹F NMR ratio, the minor isomer highlighted with star mark).

¹H NMR (400 MHz, CDCl₃) δ 7.71 (bd, *J* = 1.0 Hz, 1H), 7.19–7.09 (m, 2H), 3.21 (s, 3H), 2.32 (s, 3H), 1.64 (t, *J* = 3.1 Hz, 3H); **¹³C{¹H} NMR (126 MHz, CDCl₃)** δ 166.2 (dd, *J* = 9.1, 3.0 Hz), 153.1 (t, *J* = 290.6 Hz), 142.7, 140.4, 140.2, 130.1, 128.5 (d, *J* = 2.6 Hz), 98.0, 86.0 (dd, *J* = 22.0, 18.0 Hz), 36.9, 20.5, 11.2; **¹⁹F NMR (377 MHz, CDCl₃)** δ -(79.32–79.53) (m, 1F), -81.8* (d, *J* = 37.2 Hz, 0.12F), -(89.75–89.86) (m, 1F), -90.4* (dd, *J* = 37.3, 2.1 Hz, 0.12F, broad peaks) ppm; **HRMS (ESI-TOF) *m/z***: [M+H]⁺ calcd. for C₁₂H₁₃IF₂NO: 352.0004, found 351.9994.


3,3-Difluoro-*N*-(4-fluoro-2-iodophenyl)-*N*, 2-dimethylacrylamide (**5e**):



According to **GP-II**, the reaction of *N*-(4-fluoro-2-iodophenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1e'**, 186.5 mg, 0.5 mmol) with NaBH₄ (7.5 mg, 0.2 mmol) afforded the desired amide **5e** (85 mg) in 48% yield as a white solid; *R*_f = 0.31 (3% EtOAc, 30% DCM in hexane); Melting point: 50–52 °C. (87:13 mixture of isomers based on ¹⁹F NMR ratio, the minor isomer highlighted with star mark).

¹H NMR (400 MHz, CDCl₃) δ 7.61 (dd, *J* = 7.6, 2.8 Hz, 1H), 7.26–7.21 (m, 1H), 7.14–7.08 (m, 1H), 3.28* (s, 0.4H), 3.22 (s, 3H), 1.90* (t, *J* = 2.4 Hz, 0.4H), 1.67 (bt, *J* = 3.1 Hz, 3H); **¹³C{¹H} NMR (101 MHz, CDCl₃)** δ 165.9 (dd, *J* = 10.2, 3.8 Hz), 161.0 (d, *J* = 254.2 Hz), 152.9 (dd, *J* = 291.9, 290.2 Hz), 141.6 (d, *J* = 4.1 Hz), 129.6 (dd, *J* = 9.2, 3.3 Hz), 126.7 (d, *J* = 24.8 Hz), 116.3 (d, *J* = 22.4 Hz), 98.1 (d, *J* = 8.9 Hz), 85.8 (dd, *J* = 22.2, 17.9 Hz), 36.8, 11.2; **¹⁹F NMR (377 MHz, CDCl₃)** δ -(78.78–79.06) (m, 1F), -81.6* (d, *J* = 36.2 Hz, 0.16F), -(89.20–89.50) (m, 1F), -90.0* (d, *J* = 36.4 Hz, 0.15F), 110.9 (dd, *J* = 13.3, 7.4 Hz, 1F), -111.9 (dd, *J* = 13.1, 7.1 Hz, 0.14F) ppm; **HRMS (ESI-TOF) *m/z***: [M+H]⁺ calcd. for C₁₁H₁₀IF₃NO: 355.9754, found 355.9751.


***N*-(4-Chloro-2-iodophenyl)-3,3-difluoro-*N*, 2-dimethylacrylamide (5f):**



According to **GP-II**, the reaction of *N*-(4-chloro-2-iodophenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1f'**, 389 mg, 1.0 mmol) with NaBH₄ (15 mg, 0.4 mmol) afforded the desired amide **5f** (216 mg) in 58% yield as a white solid; *R*_f = 0.31 (3% EtOAc, 30% DCM in hexane); Melting point: 44–46 °C. (85:15 mixture of isomers based on ¹⁹F NMR ratio, the minor isomer highlighted with star mark).

¹H NMR (400 MHz, CDCl₃) δ 7.86 (d, *J* = 2.3 Hz, 1H), 7.35 (dd, *J* = 8.4, 2.3 Hz, 1H), 7.16 (dd, *J* = 8.4, 2.8 Hz, 1H), 3.26* (s, 0.45H), 3.20 (s, 3H), 1.91* (bt, *J* = 4.0 Hz, 0.6H), 1.65 (t, *J* = 3.2 Hz, 3H); **¹³C{¹H} NMR (126 MHz, CDCl₃)** δ 165.8 (dd, *J* = 9.2, 3.3 Hz), 153.1 (dd, *J* = 292.2, 290.4 Hz), 144.0, 139.4, 134.6, 129.53, 129.46 (d, *J* = 2.9 Hz), 98.5, 85.8 (dd, *J* = 21.9, 17.7 Hz), 36.8, 11.2; **¹⁹F NMR (377 MHz, CDCl₃)** δ -(78.48–78.64) (m, 1F), -81.3* (d, *J* = 35.8 Hz, 0.18F), -(88.71–88.88) (m, 1F), -89.7* (dd, *J* = 36.0, 1.5 Hz, 0.18F) ppm; **HRMS (ESI-TOF) *m/z***: [M+H]⁺ calcd. for C₁₁H₁₀ClIF₂NO: 371.9458, found 371.9455.

***N*-(4-Bromo-2-iodophenyl)-3,3-difluoro-*N*, 2-dimethylacrylamide (5g):**




According to **GP-II**, the reaction of *N*-(4-bromo-2-iodophenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1g'**, 217 mg, 0.5 mmol) with NaBH₄ (7.5 mg, 0.2 mmol) afforded the desired amide **5g** (85 mg) in 47% yield as a white solid; *R*_f = 0.33 (3% EtOAc, 30% DCM in hexane);

Melting point: 46–48 °C. (86:14 mixture of isomers based on ¹⁹F NMR ratio, the minor isomer highlighted with star mark).

¹H NMR (500 MHz, CDCl₃) δ 8.04 (d, *J* = 2.1 Hz, 1H), 7.51 (dd, *J* = 8.4, 1.9 Hz, 1H), 7.12 (dd, *J* = 8.4, 2.6 Hz, 1H), 3.27* (s, 0.43H), 3.22 (s, 3H), 1.93* (bs, 0.45H), 1.67 (bt, *J* = 3.0 Hz, 3H); **¹³C{¹H} NMR (126 MHz, CDCl₃)** δ 165.9 (dd, *J* = 9.2, 3.2 Hz), 153.2 (dd, *J* = 292.3, 290.5 Hz), 144.6, 142.2, 132.6, 129.9 (d, *J* = 2.9 Hz), 122.6, 99.1, 85.9 (dd, *J* = 22.0, 17.7 Hz), 36.8, 11.3; **¹⁹F NMR (377 MHz, CDCl₃)** δ -(78.36–78.60) (m, 1F), -81.2* (d, *J* = 35.5 Hz, 0.17F), -(88.56–88.74) (m, 1F), -89.6* (d, *J* = 35.5 Hz, 0.17F) ppm; **HRMS (ESI-TOF) *m/z***: [M+H]⁺ calcd. for C₁₁H₁₀BrIF₂NO: 415.8953, found 415.8946.

***N*-(4-Cyano-2-iodophenyl)-3,3-difluoro-*N*, 2-dimethylacrylamide (5h):**




According to **GP-II**, the reaction of *N*-(4-cyano-2-iodophenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1h'**, 362 mg, 1.0 mmol) with NaBH₄ (15 mg, 0.4 mmol) afforded the desired amide **5h** (144 mg) in 40% yield as a white solid; *R*_f = 0.11 (3% EtOAc, 30% DCM in hexane);

Melting point: 84–86 °C. (78:22 mixture of isomers based on ¹⁹F NMR ratio, the minor isomer highlighted with star mark).

¹H NMR (500 MHz, CDCl₃) δ 8.20 (s, 1H), 7.69 (d, *J* = 7.6 Hz, 1H), 7.34 (d, *J* = 8.1 Hz, 1H), 3.25 (bs, 3H), 1.70 (bs, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 165.6 (bd, *J* = 10.1 Hz), 153.4 (dd, *J* = 293.5, 291.2 Hz), 149.7, 143.5, 132.9, 129.6, 116.2, 113.8, 98.6, 85.9 (dd, *J* = 22.0, 16.6 Hz), 36.9, 11.4; ¹⁹F NMR (377 MHz, CDCl₃) δ -77.3 (d, *J* = 28.3, 1F), -80.4* (d, *J* = 34.1 Hz, 0.28F), -87.2 (d, *J* = 28.4 Hz, 1F), -88.7* (d, *J* = 32.5 Hz, 0.31F) ppm; HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. for C₁₂H₁₀F₂IN₂O: 362.9800, found 362.9796.

3,3-Difluoro-*N*-(2-iodo-4-(trifluoromethyl)phenyl)-*N*, 2-dimethylacrylamide (**5i**):




According to **GP-II**, the reaction of *N*-(2-iodo-4-(trifluoromethyl)phenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1i'**, 405 mg, 1.0 mmol) with NaBH₄ (15 mg, 0.4 mmol) afforded the desired amide **5i** (223 mg) in 55% yield as a white solid along with (*E*)-3-Fluoro-

N-(2-iodo-4-(trifluoromethyl)phenyl)-*N*,2-dimethylacrylamide (66 mg, 17% yield); *R*_f = 0.30 (3% EtOAc, 30% DCM in hexane); Melting point: 66–68 °C. (82:18 mixture of isomers based on ¹⁹F NMR ratio, the minor isomer highlighted with star mark).

¹H NMR (500 MHz, CDCl₃) δ 8.14 (d, *J* = 1.0 Hz, 1H), 7.65 (d, *J* = 8.1 Hz, 1H), 7.36 (d, *J* = 8.1 Hz, 1H), 3.30* (s, 0.51H), 3.25 (s, 3H), 1.94* (bs, 0.54H), 1.68 (bt, *J* = 2.9 Hz, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 165.7 (dd, *J* = 9.3, 3.3 Hz), 153.3 (dd, *J* = 292.7, 291.1 Hz), 148.7, 137.2 (bq, *J* = 3.6 Hz), 131.7 (q, *J* = 33.4 Hz), 129.3 (d, *J* = 2.7 Hz), 126.4 (bq, *J* = 3.3 Hz), 122.4 (q, *J* = 273.1 Hz), 98.3, 85.8 (dd, *J* = 21.9, 17.4 Hz), 36.8, 11.3; ¹⁹F NMR (377 MHz, CDCl₃) δ -62.61 (3F), -62.64 (0.5F), -(77.84–78.02) (m, 1F), -80.9* (d, *J* = 35.9 Hz, 0.22F), -(87.82–88.00) (m, 1F), -89.2* (d, *J* = 35.9 Hz, 0.22F) ppm; HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. for C₁₂H₁₀F₅INO: 405.9722, found 405.9716.


3,3-Difluoro-*N*-(2-iodo-5-methylphenyl)-*N*, 2-dimethylacrylamide (**5j**):



According to **GP-II**, the reaction of *N*-(2-iodo-5-methylphenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1j'**, 2.0 g, 5.4 mmol) with NaBH₄ (82 mg, 2.17 mmol) afforded the desired amide **5j** (793 mg) in 42% yield as a yellow liquid; *R*_f = 0.30 (3% EtOAc, 30% DCM in hexane). (86:14 mixture of isomers based on ¹⁹F NMR ratio, the minor isomer highlighted with star mark).

¹H NMR (500 MHz, CDCl₃) δ 7.73 (d, *J* = 8.1 Hz, 1H), 7.06 (s, 1H), 6.87 (d, *J* = 7.3 Hz, 1H), 3.27* (s, 0.42H), 3.22 (s, 3H), 2.31 (s, 3H), 1.93* (bs, 0.43H), 1.64 (bt, *J* = 3.0 Hz, 3H); **¹³C{¹H} NMR (126 MHz, CDCl₃)** δ 166.0 (dd, *J* = 9.1, 3.3 Hz), 153.1 (t, *J* = 290.6 Hz), 145.1, 139.8, 139.7, 130.8, 129.7 (d, *J* = 2.6 Hz), 93.9, 86.1 (dd, *J* = 21.9, 17.9 Hz), 36.8, 20.7, 11.2; **¹⁹F NMR (377 MHz, CDCl₃)** δ -(79.42–79.56) (m, 1F), -81.8* (d, *J* = 37.0 Hz, 0.17F), -(89.63–89.79) (m, 1F), -(90.31–90.46)* (m, 0.16F) ppm; **HRMS (ESI-TOF) *m/z***: [M+H]⁺ calcd. for C₁₂H₁₃F₂INO: 352.0004, found 351.9995.


3,3-Difluoro-*N*-(5-fluoro-2-iodophenyl)-*N*, 2-dimethylacrylamide (**5k**):



According to **GP-II**, the reaction of *N*-(5-fluoro-2-iodophenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1k'**, 1.18 g, 3.17 mmol) with NaBH₄ (48 mg, 1.27 mmol) afforded the desired amide **5k** (634 mg) in 56% yield as a yellow liquid; *R*_f = 0.33 (3% EtOAc, 30% DCM in hexane). (83:17 mixture of isomers based on ¹⁹F NMR ratio, the minor isomer highlighted with star mark).


¹H NMR (500 MHz, CDCl₃) δ 7.83 (dd, *J* = 8.8, 6.0 Hz 1H), 7.01 (dt, *J* = 8.8, 2.6 Hz, 1H), 6.86 (td, *J* = 8.6, 2.8 Hz, 1H), 3.28* (s, 0.49H), 3.22 (s, 3H), 1.92* (bs, 0.48H), 1.67 (bt, *J* = 3.1 Hz, 3H); **¹³C{¹H} NMR (126 MHz, CDCl₃)** δ 165.8 (dd, *J* = 9.1, 3.5 Hz), 162.9 (d, *J* = 251.0 Hz), 153.2 (t, *J* = 291.5 Hz), 146.6 (d, *J* = 9.6 Hz), 140.8 (d, *J* = 8.5 Hz), 117.5 (d, *J* = 21.5 Hz), 116.7 (dd, *J* = 22.6, 2.8 Hz), 91.5 (d, *J* = 3.8 Hz), 85.9 (dd, *J* = 22.0, 17.6 Hz), 36.8, 11.2; **¹⁹F NMR (377 MHz, CDCl₃)** δ -(78.39–78.55) (m, 1F), -81.1* (d, *J* = 35.5 Hz, 0.20F), -(88.47–88.67) (m, 1F), -89.6* (d, *J* = 35.4 Hz, 0.20F), -111.1 (bq, *J* = 6.4 Hz, 1F), -111.3 (bq, *J* = 6.4 Hz, 0.20F) ppm; **HRMS (ESI-TOF) *m/z***: [M+H]⁺ calcd. for C₁₁H₁₀F₃INO: 355.9754, found 355.9750.

N-(5-Chloro-2-iodophenyl)-3,3-difluoro-*N*, 2-dimethylacrylamide (**5l**):




According to **GP-II**, the reaction of *N*-(5-chloro-2-iodophenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**11'**, 389 mg, 1.0 mmol) with NaBH₄ (15 mg, 0.4 mmol) afforded the desired amide **5I** (181 mg) in 49% yield as a white solid; *R*_f = 0.41 (3% EtOAc, 30% DCM in hexane); Melting point: 68–70 °C. (82:18 mixture of isomers based on ¹⁹F NMR ratio, the minor isomer highlighted with star mark). ¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, *J* = 8.4 Hz, 1H), 7.26 (bs, 1H), 7.08 (bd, *J* = 8.3 Hz, 1H), 3.29* (s, 0.60H), 3.23 (s, 2.4H), 1.94* (bs, 0.54H), 1.69 (bs, 2.4H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 165.7 (dd, *J* = 9.0, 3.3 Hz), 153.2 (t, *J* = 291.7 Hz), 146.4, 140.7, 135.0, 130.1, 129.3 (d, *J* = 2.8 Hz), 95.6, 85.8 (dd, *J* = 22.0, 17.5 Hz), 36.8, 11.3; ¹⁹F NMR (377 MHz, CDCl₃) δ - (78.25–78.42) (m, 1F), -81.0* (d, *J* = 35.3 Hz, 0.22F), -(88.31–88.48) (dd, *J* = 30.7, 2.4 Hz, 1F), -89.5* (d, *J* = 35.5 Hz, 0.22F) ppm; HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. for C₁₁H₁₀ClIF₂NO: 371.9458, found 371.9455.

(*E*)-3-Fluoro-*N*-(2-iodophenyl)-*N*,2-dimethyl acrylamide (7a):



According to **GP-III**, the reaction of 3,3-difluoro-*N*-(2-iodophenyl)-*N*,2-dimethyl acrylamide (**5a**, 101 mg, 0.3 mmol) with NaBH₄ (4.5 mg, 0.12 mmol) afforded the desired amide **7a** (42 mg) in 44% yield as a white solid; *R*_f = 0.18 (3% EtOAc 30% DCM in hexane); Melting point: 60–62 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.90 (d, *J* = 7.1 Hz, 1H), 7.38 (bt, *J* = 6.8 Hz, 1H), 7.16 (bd, *J* = 6.7 Hz, 1H), 7.04 (bt, *J* = 7.8 Hz, 1H), 6.75 (d, *J* = 82.7 Hz, 1H), 3.23 (s, 3H), 1.64 (s, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 168.7 (d, *J* = 15.1 Hz), 152.7 (d, *J* = 267.6 Hz), 146.5, 140.4, 129.7, 129.5, 129.1, 116.7 (d, *J* = 9.2 Hz), 99.0, 37.4, 10.7 (d, *J* = 5.3 Hz); ¹⁹F NMR (377 MHz, CDCl₃) δ -123.6 (d, *J* = 82.0 Hz) ppm; HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. for C₁₁H₁₂FINO: 319.9942, found 319.9958.


(*E*)-3-Fluoro-*N*-(4-fluoro-2-iodophenyl)-*N*, 2-dimethylacrylamide (7b):



According to **GP-III**, the reaction of 3,3-difluoro-*N*-(4-fluoro-2-iodophenyl)-*N*,2-dimethylacrylamide (**5e**, 476 mg, 1.3 mmol) with NaBH₄ (18 mg, 0.48 mmol) afforded the desired amide **7b** (274 mg) in 63% yield as a white solid; *R*_f = 0.20 (3% EtOAc, 30% DCM in hexane); Melting point: 56–58 °C.

¹H NMR (500 MHz, CDCl₃) δ 7.58 (d, J = 6.8 Hz, 1H), 7.17–7.03 (m, 2H), 6.74 (d, J = 82.7 Hz, 1H), 3.18 (s, 3H), 1.62 (s, 3H); **¹³C{¹H} NMR (126 MHz, CDCl₃)** δ 168.6 (d, J = 15.1 Hz), 160.8 (d, J = 254.0 Hz), 152.4 (d, J = 276.2 Hz), 142.7, 129.6 (d, J = 8.6 Hz), 127.0 (d, J = 24.6 Hz), 116.7 (d, J = 22.3 Hz), 116.5 (d, J = 9.2 Hz), 98.8 (d, J = 8.5 Hz), 37.4, 10.6 (d, J = 5.3 Hz); **¹⁹F NMR (377 MHz, CDCl₃)** δ -111.4, -123.2 (bd, J = 79.4 Hz) ppm; **HRMS (ESI-TOF) m/z :** [M+H]⁺ calcd. for C₁₁H₁₁F₂INO: 337.9848, found 337.9844.


(*E*)-*N*-(4-Bromo-2-iodophenyl)-3-fluoro-*N*, 2-dimethylacrylamide (7c):



According to **GP-III**, the reaction of *N*-(4-bromo-2-iodophenyl)-3,3-difluoro-*N*,2-dimethylacrylamide (**5g**, 250 mg, 0.6 mmol) with NaBH₄ (9.0 mg, 0.24 mmol) afforded the desired amide **7c** (150 mg) in 63% yield as a white solid; R_f = 0.21 (3% EtOAc, 30% DCM in hexane); Melting point: 65–67 °C.

¹H NMR (500 MHz, CDCl₃) δ 8.04 (s, 1H), 7.51 (d, J = 8.3 Hz, 1H), 7.03 (d, J = 8.3 Hz, 1H), 6.76 (d, J = 82.4 Hz, 1H), 3.20 (s, 3H), 1.66 (s, 3H); **¹³C{¹H} NMR (126 MHz, CDCl₃)** δ 168.6 (d, J = 15.1 Hz), 152.7 (d, J = 270.4 Hz), 145.7, 142.4, 132.9, 130.0, 122.1, 116.6 (d, J = 9.4 Hz), 99.7, 37.4, 10.7 (d, J = 5.2 Hz); **¹⁹F NMR (377 MHz, CDCl₃)** δ -123.8 (d, J = 79.4 Hz) ppm; **HRMS (ESI-TOF) m/z :** [M+H]⁺ calcd. for C₁₁H₁₁BrFINO: 397.9047, found 397.9066.


(*E*)-3-Fluoro-*N*-(2-iodo-5-methylphenyl)-*N*, 2-dimethylacrylamide (7d):



According to **GP-III**, the reaction of 3,3-difluoro-*N*-(2-iodo-5-methylphenyl)-*N*,2-dimethylacrylamide (**5j**, 420 mg, 1.2 mmol) with NaBH₄ (18 mg, 0.48 mmol) afforded the desired amide **7d** (300 mg) in 75% yield as a white solid; R_f = 0.21 (3% EtOAc, 30% DCM in hexane); Melting point: 58–60 °C.

¹H NMR (500 MHz, CDCl₃) δ 7.72 (d, J = 8.1 Hz, 1H), 6.97 (s, 1H), 6.84 (d, J = 8.2 Hz, 1H), 6.76 (d, J = 80.5 Hz, 1H, one of the doublet peak merged with previous peak), 3.20 (s, 3H), 2.30 (s, 3H), 1.64 (s, 3H); **¹³C{¹H} NMR (126 MHz, CDCl₃)** δ 168.6 (d, J = 15.1 Hz), 152.5 (d, J = 270.0 Hz), 146.2, 140.1, 139.9, 130.4, 129.7, 116.6 (d, J = 9.0 Hz), 94.6, 37.3, 20.8, 10.7 (d, J = 5.3 Hz); **¹⁹F NMR (377 MHz, CDCl₃)** δ -123.8 (d, J = 89.2 Hz, 1F) ppm; **HRMS (ESI-TOF) m/z :** [M+Na]⁺ calcd. for C₁₂H₁₃FINNaO: 355.9918, found 355.9922.

(E)-N-(5-Chloro-2-iodophenyl)-3-fluoro-N, 2-dimethylacrylamide (7e):




According to **GP-III**, the reaction of *N*-(5-chloro-2-iodophenyl)-3,3-difluoro-*N*,2-dimethylacrylamide (**5l**, 175 mg, 0.47 mmol) with NaBH₄ (7.1 mg, 0.19 mmol) afforded the desired amide **7e** (96 mg) in 58% yield

as a white solid; *R*_f = 0.28 (3% EtOAc, 30% DCM in hexane); Melting point: 68–70 °C.

¹H NMR (500 MHz, CDCl₃) δ 7.81 (d, *J* = 8.5 Hz, 1H), 7.17 (s, 1H), 7.05 (d, *J* = 8.5 Hz, 1H), 6.78 (d, *J* = 82.4 Hz, 1H), 3.22 (s, 3H), 1.69 (s, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 168.5 (d, *J* = 15.2 Hz), 152.7 (d, *J* = 267.1 Hz), 147.6, 141.0, 135.4, 129.8, 129.3, 116.5 (d, *J* = 9.3 Hz), 96.3, 37.5, 10.7 (d, *J* = 5.2 Hz); ¹⁹F NMR (377 MHz, CDCl₃) δ -123.8 (d, *J* = 82.8 Hz, 1F) ppm; HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. for C₁₁H₁₁ClFINO: 353.9552, found 353.9550.

3. Experimental Procedures:


3.1 General Procedure for Palladium-Catalyzed Reductive Heck Cyclization of Di-substituted CF₃-Acrylamides (GP-IV, racemic):



Scheme S3. Reductive Heck cyclization of *o*-halo trifluoromethyl acrylamide.


General Procedure-IV (GP-IV): An oven-dried reaction vial (7.0 mL) equipped with a magnetic bead was charged with *o*-halo trifluoromethyl acrylamide (**1**, 1.0 equiv), Pd(OAc)₂ (10 mol%), HCOONa (2.5 equiv) and Ag₂CO₃ (0.4 equiv). Then the reaction vial was introduced inside the glove box and acetonitrile solvent (MeCN, 0.2 M) was added. The reaction vial was capped, taken outside, and stirred at 90 °C (oil bath/heating block) for 48 hours. After completion of the reaction (monitored by TLC), the vial was cooled to room temperature, the reaction mixture was diluted with DCM (10 mL) and filtered through a celite pad, and the filtrate was concentrated under vacuum. The crude mixture was then purified by column chromatography on silica gel (Hexane/Ethyl acetate/DCM) to afford the desired products (**2**).

Table S1. Scope study.



^aReaction Conditions: **1** (0.2 mmol), Pd(OAc)₂ (10 mol %), HCOONa (2.5 equiv), Ag₂CO₃ (0.4 equiv), MeCN (0.2 M), 90 °C, 48 h. ^b0.1 mmol reaction scale.

3.2 General Procedure for Palladium-Catalyzed Asymmetric Reductive Heck Cyclization of Di-substituted CF₃-Acrylamides (GP-V):




Scheme S4. Asymmetric reductive Heck cyclization of *o*-halo trifluoromethyl acrylamide **1**.

General Procedure-V (GP-V): An oven-dried reaction vial (7.0 mL) equipped with a magnetic bead was charged with *o*-halo trifluoromethyl acryl amide (**1**, 0.1 mmol), Pd(TFA)₂ (7 mol%), **L4** (15 mol%), HCOONa (0.25 mmol) and K₃PO₄ (0.04 mmol). Then, the reaction vial was introduced inside the glove box, and acetonitrile solvent (MeCN, 0.1 M) was added. The reaction vial was

capped, taken outside and stirred at 60 °C (oil bath/heating block) for 48 hours. After completion of the reaction (monitored by TLC), the vial was cooled to room temperature, the reaction mixture was diluted with DCM (10 mL) and filtered through a celite pad, and the filtrate was concentrated under vacuum. The crude mixture was then purified by column chromatography on silica gel (Hexane/Ethyl acetate/DCM) to afford the desired products.

3.6 General Procedure for Palladium-Catalyzed Reductive Heck of Tri-substituted β -Phenyl-CF₃-Acrylamides (GP-VI, racemic):




Scheme S5. Reductive Heck cyclization of *o*-halo β -phenyl trifluoromethyl acrylamides.

General procedure-VI (GP-VI): An oven-dried reaction vial (7.0 mL) equipped with a magnetic bead was charged with *o*-iodo β -phenyl trifluoromethyl acryl amides (**3**, 0.1 mmol), Pd(PPh₃)₄ (10 mol%), HCOONa (0.25 mol), Ag₂CO₃ (0.03 mmol) and K₃PO₄ (0.04 mmol). Then the reaction vial was introduced inside the glove box and acetonitrile solvent (MeCN, 0.1 M) was added. The reaction vial was capped, taken outside and stirred at 100 °C (oil bath/heating block) for 48 hours. After completion of the reaction (monitored by TLC), the vial was cooled to room temperature, the reaction mixture was diluted with DCM (10 mL) and filtered through a celite pad, and the filtrate was concentrated under vacuum. The crude mixture was then purified by column chromatography on silica gel (Hexane/Ethyl acetate/DCM) to afford the desired products (**4**).


Note: Compounds **4a–b** and **4d** reported in the literature.^{2,6}

Table S2. Scope study.^a



^aReaction Conditions: **3** (0.1 mmol), Pd(PPh₃)₄ (10 mol%), HCOONa (2.5 equiv), K₃PO₄ (0.4 equiv), Ag₂CO₃ (0.3 equiv), MeCN (0.1 M), 100 °C, 48 h. ^bPd(TFA)₂ (7.0 mol%) at 70 °C.


3.7 General Procedure for Palladium-Catalyzed Asymmetric Reductive Heck of Tri-substituted β -Phenyl-CF₃-Acrylamides (GP-VII):



Scheme S6. Asymmetric Reductive Heck cyclization of *o*-halo β -phenyl trifluoromethyl acrylamides.

General Procedure- VII (GP- VII): An oven-dried reaction vial (7.0 mL) equipped with a magnetic bead was charged with *o*-iodo β -phenyl trifluoromethyl acryl amides (**3**, 1.0 equiv), Pd(TFA)₂ (7 mol%), **L**₃ (20 mol%), HCOONa (2.5 equiv) and Ag₂CO₃ (0.3 equiv) and K₃PO₄ (0.4 equiv). Then the reaction vial was introduced inside the glove box and acetonitrile solvent (MeCN, 0.1 M) was added. The reaction vial was capped, taken outside and stirred at 70 °C (oil bath/heating block) for 48 hours. After completion of the reaction (monitored by TLC), the vial was cooled to room temperature, the reaction mixture was diluted with DCM (10 mL) and filtered through a celite pad, and the filtrate was concentrated under vacuum. The crude mixture was then purified by column chromatography on silica gel (Hexane/Ethyl acetate/DCM) to afford the desired products (**4**).


3.8 General Procedure for Palladium-Catalyzed Reductive Heck of Tri/Tetra-substituted *gem*-Difluoro and Monofluoro-Acrylamides (GP-VIII, racemic):



Scheme S7. Reductive Heck cyclization of *o*-iodo *gem*-difluoromethyl and monofluoromethyl acrylamide.

General Procedure-VIII (GP-VIII): An oven-dried reaction vial (7.0 mL) equipped with a magnetic bead was charged with *o*-iodo *gem*-difluoro (**5**) or monofluoro methyl acrylamide (**7**) (1.0 equiv), Pd(TFA)₂ (10 mol%), HCOONa (2.5 equiv), K₃PO₄ (0.4 equiv). Then the reaction vial was introduced inside the glove box and acetonitrile solvent (MeCN, 0.1 M) was added. The reaction vial was capped, taken outside and stirred at 90-120 °C (oil bath/heating block) for 48 hours. After completion of the reaction (monitored by TLC), the vial was cooled to room temperature, the reaction mixture was diluted with DCM (10 mL) and filtered through a celite pad, and the filtrate was concentrated under vacuum. The crude mixture was then purified by column chromatography on silica gel (Hexane/Ethyl acetate/DCM) to afford the desired products (**6/8**).


Table S3. Scope study.



^a**Reaction Conditions:** **5** (0.2 mmol), Pd(TFA)₂ (15 mol%), HCOONa (2.5 equiv), K₃PO₄ (1.5 equiv), MeCN (0.2 M), 120 °C, 36 h. ^b(0.15 mmol), MeCN (0.15 M). ^c(0.1 mmol), MeCN (0.1 M).

^d**Reaction Conditions:** **7** (0.1 mmol), Pd(TFA)₂ (10 mol%), HCOONa (2.5 equiv), K₃PO₄ (1.5 equiv), MeCN (0.1 M), 90 °C, 36 h.

3.9 General Procedure for Palladium-Catalyzed Asymmetric Reductive Heck of Tetra-substituted *gem*-Difluoro Acrylamides (GP-IX):




Scheme S8. Asymmetric reductive Heck cyclization of *o*-iodo *gem*-difluoro acrylamide.

General Procedure- IX (GP- IX): An oven-dried reaction vial (7.0 mL) equipped with a magnetic bead was charged with *o*-iodo *gem*-difluoro acrylamides (**5**, 1.0 equiv), Pd(TFA)₂ (7 mol%), **L₅** (15 mol%), HCOONa (2.5 equiv) and Ag₃PO₄ (0.5 equiv). Then the reaction vial was introduced

inside the glove box and acetonitrile solvent (MeCN, 0.1 M) was added. The reaction vial was capped, taken outside and stirred at desired temperature (oil bath/heating block) for 48 hours. After completion of the reaction (monitored by TLC), the vial was cooled to room temperature, the reaction mixture was diluted with DCM (10 mL) and filtered through a celite pad, and the filtrate was concentrated under vacuum. The crude mixture was then purified by column chromatography on silica gel (Hexane/Ethyl acetate/DCM) to afford the desired products (**6**).

3.10 General Procedure for Palladium-Catalyzed Asymmetric Reductive Heck of Tri-substituted Monofluoro Acrylamides (GP-X):





Scheme S9. Asymmetric reductive Heck cyclization of *o*-iodo monofluoro acrylamide.

General Procedure-X (GP-X): An oven-dried reaction vial (7.0 mL) equipped with a magnetic bead was charged with *o*-iodo monofluoromethyl acrylamide (**7**, 1.0 equiv), Pd(TFA)₂ (7 mol%), **L**₅ (20 mol%), HCOONa (2.5 equiv) and Ag₃PO₄ (0.4 equiv). Then, the reaction vial was introduced inside the glove box, and acetonitrile solvent (MeCN, 0.1 M) was added. The reaction vial was capped, taken outside and stirred at 35 °C (oil bath/heating block) for 48 hours. After completion of the reaction (monitored by TLC), the vial was cooled to room temperature, the reaction mixture was diluted with DCM (10 mL) and filtered through a celite pad, and the filtrate was concentrated under vacuum. The crude mixture was then purified by column chromatography on silica gel (Hexane/Ethyl acetate/DCM). Afterward, all the compounds were further purified by preparative HPLC (Shim-pack, SHIMADZU, C18 column, 70% acetonitrile in water, flow rate 20 mL/min, T = 25 °C, λ = 254 nm) to afford the desired products (**8**).

4. Optimization of Reaction Conditions:

Table S4: Optimization of Asymmetric Reaction Conditions for Di-substituted Trifluoromethyl Acrylamides^a




Entry	Metal	Ligand	[H]	Additive	Solvent	Conversion(%) ^b	ee ^c %
1	Pd(OAc) ₂	L ₁	HCOONa	K ₃ PO ₄	MeCN	<5	14
2	Pd(OAc) ₂	L ₂	HCOONa	K ₃ PO ₄	MeCN	<5	<5
3	Pd(OAc) ₂	L ₃	HCOONa	K ₃ PO ₄	MeCN	60	90
4	Pd(OAc) ₂	L ₄	HCOONa	K ₃ PO ₄	MeCN	50	96
5	Pd(OAc) ₂	L ₅	HCOONa	K ₃ PO ₄	MeCN	<5	-8
6	Pd(OAc) ₂	L ₆	HCOONa	K ₃ PO ₄	MeCN	30	<5
7	Pd(OAc) ₂	L ₇	HCOONa	K ₃ PO ₄	MeCN	10	15
8	Pd(OAc) ₂	L ₈	HCOONa	K ₃ PO ₄	MeCN	45	<5
9	Pd(OAc) ₂	L ₉	HCOONa	K ₃ PO ₄	MeCN	89	-12
10 ^d	Pd(OAc) ₂	L ₄	HCOONa	K ₃ PO ₄	MeCN	76 ^e	95 ^e
11 ^d	Pd(OAc) ₂	L ₄	HCOONH₄	K ₃ PO ₄	MeCN	10	90
12 ^d	Pd(OAc) ₂	L ₄	HSiEt₃	K ₃ PO ₄	MeCN	27	40
13 ^d	Pd(OAc) ₂	L ₄	HCOONa	Cs₂CO₃	MeCN	56	97
14 ^d	Pd(OAc) ₂	L ₄	HCOONa	Ag₂CO₃	MeCN	62 ^e	96 ^e
15 ^d	Pd(OAc) ₂	L ₄	HCOONa	K ₃ PO ₄	1,4-Dioxane	10	-20

16 ^d	Pd(OAc) ₂	L ₄	HCOONa	K ₃ PO ₄	DMA	25	64
17 ^d	Pd(OAc) ₂	L ₄	HCOONa	K ₃ PO ₄	Toluene	18	-38
18 ^d	Pd(OAc) ₂	-	HCOONa	K ₃ PO ₄	MeCN	65	-
19 ^d	Pd(OAc) ₂	L ₄	-	K ₃ PO ₄	MeCN	NR	-
20 ^d	Pd(OAc) ₂	L ₄	HCOONa	-	MeCN	17	94
21 ^d	Pd(acac)₂	L ₄	HCOONa	K ₃ PO ₄	MeCN	88	96
22 ^d	Pd(TFA)₂	L ₄	HCOONa	K ₃ PO ₄	MeCN	>98	97
23 ^d	Pd₂dba₃	L ₄	HCOONa	K ₃ PO ₄	MeCN	95	96
24 ^{f, g}	Pd(TFA) ₂	L ₄	HCOONa	K ₃ PO ₄	MeCN	88	95
25 ^{g, h}	Pd(TFA) ₂	L ₄	HCOONa	K ₃ PO ₄	MeCN	96	95
26 ^{g, i}	Pd(TFA)₂	L₄	HCOONa	K₃PO₄	MeCN	>98 (89)^e	96 (94)^e
27 ^{g, j}	Pd(TFA) ₂	L ₄	HCOONa	K ₃ PO ₄	MeCN	>98	91
28 ^{g, i}	Pd(TFA) ₂	L ₄	DMP	K ₃ PO ₄	MeCN	10	91
29 ^{g, i}	Pd(TFA) ₂	L ₄	<i>L</i> -Menthol	K ₃ PO ₄	MeCN	-	-
30 ^{g, i}	Pd(TFA) ₂	L ₄	IPA	K ₃ PO ₄	MeCN	-	-
31 ^{g, i}	Pd(TFA) ₂	L ₄	HCOONa	Na ₃ PO ₄	MeCN	33	94
32 ^{g, i}	Pd(TFA) ₂	L ₄	HCOONa	Ag ₃ PO ₄	MeCN	>90	94

^a**Reactions Conditions:** Reaction conditions: **1a** (0.025 mmol), [**Pd**] (5 mol%), **L_n^{*}** (10 mol%), [**H**] (2.5 equiv), additive (0.4 equiv), solvent (0.05 M) at 60 °C for 48 h. ^bCrude ¹⁹F NMR conversion. ^cEnantiomeric excess (*ee*) determined by chiral HPLC. ^d[**Pd**] (10 mol%), **L₄** (20 mol%). ^e0.1 mmol scale, isolated yield. ^f[**Pd**] (5 mol%), **L₄** (10 mol%). ^g0.05 mmol reaction scale. ^h[**Pd**] (5 mol%), **L₄** (15 mol%). ⁱ[**Pd**] (7 mol%), **L₄** (15 mol%), ^j[**Pd**] (7 mol%), **L₄** (10 mol%). NR = No Reaction. DMP = 2,4-Dimethyl-3-pentanol, IPA = Isopropanol.

Table S5: Optimization of Asymmetric Reaction Conditions for Tri-substituted β -Phenyl Trifluoromethyl Acrylamides^a




Entry	Metal	Ligand	[H]	Additive	Solvent	Conversion(%) ^b	ee ^c %
1	Pd(TFA) ₂	L ₁	HCOONa	K ₃ PO ₄	MeCN	63	-32
2	Pd(TFA) ₂	L ₃	HCOONa	K ₃ PO ₄	MeCN	36	85
3	Pd(TFA) ₂	L ₄	HCOONa	K ₃ PO ₄	MeCN	30	31
4	Pd(TFA) ₂	L ₅	HCOONa	K ₃ PO ₄	MeCN	29	-10
5	Pd(TFA) ₂	L ₁₀	HCOONa	K ₃ PO ₄	MeCN	48	06
6	Pd(TFA) ₂	L ₁₁	HCOONa	K ₃ PO ₄	MeCN	27	72
7 ^d	Pd(TFA) ₂	L ₃	HCOONa	K ₃ PO ₄	MeCN	28	82
8 ^e	Pd(TFA) ₂	L ₃	HCOONa	K ₃ PO ₄	MeCN	20	52
9 ^e	Pd(OAc) ₂	L ₃	HCOONa	K ₃ PO ₄	MeCN	58	18
10 ^e	Pd(allyl)Cl ₂	L ₃	HCOONa	K ₃ PO ₄	MeCN	23	78
11 ^{f, g}	Pd(TFA) ₂	L ₃	HCOONa	K ₃ PO ₄ (0.4 equiv)+Ag ₂ CO ₃ (0.3 equiv)	MeCN	42	83
12 ^{f, h}	Pd(TFA) ₂	L ₃	HCOONa	K ₃ PO ₄ (0.4 equiv)+Ag ₂ CO ₃ (0.3 equiv)	MeCN	49	26
13 ^{f, i}	Pd(TFA) ₂	L ₃	HCOONa	K ₃ PO ₄ (0.4 equiv)+Ag ₂	MeCN	56	20

				CO ₃ (0.3 equiv)			
14 ^{f, g}	Pd(TFA) ₂	L ₃	HCOONa	Ag ₂ CO ₃ (1.0 equiv)	MeCN	<5	16

^a**Reaction Conditions:** **3a** (0.025 mmol), [**Pd**] (7 mol%), **L_n^{*}** (15 mol%), HCOONa (2.5 equiv), additive (0.4 equiv), solvent (0.05 M) at 60 °C for 48 h. ^bCrude ¹⁹F NMR conversion. ^cEnantiomeric excess (*ee*) determined by chiral HPLC. ^d[**Pd**] (10 mol%), **L₃** (15 mol%), ^e[**Pd**] (10 mol%), **L₃** (20 mol). ^f[**Pd**] (7.0 mol%), **L₃** (20 mol%), ^g70 °C. ^h75 °C. ⁱ80 °C.

Table S6: Optimization of Asymmetric Reaction Conditions for Tetra-substituted *gem*-Difluoromethyl Acrylamides^a



Entry	Metal	Ligand	[H]	Additive	Solvent	Yield ^b %	<i>ee</i> ^c %
1	Pd(TFA) ₂	L1	HCOONa	K ₃ PO ₄	MeCN	05	40
2	Pd(TFA) ₂	L3	HCOONa	K ₃ PO ₄	MeCN	04	-36
3	Pd(TFA) ₂	L4	HCOONa	K ₃ PO ₄	MeCN	04	15
4	Pd(TFA) ₂	L5	HCOONa	K ₃ PO ₄	MeCN	13	59
5	Pd(TFA) ₂	L7	HCOONa	K ₃ PO ₄	MeCN	16	20
6	Pd(TFA) ₂	L8	HCOONa	K ₃ PO ₄	MeCN	20	<5
7	Pd(TFA) ₂	L10	HCOONa	K ₃ PO ₄	MeCN	69	17


8	Pd(TFA) ₂	L₁₂	HCOONa	K ₃ PO ₄	MeCN	33	<5
9	Pd(TFA) ₂	L₁₅	HCOONa	K ₃ PO ₄	MeCN	20	<5
10 ^d	Pd(TFA) ₂	L ₅	HCOONa	Ag ₂ CO ₃	MeCN	19	94
11 ^d	Pd(TFA) ₂	L ₅	HCOONa	AgNO ₃	MeCN	15	90
12 ^d	Pd(TFA) ₂	L ₅	HCOONa	Ag ₃ PO ₄	MeCN	17	96
13 ^e	Pd(TFA) ₂	L ₅	HCOONa	Ag ₃ PO ₄	MeCN	49	94
14^f	Pd(TFA)₂	L₅	HCOONa	Ag₃PO₄	MeCN	70	93

^a**Reactions Conditions:** Reaction conditions: **5a** (0.025 mmol), Pd(TFA)₂ (7 mol%), **L_n**^{*} (15 mol%), HCOONa (2.5 equiv), K₃PO₄ (0.4 equiv), MeCN (0.05 M) at 60 °C for 48 h. ^bCrude ¹H NMR yield (yields measured with tri-methoxybenzene as internal standard). ^cEnantiomeric excess (*ee*) determined by chiral HPLC. ^dAt 50 °C. ^eAt 60 °C. ^f**5a** (0.1 mmol) at 70 °C, 48 h, isolated yield.

5. Characterization data and HPLC Spectra of Products:

Di-substituted Trifluoromethyl Acrylamides (2):

(*S*)-1,3-Dimethyl-3-(trifluoromethyl)indolin-2-one (2a):⁵



According to **GP-V**, the reaction of *N*-(2-bromophenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide **1a** (31 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), *S*-PHOX (**L₄**, 5.6 mg, 15 mol%), HCOONa (17 mg, 0.25 mmol) and K₃PO₄ (8.5 mg, 0.04 mmol) afforded **2a** (20.3 mg) in 89% yield and 94% *ee* as a white solid; *R_f* = 0.50 (3% EtOAc, 30% DCM in hexane). Melting point: 59–61 °C. For 1.0 mmol reaction, **2a** (218.3 mg) in 95% yield and 96% *ee*.

¹H NMR (500 MHz, CDCl₃) δ 7.42–7.35 (m, 2H), 7.12 (t, *J* = 7.6 Hz, 1H), 6.89 (d, *J* = 8.0 Hz, 1H), 3.25 (s, 3H), 1.64 (s, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 172.3 (q, *J* = 2.1 Hz) 143.7, 129.9, 126.2, 124.9 (q, *J* = 281.8 Hz), 124.5, 123.2, 108.6, 52.1 (q, *J* = 27.6 Hz), 26.6, 17.7 (q, *J* = 2.2 Hz); ¹⁹F{¹H} NMR (471 MHz, CDCl₃) δ -73.6 ppm; HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. for C₁₁H₁₁F₃NO: 230.0787, found 230.0783.

Enantiomeric excess = 94%, determined by HPLC (Daicel Chiralpak OJ-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 25 °C, λ = 254 nm): t_R = 20.45 min (major), t_R = 21.79 min (minor). $[\alpha]_D^{26.3}$ = +17° (c = 10⁻³, CHCl₃).





Figure S5. HPLC chromatograms for racemic **2a** and enantioenriched **2a**.

(S)-1-Benzyl-3-methyl-3-(trifluoromethyl)indolin-2-one (2b):



According to **GP-V**, the reaction of *N*-benzyl-*N*-(2-bromophenyl)-2-(trifluoromethyl)acrylamide **1b** (38 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), *S*-PHOX (**L4**, 5.6 mg, 15 mol%), HCOONa (17 mg, 0.25 mmol) and K₃PO₄ (8.5 mg, 0.04 mmol) afforded **2b** (30.4 mg) in >99% yield and 98% *ee* as a white solid; R_f = 0.64 (3% EtOAc, 30% DCM in hexane);

Melting point: 46–48 °C.

¹H NMR (500 MHz, CDCl₃) δ 7.30 (d, J = 7.3 Hz, 1H), 7.26–7.21 (m, 2H), 7.20–7.14 (m, 4H), 7.00 (t, J = 7.5 Hz, 1H), 6.66 (d, J = 7.8 Hz, 1H), 4.99 (d, J = 15.7 Hz, 1H), 4.73 (d, J = 15.7 Hz, 1H), 1.63 (s, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 172.5 (bq, J = 2.3 Hz), 142.7, 135.1, 129.8, 128.9, 127.8, 127.0, 126.2, 125.0 (q, J = 281.8 Hz), 124.6, 123.2, 109.6, 52.2 (q, J = 27.6 Hz), 43.9, 17.9 (bq, J = 2.3 Hz); ¹⁹F{¹H} NMR (471 MHz, CDCl₃) δ -73.5 ppm; HRMS (ESI-TOF) m/z : [M+H]⁺ calcd. for C₁₇H₁₅F₃NO: 306.1100, found 306.1104.

Enantiomeric excess = 98%, determined by HPLC (Daicel Chiralpak OJ-H Column, 2.5% *i*PrOH in *n*-Hexane, flow rate 1.0 mL/min, T = 25 °C, λ = 254 nm): t_R = 11.71 min (major), t_R = 30.92 min (minor). $[\alpha]_D^{28.4}$ = +2° (c = 10⁻³, CHCl₃).





Figure S6. HPLC chromatograms for racemic **2b** and enantioenriched **2b**.

(S)-5-Methoxy-1,3-dimethyl-3-(trifluoromethyl)indolin-2-one (2c):



According to **GP-V**, the reaction of *N*-(2-bromo-4-methoxyphenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide **1c** (34 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), *S*-PHOX (**L4**, 5.6 mg, 15 mol%), HCOONa (17 mg, 0.25 mmol) and K₃PO₄ (8.5 mg, 0.04 mmol) afforded **2c** (23.4 mg) in 90% yield and 97% *ee* as a white solid; R_f = 0.42 (3% EtOAc, 30% DCM in hexane); Melting point: 59–61 °C.

¹H NMR (500 MHz, CDCl₃) 6.98 (bs, 1H), 6.90 (dd, J = 8.5, 2.5 Hz, 1H), 6.79 (d, J = 8.5 Hz, 1H), 3.81 (s, 3H), 3.22 (s, 3H), 1.63 (s, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 171.9 (bq, J = 2.1 Hz), 156.3, 137.0, 127.4, 124.9 (q, J = 281.8 Hz), 114.0, 112.0, 108.9, 55.8, 52.4 (q, J = 27.6 Hz), 26.6, 17.8 (bq, J = 2.2 Hz); ¹⁹F{¹H} NMR (471 MHz, CDCl₃) δ -73.6 ppm; HRMS (ESI-TOF) m/z : [M+H]⁺ calcd. for C₁₂H₁₃F₃NO₂: 260.0893, found 260.0911.

Enantiomeric excess = 97%, determined by HPLC (Daicel Chiralpak OD-H Column, 2.5% *i*PrOH in *n*-Hexane, flow rate 1.0 mL/min, T = 15 °C, λ = 254 nm): t_R = 10.13 min (major), t_R = 12.77 min (minor). $[\alpha]_D^{28} = +31^\circ$ ($c = 10^{-3}$, CHCl₃).





Figure S7. HPLC chromatograms for racemic **2c** and enantioenriched **2c**.

(S)-1,3,5-Trimethyl-3-(trifluoromethyl)indolin-2-one (2d):



According to **GP-V**, the reaction of *N*-(2-bromo-4-methylphenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide **1d** (32.2 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), *S*-PHOX (**L4**, 5.6 mg, 15 mol%), HCOONa (17 mg, 0.25 mmol) and K₃PO₄ (8.5 mg, 0.04 mmol) afforded **2d** (20.2 mg) in 83% yield and 99% *ee* as a white solid; R_f = 0.50 (3% EtOAc, 30% DCM in hexane); Melting point: 81–83 °C.

¹H NMR (500 MHz, CDCl₃) δ 7.20–7.15 (m, 2H), 6.77 (d, J = 7.8 Hz, 1H), 3.22 (s, 3H), 2.36 (s, 3H), 1.63 (s, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 172.2 (q, J = 3.3 Hz), 141.2, 132.8, 130.1, 126.2, 125.3, 125.0 (q, J = 282.0 Hz), 108.3, 52.2 (q, J = 27.5 Hz), 26.6, 21.1, 17.8 (q, J = 2.1 Hz); ¹⁹F{¹H} NMR (471 MHz, CDCl₃) δ -73.6 ppm; HRMS (ESI-TOF) m/z : [M+H]⁺ calcd. for C₁₂H₁₃F₃NO: 244.0944, found 244.0942.

Enantiomeric excess = 99%, determined by HPLC (Daicel Chiralpak OD-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 15 °C, λ = 254 nm): t_R = 16.64 min (major), t_R = 20.76 min (minor). $[\alpha]_D^{26.7} = +29^\circ$ ($c = 10^{-3}$, CHCl₃).





Figure S8. HPLC chromatograms for racemic **2d** and enantioenriched **2d**.

(S)-5-Fluoro-1,3-dimethyl-3-(trifluoromethyl)indolin-2-one (2e):



Using the above method **GP-V**, the reaction of *N*-(2-Bromo-4-fluorophenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1e**; 32.6 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), *S*-PHOX (**L4**, 5.6 mg, 15 mol%), HCOONa (17 mg, 0.25 mmol) and K₃PO₄ (8.5 mg, 0.04 mmol) afforded the **2e** (13.1 mg) in 53% yield and 91% *ee* as a white solid; *R*_f = 0.46 (3% EtOAc, 30% DCM in hexane); Melting point: 76–78 °C.

¹H NMR (500 MHz, CDCl₃) δ 7.16–7.06 (m, 2H), 6.82 (dd, *J* = 8.3, 3.8 Hz, 1H), 3.24 (s, 3H), 1.64 (s, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 171.8 (bd, *J* = 1.3 Hz), 159.3 (d, *J* = 242.1 Hz), 139.6 (d, *J* = 2.0 Hz), 127.5 (d, *J* = 8.3 Hz), 124.6 (q, *J* = 281.8 Hz), 116.2 (d, *J* = 23.5 Hz), 112.9 (d, *J* = 25.6 Hz), 109.2 (d, *J* = 8.1 Hz), 52.5 (qd, *J* = 29.1, 1.5 Hz), 26.7, 17.7 (bq, *J* = 2.4 Hz); ¹⁹F{¹H} NMR (471 MHz, CDCl₃) δ -73.6, -119.3 ppm; HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. for C₁₁H₁₀F₄NO: 248.0693, found 248.0688.

Enantiomeric excess = 91%, determined by HPLC (Daicel Chiralpak OJ-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 15 °C, λ = 254 nm): *t*_R = 32.38 min (major), *t*_R = 44.10 min (minor). [α]_D^{28.5} = +6° (c = 5·10⁻⁴, CHCl₃).





Figure S9. HPLC chromatograms for racemic **2e** and enantioenriched **2e**.

(S)-5-Chloro-1,3-dimethyl-3-(trifluoromethyl)indolin-2-one (2f**):**



According to **GP-V**, the reaction of *N*-(2-Bromo-4-chlorophenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1f**; 34 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), *S*-PHOX (**L4**, 5.6 mg, 15 mol%), HCOONa (17 mg, 0.25 mmol) and K₃PO₄ (8.5 mg, 0.04 mmol) afforded **2f** (23.5 mg) in 89% yield and 91% *ee* as a white solid; *R*_f = 0.54 (3% EtOAc, 30% DCM in hexane); Melting point: 68–70 °C.

¹H NMR (500 MHz, CDCl₃) δ 7.39–7.33 (m, 2H), 6.82 (d, *J* = 8.2 Hz, 1H), 3.23 (s, 3H), 1.64 (s, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 171.7 (d, *J* = 1.7 Hz), 142.2, 130.0, 128.6, 127.7, 125.1, 124.6 (q, *J* = 281.9 Hz), 109.5, 52.3 (q, *J* = 28.0 Hz), 26.7, 17.7 (bq, *J* = 2.1 Hz); ¹⁹F{¹H} NMR (471 MHz, CDCl₃) δ -73.6 ppm; HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. for C₁₁H₁₀ClF₃NO: 264.0398, found 264.0406.

Enantiomeric excess = 91%, determined by HPLC (Daicel Chiralpak OD-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 15 °C, λ = 254 nm): *t*_R = 23.92 min (major), *t*_R = 33.75 min (minor). [α]_D^{27.4} = +40° (c = 5·10⁻⁴, CHCl₃).





Figure S10. HPLC chromatograms for racemic **2f** and enantioenriched **2f**.

(S)-5-Bromo-1,3-dimethyl-3-(trifluoromethyl)indolin-2-one (2g**):**



According to **GP-V**, the reaction of *N*-(4-bromo-2-iodophenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1g'**; 86.8 mg, 0.2 mmol) using Pd(TFA)₂ (4.65 mg, 7 mol%), *S*-PHOX (**L4**, 11.2 mg, 15 mol%), HCOONa (34 mg, 0.5 mmol) and K₃PO₄ (17 mg, 0.08 mmol) afforded **2g** (39.6 mg) in 59% yield and 94% *ee* as a white solid; *R*_f = 0.54 (3% EtOAc, 30% DCM in hexane); Melting point: 97–99 °C.

¹H NMR (500 MHz, CDCl₃) δ 7.51 (bd, *J* = 8.3 Hz, 1H), 7.48 (bs, 1H), 6.77 (d, *J* = 8.2 Hz, 1H), 3.23 (s, 3H), 1.64 (s, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 171.6 (bq, *J* = 2.0 Hz), 142.7, 132.8, 128.0, 127.8, 124.6 (q, *J* = 281.9 Hz), 115.7, 110.0, 52.2 (q, *J* = 27.9 Hz), 26.7, 17.7 (q, *J* = 1.8 Hz); ¹⁹F NMR (377 MHz, CDCl₃) δ -73.4 ppm; HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. for C₁₁H₁₀BrF₃NO: 307.9892, found 307.9889.

Enantiomeric excess = 94%, determined by HPLC (Daicel Chiralpak OJ-H Column, 2.5% *i*PrOH in *n*-Hexane, flow rate 1.0 mL/min, T = 25 °C, λ = 254 nm): *t*_R = 14.09 min (major), *t*_R = 27.16 min (minor). [α]_D^{28.7} = +30° (c = 5·10⁻⁴, CHCl₃).





Figure S11. HPLC chromatograms for racemic **2g** and enantioenriched **2g**.

(S)-1,3-Dimethyl-3,5-bis(trifluoromethyl)indolin-2-one (2h):



According to **GP-V**, the reaction of *N*-(2-bromo-4-(trifluoromethyl)phenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1h**; 37.6 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), *S*-PHOX (**L4**, 5.6 mg, 15 mol%), HCOONa (17 mg, 0.25 mmol) and K₃PO₄ (8.5 mg, 0.04 mmol) afforded **2h** (14.2 mg)

in 48% yield and 97% *ee* as a white solid; *R*_f = 0.54 (3% EtOAc, 30% DCM in hexane); Melting point: 82–84 °C.

¹H NMR (500 MHz, CDCl₃) δ 7.68 (d, *J* = 8.2 Hz, 1H), 7.60 (s, 1H), 6.98 (d, *J* = 8.1 Hz, 1H), 3.28 (s, 3H), 1.68 (s, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 172.1 (bq, *J* = 2.1 Hz), 146.6, 127.7 (q, *J* = 3.8 Hz), 126.7, 125.6 (q, *J* = 33.1 Hz), 124.6 (q, *J* = 276.5 Hz), 124.0 (q, *J* = 271.6 Hz), 121.7 (q, *J* = 3.7 Hz), 108.5, 52.1 (q, *J* = 28.1 Hz), 26.8, 17.6 (bq, *J* = 1.9 Hz); ¹⁹F{¹H} NMR (471 MHz, CDCl₃) δ -61.7, -73.5 ppm; HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. for C₁₂H₁₀F₆NO: 298.0661, found 298.0668.

Enantiomeric excess = 97%, determined by HPLC (Daicel Chiralpak OD-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 15 °C, λ = 254 nm): *t*_R = 26.90 min (major), *t*_R = 31.19 min (minor). [α]_D²⁸ = +2° (c = 5·10⁻⁴, CHCl₃).





Figure S12. HPLC chromatograms for racemic **2h** and enantioenriched **2h**.

(S)-1,3-Dimethyl-5-(trifluoromethoxy)-3-(trifluoromethyl)indolin-2-one (2i**):**



According to **GP-V**, the reaction of *N*-(2-bromo-4-(trifluoromethoxy)phenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1i**; 39.2 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), *S*-PHOX (**L4**, 5.6 mg, 15 mol%), HCOONa (17 mg, 0.25 mmol) and K₃PO₄ (8.5 mg, 0.04 mmol) afforded **2i** (19.7 mg) in 63% yield and 98% *ee* as a yellow liquid; *R*_f = 0.54 (3% EtOAc, 30% DCM in hexane).

¹H NMR (500 MHz, CDCl₃) δ 7.30–7.24 (m, 2H), 6.89 (d, *J* = 8.2 Hz, 1H), 3.26 (s, 3H), 1.66 (s, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 171.9 (bq, *J* = 1.8 Hz), 145.0, 142.4, 127.5, 124.5 (q, *J* = 281.8 Hz), 123.1, 120.5 (q, *J* = 257.1 Hz), 118.7, 109.1, 52.4 (q, *J* = 28.0 Hz), 26.8, 17.7 (bq, *J* = 2.1 Hz); ¹⁹F{¹H} NMR (471 MHz, CDCl₃) δ -58.5, -73.6 ppm; HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. for C₁₂H₁₀F₆NO₂: 314.0610, found 314.0610.

Enantiomeric excess = 98%, determined by HPLC (Daicel Chiralpak OJ-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 15 °C, λ = 254 nm): *t*_R = 17.90 min (major), *t*_R = 27.94 min (minor). [α]_D^{28.6} = +13° (c = 10⁻³, CHCl₃).





Figure S13. HPLC chromatograms for racemic **2i** and enantioenriched **2i**.

(S)-1,3-Dimethyl-2-oxo-3-(trifluoromethyl)indoline-5-carbonitrile (2j**):**



According to **GP-V**, the reaction of *N*-(2-bromo-4-cyanophenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1j**; 33.3 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), *S*-PHOX (**L4**, 5.6 mg, 15 mol%), HCOONa (17 mg, 0.25 mmol), K₃PO₄ (42.5 mg, 0.2 mmol) and Ag₂CO₃ (55.2 mg, 0.2 mmol) afforded **2j** (17 mg) in 67% yield and 93% *ee* as a white solid; *R*_f = 0.17 (3% EtOAc, 30% DCM in hexane); Melting point: 123–125 °C.

¹H NMR (500 MHz, CDCl₃) δ 7.72 (dd, *J* = 8.2, 1.5 Hz, 1H), 7.63 (s, 1H), 6.98 (d, *J* = 8.2 Hz, 1H), 3.28 (s, 3H), 1.67 (s, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 171.7 (bq, *J* = 2.0 Hz), 147.4, 135.1, 128.0, 127.1, 124.3 (q, *J* = 281.9 Hz), 118.4, 109.2, 106.6, 51.9 (q, *J* = 28.3 Hz), 26.8, 17.5 (bq, *J* = 1.9 Hz); ¹⁹F{¹H} NMR (471 MHz, CDCl₃) δ -73.5 ppm; HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. for C₁₂H₁₀F₃N₂O: 255.0740, found 255.0755.

Enantiomeric excess = 93%, determined by HPLC (Daicel Chiralpak OD-H Column, 3% *i*PrOH in *n*-Hexane, flow rate 1.3 mL/min, T = 15 °C, λ = 254 nm): *t*_R = 16.72 min (minor), *t*_R = 18.80 min (major). [α]_D²⁸ = +36° (c = 5·10⁻⁴, CHCl₃).





Figure S14. HPLC chromatograms for racemic **2j** and enantioenriched **2j**.

Methyl (*S*)-1,3-dimethyl-2-oxo-3-(trifluoromethyl)indoline-5-carboxylate (2k**):**



According to **GP-V**, the reaction of methyl 3-bromo-4-(*N*-methyl-2-(trifluoromethyl)acrylamido)benzoate (**1k**; 36.6 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), *S*-PHOX (**L4**, 5.6 mg, 15 mol%), HCOONa (17 mg, 0.25 mmol) and K₃PO₄ (8.5 mg, 0.04 mmol) afforded the desired amide **2k** (27.4 mg) in 95% yield and 96% *ee* as a white solid; *R*_f = 0.32 (3% EtOAc, 30% DCM in hexane); Melting point: 96–98 °C.

¹H NMR (500 MHz, CDCl₃) δ 8.14 (dd, *J* = 8.2, 1.6 Hz, 1H), 8.04 (s, 1H), 6.94 (d, *J* = 8.2 Hz, 1H), 3.92 (s, 3H), 3.28 (s, 3H), 1.67 (s, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 172.5 (q, *J* = 1.8 Hz), 166.3, 147.6, 132.5, 126.1, 125.9, 125.3, 124.6 (q, *J* = 281.3 Hz), 108.2, 52.2, 52.0 (q, *J* = 28.0 Hz), 26.8, 17.6 (bq, *J* = 2.0 Hz); ¹⁹F{¹H} NMR (471 MHz, CDCl₃) δ -73.5 ppm; HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. for C₁₃H₁₃F₃NO₃: 288.0842, found 288.0854.

Enantiomeric excess = 96%, determined by HPLC (Daicel Chiralpak OD-H Column, 12% *i*PrOH in *n*-Hexane, flow rate 1.0 mL/min, T = 15 °C, λ = 254 nm): *t*_R = 17.43 min (major), *t*_R = 30.45 min (minor). [α]_D^{28.2} = +35° (c = 10⁻³, CHCl₃).





Figure S15. HPLC chromatograms for racemic **2k** and enantioenriched **2k**.

(S)-1,3,6-Trimethyl-3-(trifluoromethyl)indolin-2-one (2l):



According to **GP-V**, the reaction of *N*-(2-bromo-5-methylphenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1l**; 32.2 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), *S*-PHOX (**L4**, 5.6 mg, 15 mol%), HCOONa (17 mg, 0.25 mmol) and K₃PO₄ (8.5 mg, 0.04 mmol) afforded **2l** (21.3 mg) in 88% yield and 96% *ee* as a white solid; *R*_f = 0.56 (3% EtOAc, 30% DCM in hexane); Melting point: 69–71 °C.

¹H NMR (500 MHz, CDCl₃) δ 7.28–7.23 (m, 1H), 6.94 (d, *J* = 7.6 Hz, 1H), 6.72 (s, 1H), 3.23 (s, 3H), 2.41 (s, 3H), 1.62 (s, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 172.6 (bd, *J* = 1.6 Hz), 143.7, 140.3, 125.0 (q, *J* = 281.6 Hz), 124.2, 123.7, 123.3, 109.5, 51.9 (q, *J* = 27.6 Hz), 26.6, 21.8, 17.8 (bd, *J* = 2.0 Hz); ¹⁹F{¹H} NMR (471 MHz, CDCl₃) δ -73.8 ppm; HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. for C₁₂H₁₃F₃NO: 244.0944, found 244.0947.

Enantiomeric excess = 96%, determined by HPLC (Daicel Chiralpak OD-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 15 °C, λ = 254 nm): *t*_R = 21.86 min (minor), *t*_R = 25.31 min (major). [α]_D^{28.3} = +8° (c = 5·10⁻⁴, CHCl₃).





Figure S16. HPLC chromatograms for racemic **2l** and enantioenriched **2l**.

(S)-6-Methoxy-1,3-dimethyl-3-(trifluoromethyl)indolin-2-one (2m):



According to **GP-V**, the reaction of *N*-(2-bromo-5-methoxyphenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1m**; 33.8 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), *S*-PHOX (**L4**, 5.6 mg, 15 mol%), HCOONa (17 mg, 0.25 mmol) and K₃PO₄ (8.5 mg, 0.04 mmol) afforded **2m** (14.8 mg) in 57% yield and 93% *ee* as a white solid; *R*_f = 0.44 (3% EtOAc, 30% DCM in hexane); Melting point: 55–57 °C.

¹H NMR (500 MHz, CDCl₃) δ 7.30–7.23 (m, 1H), 6.61 (dd, *J* = 8.2, 1.8 Hz, 1H), 6.46 (d, *J* = 1.6 Hz, 1H), 3.84 (s, 3H), 3.22 (s, 3H), 1.61 (s, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 172.9 (bs), 161.4, 145.0, 125.3, 125.0 (q, *J* = 283.4 Hz), 118.1, 106.9, 96.6, 55.6, 51.7 (q, *J* = 28.6 Hz), 26.6, 17.8 (bd, *J* = 1.6 Hz); ¹⁹F{¹H} NMR (471 MHz, CDCl₃) δ -73.9 ppm; HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. for C₁₂H₁₃F₃NO₂: 260.0893, found 260.0903.

Enantiomeric excess = 93%, determined by HPLC (Daicel Chiralpak OJ-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 25 °C, λ = 254 nm): *t*_R = 52.79 min (minor), *t*_R = 56.49 min (major). [α]_D^{28.4} = +2° (c = 5·10⁻⁴, CHCl₃).





Figure S17. HPLC chromatograms for racemic **2m** and enantioenriched **2m**.

(S)-6-Chloro-1,3-dimethyl-3-(trifluoromethyl)indolin-2-one (2n):



Using the above method **GP-V**, the reaction of *N*-(2-bromo-5-chlorophenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1n**; 34 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), *S*-PHOX (**L4**, 5.6 mg, 15 mol%), HCOONa (17 mg, 0.25 mmol) and K₃PO₄ (8.5 mg, 0.04 mmol) afforded **2n** (22.7 mg) in 86% yield and 91% *ee* as a white solid; *R*_f = 0.56 (3% EtOAc, 30% DCM in hexane); Melting point: 80–82 °C.

¹H NMR (500 MHz, CDCl₃) δ 7.28 (d, *J* = 7.9 Hz, 1H), 7.10 (d, *J* = 8.0 Hz 1H), 6.89 (s, 1H), 3.23 (s, 3H), 1.63 (s, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 172.2 (bq, *J* = 1.6 Hz), 144.8, 135.9, 125.5, 124.6 (q, *J* = 281.8 Hz), 124.5, 123.0, 109.4, 51.9 (q, *J* = 28.0 Hz), 26.7, 17.7 (bq, *J* = 1.8 Hz); ¹⁹F{¹H} NMR (471 MHz, CDCl₃) δ -73.6 ppm; HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. for C₁₁H₁₀ClF₃NO: 264.0398, found 264.0392.

Enantiomeric excess = 91%, determined by HPLC (Daicel Chiralpak OJ-H Column, 2% *i*PrOH in *n*-Hexane, flow rate 1.0 mL/min, T = 15 °C, λ = 254 nm): *t*_R = 15.84 min (minor), *t*_R = 21.09 min (major). [α]_D^{27.1} = +7° (c = 10⁻³, CHCl₃).





Figure S18. HPLC chromatograms for racemic **2n** and enantioenriched **2n**.

(S)-7-Fluoro-1,3-dimethyl-3-(trifluoromethyl)indolin-2-one (2o**):**



According to **GP-V**, the reaction of *N*-(2-bromo-6-fluorophenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1o**; 32.6 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), *S*-PHOX (**L4**, 5.6 mg, 15 mol%), HCOONa (17 mg, 0.25 mmol) and K₃PO₄ (8.5 mg, 0.04 mmol) afforded **2o** (7 mg) in 28% yield and 99% *ee* as a yellow solid; *R*_f = 0.64 (3%, EtOAc 30% DCM in hexane); Melting point: 106–108 °C.

¹H NMR (500 MHz, CDCl₃) δ 7.18 (bd, *J* = 7.1 Hz, 1H), 7.12 (bt, *J* = 9.8 Hz, 1H), 7.09–7.03 (m, 1H), 3.47 (s, 3H), 1.66 (s, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 171.8 (q, *J* = 2.1 Hz), 147.6 (d, *J* = 244.4 Hz), 130.5 (d, *J* = 8.8 Hz), 128.8 (d, *J* = 2.4 Hz), 124.6 (q, *J* = 281.9 Hz), 123.8 (d, *J* = 6.4 Hz), 120.4 (d, *J* = 3.0 Hz), 117.9 (d, *J* = 19.1 Hz), 52.3 (qd, *J* = 27.9, 2.0 Hz), 29.1 (d, *J* = 6.0 Hz), 17.9 (q, *J* = 2.2 Hz); ¹⁹F{¹H} NMR (471 MHz, CDCl₃) δ -73.7, -(135.6–135.8) (m, 1F) ppm; HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. for C₁₁H₁₀F₄NO: 248.0693, found 248.0712.

Enantiomeric excess = 99%, determined by HPLC (Daicel Chiralpak OJ-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 15 °C, λ = 254 nm): *t*_R = 17.14 min (minor), *t*_R = 18.00 min (major). [α]_D^{27.6} = +10° (c = 2·10⁻⁴, CHCl₃).





Figure S19. HPLC chromatograms for racemic **2o** and enantioenriched **2o**.

(S)-1,3-Dimethyl-3-(trifluoromethyl)-1,3-dihydro-2H-pyrrolo[3,2-b]pyridin-2-one (2p):



According to **GP-V**, the reaction of *N*-(2-bromopyridin-3-yl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1p**; 30.9 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), *S*-PHOX (**L4**, 5.6 mg, 15 mol%), HCOONa (17 mg, 0.25 mmol) and K₃PO₄ (8.5 mg, 0.04 mmol) afforded **2p** (19.3 mg) in 84% yield and 97% *ee* as a brown solid; *R*_f = 0.12 (3.0%, EtOAc, 30% DCM in hexane); Melting point: 75–77 °C.

¹H NMR (500 MHz, CDCl₃) δ 8.32 (d, *J* = 4.8 Hz, 1H), 7.29 (bt, *J* = 6.2 Hz, 1H), 7.15 (d, *J* = 7.9 Hz, 1H), 3.26 (s, 3H), 1.71 (s, 3H); ¹³C{¹H} (126 MHz, CDCl₃) δ 170.9 (bq, *J* = 1.9 Hz), 147.1, 143.8, 139.1, 124.4, 124.2 (q, *J* = 282.9 Hz), 115.0, 52.2 (q, *J* = 27.7 Hz), 26.4, 15.9 (bq, *J* = 1.8 Hz); ¹⁹F{¹H} NMR (471 MHz, CDCl₃) δ -72.6 ppm; HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. for C₁₀H₁₀F₃N₂O: 231.0740, found 231.0743.

Enantiomeric excess = 97%, determined by HPLC (Daicel Chiralpak OD-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 15 °C, λ = 254 nm): *t*_R = 40.22 min (minor), *t*_R = 45.70 min (major). [α]_D^{28.6} = +2° (c = 5·10⁻⁴, CHCl₃).





Figure S20. HPLC chromatograms for racemic **2p** and enantioenriched **2p**.

(S)-2-(3-Methyl-2-oxo-3-(trifluoromethyl)indolin-1-yl)ethyl-3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate (2q**):**



According to **GP-V**, the reaction of 2-(*N*-(2-bromophenyl)-2-(trifluoromethyl)acrylamido)ethyl-3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate (**1q**; 60 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), *S*-PHOX (**L4**, 5.6 mg, 15 mol%), HCOONa (17 mg, 0.25 mmol) and K₃PO₄ (8.5 mg, 0.04 mmol) afforded **2q** (32.2 mg) in 62% yield and 96% *ee* as a white solid; *R*_f = 0.04 (3% EtOAc, 30% DCM in hexane); Melting point: 153–155 °C.

¹H NMR (500 MHz, CDCl₃) δ 8.45 (dd, *J* = 7.9, 1.6 Hz, 1H), 8.09 (dd, *J* = 7.5, 1.6 Hz, 1H), 7.79 (dd, *J* = 7.4, 1.9 Hz, 2H), 7.57–7.48 (m, 3H), 7.38 (t, *J* = 7.7 Hz, 1H), 7.34 (d, *J* = 7.4 Hz, 1H), 7.29–7.24 (m, 1H), 7.09 (t, *J* = 7.6 Hz, 1H), 6.90 (d, *J* = 7.9 Hz, 1H), 4.66–4.55 (m, 2H), 4.20–4.06 (m, 2H), 2.24 (s, 3H), 1.60 (s, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 178.2, 172.5 (bq, *J* = 1.8 Hz), 163.5, 160.9, 154.6, 142.5, 136.2, 133.0, 131.2, 130.5, 129.8, 129.3, 128.5, 126.1, 124.85, 124.78 (q, *J* = 281.5 Hz), 123.9, 123.3, 123.2, 119.5, 117.6, 108.6, 61.3, 52.0 (q, *J* = 27.7 Hz), 39.2, 17.6 (bq, *J* = 2.0 Hz), 11.8; ¹⁹F NMR (377 MHz, CDCl₃) δ -73.6 ppm; HRMS (ESI-TOF) *m/z*: [M+Na]⁺ calcd. for C₂₉H₂₂F₃N Na O₅: 544.1342, found 544.1348.

Enantiomeric excess = 96%, determined by HPLC (Daicel Chiralpak AD-H Column, 2.5% *i*PrOH in *n*-Hexane, flow rate 1.5 mL/min, T = 15 °C, λ = 254 nm): *t*_R = 72.66 min (major), *t*_R = 78.82 min (minor). [α]_D^{27.8} = +6° (c = 5 × 10⁻⁴, CHCl₃).





Figure S21. HPLC chromatograms for racemic **2q** and enantioenriched **2q**.

2-((S)-3-Methyl-2-oxo-3-(trifluoromethyl)indolin-1-yl)ethyl 2-(4-isobutylphenyl)propanoate (2r**):**




According to **GP-V**, the reaction of 2-(*N*-(2-bromophenyl)-2-(trifluoromethyl)acrylamido)ethyl 2-(4-isobutylphenyl)propanoate (**1r**; 52.6 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), *S*-PHOX (**L4**, 5.6 mg, 15 mol%),


HCOONa (17 mg, 0.25 mmol) and K₃PO₄ (8.5 mg, 0.04 mmol) afforded **2r** (41.5 mg) in 93% yield and 96% *ee* as a yellow liquid; *R*_f = 0.42 (3% EtOAc, 30% DCM in hexane). Based on ¹H NMR 1:1 diastereomeric ratio observed.

¹H NMR (500 MHz, CDCl₃) δ 7.37 (d, *J* = 7.4 Hz, 1H), 7.32 (tt, *J* = 7.8, 1.6 Hz, 1H), 7.12 (bt, *J* = 7.6 Hz, 1H), 7.09–6.98 (m, 4H), 6.87 (t, *J* = 7.2 Hz, 1H), 4.43–4.31 (m, 1H), 4.30–4.20 (m, 1H), 4.10–3.97 (m, 1H), 3.96–3.86 (m, 1H), 3.57 (q, *J* = 7.2 Hz, 1H), 2.41 (d, *J* = 7.2 Hz, 2H), 1.82 (sept, *J* = 6.8 Hz, 1H), 1.61 (s, 1.5H), 1.59 (s, 1.5H), 1.40 (d, *J* = 7.2 Hz, 1.5H), 1.35 (d, *J* = 7.2 Hz, 3H), 0.88 (d, *J* = 6.6 Hz, 6H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 174.51, 174.50, 172.4 (bq, *J* = 2.3 Hz, 1H), 142.9, 142.8, 140.59, 140.56, 137.21, 137.16, 129.79, 129.78, 129.3 (bs), 127.09, 127.07, 126.12, 126.08, 124.8 (q, *J* = 281.7 Hz), 124.6, 123.1, 108.94, 108.90, 61.25, 61.18, 52.0 (q, *J* = 27.8 Hz), 45.00, 44.96, 44.93, 39.2, 30.1, 22.4, 18.23, 18.18, 17.7 (bq, *J* = 2.1 Hz); ¹⁹F NMR (377 MHz, CDCl₃) δ -73.5 ppm; HRMS (ESI-TOF) *m/z*: [M+Na]⁺ calcd. for C₂₅H₂₈F₃NNaO₃: 470.1913, found 470.1922.


Enantiomeric excess = 96%, determined by HPLC (Daicel Chiralpak OD-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 15 °C, λ = 254 nm): t_R = 21.84 min (minor), t_R = 26.67 min (major). $[\alpha]_D^{29.3} = +6.5^\circ$ ($c = 2 \cdot 10^{-3}$, CHCl₃).




Peak#	Ret. Time	Area	Height	Conc.	Area%
1	21.717	8614619	328053	50.363	50.363
2	26.677	8490345	236140	49.637	49.637
Total		17104964	564193		100.000



Peak#	Ret. Time	Area	Height	Conc.	Area%
1	21.835	400373	16323	2.130	2.130
2	26.667	18392822	497997	97.870	97.870
Total		18793195	514320		100.000




Peak#	Ret. Time	Area	Height	Conc.	Area%
1	21.717	8614619	328053	27.974	27.974
2	23.979	13584040	379630	44.111	44.111
3	26.677	8596548	237049	27.915	27.915
Total		30795207	944732		100.000



Peak#	Ret. Time	Area	Height	Conc.	Area%
1	21.835	421775	16664	1.131	1.131
2	24.043	18381771	562073	49.288	49.288
3	26.667	18491367	498821	49.581	49.581
Total		37294913	1077559		100.000

Figure S22. HPLC chromatograms for racemic **2r** and enantioenriched **2r**.

(S)-2-(3-Methyl-2-oxo-3-(trifluoromethyl)indolin-1-yl)ethyl-2-(4-chlorophenoxy)-2-methylpropanoate (2s):



According to **GP-V**, the reaction of 2-(*N*-(2-bromophenyl)-2-(trifluoromethyl)acrylamido)ethyl 2-(4-chlorophenoxy)-2-methylpropanoate (**1s**; 53.47 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), *S*-PHOX (**L4**, 5.6 mg, 15 mol%), HCOONa (17 mg,

0.25 mmol) and K₃PO₄ (8.5 mg, 0.04 mmol) afforded **2s** (43.5 mg) in 95% yield and 96% *ee* as a yellow liquid; *R*_f = 0.35 (3% EtOAc, 30% DCM in hexane).

¹H NMR (500 MHz, CDCl₃) δ 7.37 (bd, *J* = 7.5 Hz, 1H), 7.33 (td, *J* = 7.8, 1.0 Hz, 1H), 7.14–7.09 (m, 3H), 6.90 (d, *J* = 7.9 Hz, 1H), 6.72–6.67 (m, 2H), 4.46–4.36 (m, 2H), 4.09–4.02 (m, 1H), 4.00–3.93 (m, 1H), 1.61 (s, 3H), 1.47 (s, 3H), 1.45 (s, 3H); **¹³C{¹H} NMR (126 MHz, CDCl₃)** δ 173.7, 172.4 (bq, *J* = 2.1 Hz), 153.7, 142.5, 129.8, 129.0, 127.4, 126.0, 124.8 (q, *J* = 281.9 Hz), 124.7, 123.3, 120.7, 108.9, 79.4, 62.0, 52.0 (q, *J* = 27.8 Hz), 39.1, 25.2, 25.0, 17.6 (bq, *J* = 1.7 Hz); **¹⁹F NMR (377 MHz, CDCl₃)** δ -73.6 ppm; **HRMS (ESI-TOF) *m/z***: [M+Na]⁺ calcd. for C₂₂H₂₁ClF₃N NaO₄: 478.1003, found 478.1003.

Enantiomeric excess = 96%, determined by HPLC (Daicel Chiralpak AD-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 15 °C, λ = 254 nm): *t*_R = 50.22 min (major), *t*_R = 54.80 min (minor). [α]_D^{28.3} = +14° (c = 5*10⁻⁴, CHCl₃).





Figure S23. HPLC chromatograms for racemic **2s** and enantioenriched **2s**.

Tri-substituted β -Phenyl Trifluoromethyl Acrylamides (**4**):

(*S*)-3-Benzyl-1-methyl-3-(trifluoromethyl)indolin-2-one (**4a**):⁶



According to **GP-VII**, the reaction of (*Z*)-*N*-(2-iodophenyl)-*N*-methyl-3-phenyl-2-(trifluoromethyl)acrylamide (**3a**; 21.56 mg, 0.05 mmol) using Pd(TFA)₂ (1.2 mg, 7 mol%), (*S*, *Sp*)-*t*Bu-Phosferrox (**L3**, 4.95 mg, 20 mol%), HCOONa (8.5 mg, 0.125 mmol), K₃PO₄ (4.25 mg, 0.02 mmol) and Ag₂CO₃ (4.13 mg, 0.015

mmol) afforded **4a** (6.7 mg) in 44% yield and 88% *ee* as a white solid; R_f = 0.35 (3% EtOAc, 30% DCM in hexane); Melting point: 83–85 °C.

^1H NMR (500 MHz, CDCl_3) δ 7.47 (d, J = 7.4 Hz, 1H), 7.30–7.25 (m, 1H), 7.12 (t, J = 7.5 Hz, 1H), 7.08–7.04 (m, 1H), 7.01 (t, J = 7.2 Hz, 2H), 6.85–6.80 (m, 2H), 6.58 (d, J = 7.8 Hz, 1H), 3.61 (d, J = 12.9 Hz, 1H), 3.31 (d, J = 12.9 Hz, 1H), 2.94 (s, 3H); $^{19}\text{F}\{^1\text{H}\}$ NMR (471 MHz, CDCl_3) δ -71.5 ppm.

Enantiomeric excess = 88%, determined by HPLC (Daicel Chiralpak OJ-H Column, 1% i PrOH in n -Hexane, flow rate 0.5 mL/min, T = 15 °C, λ = 254 nm): t_R = 23.99 min (major), t_R = 28.59 min (minor). $[\alpha]_D^{28.3}$ = +39° (c = 10^{-3} , CHCl_3).





Figure S24. HPLC chromatograms for racemic **4a** and enantioenriched **4a**.

(S)-1,3-Dibenzyl-3-(trifluoromethyl)indolin-2-one (4b**)⁶:**



According to **GP-VII**, the reaction of (Z)-*N*-benzyl-*N*-(2-iodophenyl)-3-phenyl-2-(trifluoromethyl)acrylamide (**3b**; 25.36 mg, 0.05 mmol) using $\text{Pd}(\text{TFA})_2$ (1.2 mg, 7 mol%), (*S*, *Sp*)- t Bu-Phosferrox (**L**₃, 4.95 mg, 20 mol%), HCOONa (8.5 mg, 0.125 mmol), K_3PO_4 (4.25 mg, 0.02 mmol) and Ag_2CO_3 (4.13 mg, 0.015 mmol) afforded **4b** (7.3 mg) in 38% yield and 75% *ee* as a white solid; R_f = 0.46 (3% EtOAc, 30% DCM in hexane); Melting point: 76–78 °C.

^1H NMR (400 MHz, CDCl_3) δ 7.55 (d, J = 7.2 Hz, 1H), 7.20–7.10 (m, 6H), 7.06 (t, J = 7.6 Hz, 2H), 6.91 (d, J = 7.7 Hz, 2H), 6.63 (d, J = 7.2 Hz, 2H), 6.41 (d, J = 7.7 Hz, 1H), 4.90 (d, J = 16.0

Hz, 1H), 4.56 (d, $J = 16.0$ Hz, 1H), 3.71 (d, $J = 13.0$ Hz, 1H), 3.42 (d, $J = 13.0$ Hz, 1H); ^{19}F NMR (377 MHz, CDCl_3) δ -71.8 ppm.

Enantiomeric excess = 75%, determined by HPLC (Daicel Chiralpak OJ-H Column, 1% i PrOH in n -Hexane, flow rate 0.5 mL/min, $T = 15^\circ\text{C}$, $\lambda = 254$ nm): $t_R = 23.53$ min (major), $t_R = 37.30$ min (minor). $[\alpha]_D^{28.8} = +20^\circ$ ($c = 5 \times 10^{-4}$, CHCl_3).





Figure S25. HPLC chromatograms for racemic **4b** and enantioenriched **4b**.

(S)-3-Benzyl-1,5-dimethyl-3-(trifluoromethyl)indolin-2-one (4c):



According to **GP-VII**, the reaction of (*Z*)-*N*-(2-iodo-4-methylphenyl)-*N*-methyl-3-phenyl-2-(trifluoromethyl)acrylamide (**3c**; 44.52 mg, 0.1 mmol) using $\text{Pd}(\text{TFA})_2$ (2.33 mg, 7 mol%), (*S*, *Sp*)-*t*Bu-Phosferrox (**L3**, 10 mg, 20 mol%), HCOONa (17 mg, 0.25 mmol), K_3PO_4 (8.5 mg, 0.04 mmol) and Ag_2CO_3 (8.3 mg, 0.03 mmol) afforded **4c** (12 mg) in 38% yield and 82% *ee* as a semi-solid; $R_f = 0.22$ (3% EtOAc, 30% DCM in hexane).

^1H NMR (500 MHz, CDCl_3) δ 7.28 (s, 1H), 7.09–7.05 (m, 2H), 7.04–7.00 (m, 2H), 6.83 (d, $J = 7.1$ Hz, 2H), 6.47 (d, $J = 7.9$ Hz, 1H), 3.59 (d, $J = 12.9$ Hz, 1H), 3.29 (d, $J = 12.9$ Hz, 1H), 2.91 (s, 3H), 2.39 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ (126 MHz, CDCl_3) δ 170.8 (q, $J = 2.2$ Hz), 141.8, 133.0, 132.3, 130.1, 130.0, 127.7, 127.0, 125.9, 124.7 (q, $J = 281.9$ Hz), 123.6, 108.0, 58.2 (q, $J = 26.1$ Hz), 37.3 (bq, $J = 2.5$ Hz), 26.1, 21.2; ^{19}F NMR (377 MHz, CDCl_3) δ -71.4 ppm; HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ calcd. for $\text{C}_{18}\text{H}_{16}\text{F}_3\text{NNaO}$: 342.1076, found 342.1067.

Enantiomeric excess = 82%, determined by HPLC (Daicel Chiralpak OJ-H Column, 2.5% *i*PrOH in *n*-Hexane, flow rate 1.0 mL/min, T = 25 °C, λ = 254 nm): t_R = 8.27 min (minor), t_R = 24.08 min (major). $[\alpha]_D^{28.6}$ = +84° (c = 5*10⁻⁴, CHCl₃).





Figure S26. HPLC chromatograms for racemic **4c** and enantioenriched **4c**.

(S)-3-Benzyl-5-fluoro-1-methyl-3-(trifluoromethyl)indolin-2-one (4d**):²**



According to **GP-VII**, the reaction of (*Z*)-*N*-(4-fluoro-2-iodophenyl)-*N*-methyl-3-phenyl-2-(trifluoromethyl)acrylamide (**3d**; 44.9 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), (*S*, *Sp*)-*t*Bu-Phosferrox (**L3**, 10 mg, 20 mol%), HCOONa (17 mg, 0.25 mmol), K₃PO₄ (8.5 mg, 0.04 mmol) and Ag₂CO₃ (8.3 mg, 0.03 mmol) afforded **4d** (13.1 mg) in 41% yield and 83% *ee* as a white solid; *R*_f = 0.35 (3% EtOAc, 30% DCM in hexane); Melting point: 106–108 °C.

¹H NMR (500 MHz, CDCl₃) δ 7.23 (d, *J* = 7.6 Hz, 1H), 7.12–7.02 (m, 3H), 6.98 (t, *J* = 8.7 Hz, 1H), 6.85 (d, *J* = 7.3 Hz, 2H), 6.51 (dd, *J* = 8.5, 4.0 Hz, 1H), 3.62 (d, *J* = 13.0 Hz, 1H), 3.28 (d, *J* = 13.0 Hz, 1H), 2.94 (s, 3H); ¹⁹F NMR (377 MHz, CDCl₃) δ -119.4 (td, *J* = 8.5, 4.2 Hz), -71.4 ppm.

Enantiomeric excess = 83%, determined by HPLC (Daicel Chiralpak OD-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 15 °C, λ = 254 nm): t_R = 28.82 min (major), t_R = 42.92 min (minor). $[\alpha]_D^{28.5}$ = +42° (c = 5*10⁻⁴, CHCl₃).





Figure S27. HPLC chromatograms for racemic **4d** and enantioenriched **4d**.

(S)-1-Methyl-3-(trifluoromethyl)-3-(4-(trifluoromethyl)benzyl)indolin-2-one (4e**):**



According to **GP-VII**, the reaction of (*Z*)-*N*-(2-iodophenyl)-*N*-methyl-2-(trifluoromethyl)-3-(4-(trifluoromethyl)phenyl)acrylamide (**3e**; 25 mg, 0.05 mmol) using Pd(TFA)₂ (1.2 mg, 7 mol%), (*S*, *Sp*)-*t*Bu-Phosferrox (**L3**, 4.95 mg, 20 mol%), HCOONa (2.5 mg, 0.125 mmol), K₃PO₄ (4.25 mg, 0.02 mmol) and Ag₂CO₃ (4.13 mg, 0.015 mmol) afforded **4e** (14.6 mg) in 78% yield and 81% *ee* as a white solid; *R*_f = 0.44 (3% EtOAc, 30% DCM in hexane); Melting point: 71–73 °C.

¹H NMR (400 MHz, CDCl₃) δ 7.48 (d, *J* = 8.0 Hz, 1H), 7.34–7.25 (m, 3H), 7.14 (td, *J* = 7.6, 1.0 Hz, 1H), 6.95 (d, *J* = 8.0 Hz, 2H), 6.62 (d, *J* = 7.8 Hz, 1H), 3.65 (d, *J* = 12.9 Hz, 1H), 3.36 (d, *J* = 12.9 Hz, 1H), 2.94 (s, 3H); ¹³C{¹H} (126 MHz, CDCl₃) δ 170.4 (bq, *J* = 1.7 Hz), 144.0, 137.0, 130.4, 130.3, 129.5 (q, *J* = 32.4 Hz), 125.1, 124.6 (q, *J* = 3.6 Hz), 124.5 (q, *J* = 282.2 Hz), 123.9 (q, *J* = 272.0 Hz), 123.0, 108.6, 57.9 (q, *J* = 26.4 Hz), 36.9 (bq, *J* = 1.9 Hz), 26.2 (one of the aromatic ¹³C merged with other peaks); ¹⁹F{¹H} NMR (471 MHz, CDCl₃) δ -62.7, -71.7 ppm; HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. for C₁₈H₁₄F₆NO: 374.0974, found 374.0990.

Enantiomeric excess = 81%, determined by HPLC (Daicel Chiralpak OD-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 15 °C, λ = 254 nm): *t*_R = 13.41 min (minor), *t*_R = 15.18 min (major). [α]_D^{28.9} = +28° (c = 5·10⁻⁴, CHCl₃).






Figure S28. HPLC chromatograms for racemic **4e** and enantioenriched **4e**.



Scheme S10. Asymmetric Reductive Heck cyclization of *o*-halo β -methyl meth-acrylamides.

Tetra-substituted *gem*-Difluoromethyl Acrylamides (**6**):

(*R*)-3-(Difluoromethyl)-1,3-dimethylindolin-2-one (**6a**):



According to **GP-IX**, the reaction of **5a** (33.7 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), (*R*)-SEPHOS (**L5**, 9.2 mg, 15 mol%), HCOONa (17 mg, 0.25 mmol) and Ag₃PO₄ (21 mg, 0.05 mmol) afforded **6a** (14.7 mg) in 70% yield and 93% *ee* as a colorless liquid; *R_f* = 0.32 (3% EtOAc, 30% DCM in hexane).

¹H NMR (500 MHz, CDCl₃) δ 7.40–7.33 (m, 2H), 7.12 (t, *J* = 7.6 Hz, 1H), 6.88 (d, *J* = 7.8 Hz, 1H), 5.95 (t, *J* = 56.0 Hz, 1H), 3.23 (s, 3H), 1.52 (s, 3H); **¹³C{¹H} (126 MHz, CDCl₃)** δ 174.9 (dd, *J* = 9.2, 1.6 Hz), 143.8, 129.2, 127.0, 124.8, 123.0, 116.7 (dd, *J* = 247.7, 244.8 Hz), 108.4, 51.9 (t, *J* = 21.1 Hz), 26.4, 17.7 (dd, *J* = 5.2, 2.7 Hz); **¹⁹F NMR (377 MHz, CDCl₃)** δ -122.1 (dd, *J* = 280.9, 55.7 Hz), -129.8 (dd, *J* = 280.9, 56.3 Hz) ppm; **HRMS (ESI-TOF) *m/z***: [M+H]⁺ calcd. for C₁₁H₁₂F₂NO: 212.0881, found 212.0878.

Enantiomeric excess = 93%, determined by HPLC (Daicel Chiralpak OJ-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 25 °C, λ = 254 nm): t_R = 24.24 min (minor), t_R = 25.56 min (major). $[\alpha]_D^{28.3}$ = -6° (c = 5×10^{-4} , CHCl₃).





Figure S29. HPLC chromatograms for racemic **6a** and enantioenriched **6a**.

(*R*)-3-(Difluoromethyl)-1-ethyl-3-methylindolin-2-one (6b**):**



According to **GP-IX**, the reaction of **5b** (35 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), (*R*)-SEGPPOS (**L5**, 9.2 mg, 15 mol%), HCOONa (17 mg, 0.25 mmol) and Ag₃PO₄ (21 mg, 0.05 mmol) at 115 °C afforded **6b** (19.6 mg) in 87% yield and 88% *ee* as a yellow liquid; R_f = 0.39 (3% EtOAc, 30% DCM in hexane).

¹H NMR (500 MHz, CDCl₃) δ 7.39 (d, J = 7.4 Hz, 1H), 7.35 (t, J = 7.8 Hz, 1H), 7.10 (t, J = 7.6 Hz, 1H), 6.90 (d, J = 7.8 Hz, 1H), 5.95 (t, J = 56.0 Hz, 1H), 3.85–3.70 (m, 2H), 1.51 (s, 3H), 1.26 (bt, J = 7.2 Hz, 3H); **¹³C{¹H} (126 MHz, CDCl₃)** δ 174.5 (dd, J = 9.2, 1.4 Hz), 142.9, 129.2, 127.3, 125.0, 122.8, 116.8 (dd, J = 247.7, 244.7 Hz), 108.5, 51.8 (t, J = 21.0 Hz), 34.8, 17.7 (dd, J = 5.2, 2.6 Hz), 12.5; **¹⁹F NMR (377 MHz, CDCl₃)** δ -122.4 (dd, J = 280.9, 55.8 Hz), -129.9 (dd, J = 280.9, 56.3 Hz) ppm; **HRMS (ESI-TOF) m/z** : $[M+H]^+$ calcd. for C₁₂H₁₄F₂NO: 226.1038, found 226.1037.

Enantiomeric excess = 88%, determined by HPLC (Daicel Chiralpak OD-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 25 °C, λ = 254 nm): t_R = 14.53 min (major), t_R = 15.23 min (minor). $[\alpha]_D^{28.2}$ = -2.7° (c = 1.5×10^{-3} , CHCl₃).





Figure S30. HPLC chromatograms for racemic **6b** and enantioenriched **6b**.

(*R*)-1-Benzyl-3-(difluoromethyl)-3-methylindolin-2-one (6c**):**



According to **GP-IX**, the reaction of **5c** (62 mg, 0.15 mmol) using Pd(TFA)₂ (3.5 mg, 7 mol%), (*R*)-SEGPPOS (**L5**, 18.3 mg, 20 mol%), HCOONa (26 mg, 0.375 mmol) and Ag₃PO₄ (32 mg, 0.075 mmol) at 110 °C afforded **6c** (10.4 mg) in 24% yield and 82% *ee* as a yellow liquid; *R_f* = 0.46 (3% EtOAc, 30% DCM in hexane).

¹H NMR (500 MHz, CDCl₃) δ 7.40 (d, *J* = 7.4 Hz, 1H), 7.34–7.29 (m, 2H), 7.28–7.20 (m, 4H), 7.08 (t, *J* = 7.6 Hz, 1H), 6.74 (d, *J* = 7.9 Hz, 1H), 6.05 (t, *J* = 56.0 Hz, 1H), 5.04 (d, *J* = 15.8 Hz, 1H), 4.83 (d, *J* = 15.8 Hz, 1H), 1.59 (s, 3H); **¹³C{¹H} (126 MHz, CDCl₃)** δ 175.1 (dd, *J* = 9.3, 1.0 Hz), 142.9, 135.2, 129.1, 128.8, 127.7, 126.99 (d, *J* = 1.3 Hz), 126.95, 124.8 (d, *J* = 1.2 Hz), 123.0, 116.9 (dd, *J* = 247.8, 244.6 Hz), 109.5, 51.9 (t, *J* = 21.1 Hz), 43.7, 18.0 (dd, *J* = 5.2, 2.4 Hz); **¹⁹F NMR (377 MHz, CDCl₃)** δ -122.1 (ddd, *J* = 280.9, 55.8, 1.1 Hz), -129.8 (dd, *J* = 280.9, 56.2 Hz) ppm; **HRMS (ESI-TOF) *m/z***: [M+H]⁺ calcd. for C₁₇H₁₆F₂NO: 288.1194, found 288.1192.

Note: Each ¹⁹F peak appears as a broad quartet and quintet (four peaks for each fluorine atom), but not distinctly enough for clear assignment. As a result, MestReNova software could not assign values to all peaks, so we have provided the ¹⁹F values accordingly.

Enantiomeric excess = 82%, determined by HPLC (Daicel Chiralpak AD-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 25 °C, λ = 254 nm): t_R = 28.31 min (minor), t_R = 31.32 min (major). $[\alpha]_D^{28.5}$ = -34° (c = 5*10⁻⁴, CHCl₃).





Figure S31. HPLC chromatograms for racemic **6c** and enantioenriched **6c**.

(*R*)-3-(Difluoromethyl)-1,3,5-trimethylindolin-2-one (6d**):**



According to **GP-IX**, the reaction of **5d** (35 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), (*R*)-SEGPPOS (**L5**, 9.2 mg, 15 mol%), HCOONa (17 mg, 0.25 mmol) and Ag₃PO₄ (21 mg, 0.05 mmol) afforded **6d** (15.6 mg) in 69% yield and 94% *ee* as a white solid; R_f = 0.31 (3% EtOAc, 30% DCM in hexane); Melting point: 116–118 °C.

¹H NMR (500 MHz, CDCl₃) δ 7.20 (s, 1H), 7.15 (d, J = 7.9 Hz, 1H), 6.77 (d, J = 7.9 Hz, 1H), 5.94 (t, J = 56.1 Hz, 1H), 3.20 (s, 3H), 2.36 (s, 3H), 1.50 (s, 3H); ¹³C{¹H} (126 MHz, CDCl₃) δ 174.9 (dd, J = 9.4, 1.5 Hz), 141.4, 132.6, 129.5, 127.1, 125.6, 116.8 (dd, J = 247.6, 244.7 Hz), 108.1, 51.9 (t, J = 21.0 Hz), 26.4, 21.1, 17.8 (dd, J = 5.3, 2.6 Hz); ¹⁹F NMR (377 MHz, CDCl₃) δ -122.1 (ddd, J = 280.5, 55.9, 1.0 Hz), -129.8 (ddd, J = 280.6, 56.3, 0.9 Hz) ppm; HRMS (ESI-TOF) m/z : [M+H]⁺ calcd. for C₁₂H₁₄F₂NO: 226.1038, found 226.1036.

Note: Each ¹⁹F peak appears as a broad quartet and quintet (four peaks for each fluorine atom), but not distinctly enough for clear assignment. As a result, MestReNova software could not assign values to all peaks, so we have provided the ¹⁹F values accordingly.

Enantiomeric excess = 94%, determined by HPLC (Daicel Chiralpak OJ-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 25 °C, λ = 254 nm): t_R = 22.66 min (minor), t_R = 23.80 min (major). $[\alpha]_D^{28.2}$ = -6° ($c = 5 \cdot 10^{-4}$, CHCl₃).





Figure S32. HPLC chromatograms for racemic **6d** and enantioenriched **6d**.

(*R*)-3-(Difluoromethyl)-5-fluoro-1,3-dimethylindolin-2-one (6e**):**



According to **GP-IX**, the reaction of **5e** (35.5 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), (*R*)-SEGPPOS (**L5**, 9.2 mg, 15 mol%), HCOONa (17 mg, 0.25 mmol) and Ag₃PO₄ (21 mg, 0.05 mmol) at 115 °C afforded **6e** (12.5 mg) in 55% yield and 87% *ee* as a white solid; R_f = 0.35 (3% EtOAc, 30% DCM in hexane); Melting point: 87–89 °C.

¹H NMR (500 MHz, CDCl₃) δ 7.14 (d, J = 7.6 Hz, 1H), 7.06 (td, J = 8.8, 1.9 Hz, 1H), 6.80 (dd, J = 8.4, 3.9 Hz, 1H), 5.96 (t, J = 55.8 Hz, 1H), 3.22 (s, 3H), 1.52 (s, 3H); **¹³C{¹H} (126 MHz, CDCl₃)** δ 174.5 (d, J = 8.7 Hz), 159.4 (d, J = 241.5 Hz), 139.8 (d, J = 1.9 Hz), 128.5 (d, J = 8.7 Hz), 116.5 (dd, J = 247.9, 245.0 Hz), 115.5 (d, J = 23.5 Hz), 113.1 (dd, J = 25.2, 1.4 Hz), 108.9 (d, J = 8.2 Hz), 52.3 (td, J = 21.1, 1.7 Hz), 26.5, 17.8 (dd, J = 5.2, 2.5 Hz); **¹⁹F NMR (377 MHz, CDCl₃)** δ -119.7 (ddd, J = 9.2, 7.8, 4.1 Hz), -122.0 (ddd, J = 281.8, 55.6, 1.1 Hz), -122.3 (dd, J = 5.6, 1.1 Hz) ppm; **HRMS (ESI-TOF) m/z :** $[M+H]^+$ calcd. for C₁₁H₁₁F₃NO: 230.0787, found 230.0782.

Note: Each ^{19}F peak appears as a broad quartet and quintet (four peaks for each fluorine atom), but not distinctly enough for clear assignment. As a result, MestReNova software could not assign values to all peaks, so we have provided the ^{19}F values accordingly.

Enantiomeric excess = 87%, determined by HPLC (Daicel Chiralpak OD-H Column, 1% $i\text{PrOH}$ in $n\text{-Hexane}$, flow rate 0.5 mL/min, $T = 25\text{ }^{\circ}\text{C}$, $\lambda = 254\text{ nm}$): $t_{\text{R}} = 19.24\text{ min}$ (major), $t_{\text{R}} = 21.01\text{ min}$ (minor). $[\alpha]_{\text{D}}^{28.3} = -24^{\circ}$ ($c = 5 \times 10^{-4}$, CHCl_3).





Figure S33. HPLC chromatograms for racemic **6e** and enantioenriched **6e**.

(*R*)-5-Chloro-3-(difluoromethyl)-1,3-dimethylindolin-2-one (6f**):**



According to **GP-IX**, the reaction of **5f** (37 mg, 0.1 mmol) using $\text{Pd}(\text{TFA})_2$ (2.33 mg, 7 mol%), (*R*)-SEGPPOS (**L5**, 9.2 mg, 15 mol%), HCOONa (17 mg, 0.25 mmol) and Ag_3PO_4 (21 mg, 0.05 mmol) afforded **6f** (11.4 mg) in 46% yield and 82% *ee* as a white solid; $R_{\text{f}} = 0.31$ (3% EtOAc , 30% DCM in hexane); Melting point: $93\text{--}95\text{ }^{\circ}\text{C}$.

^1H NMR (500 MHz, CDCl_3) δ 7.36 (s, 1H), 7.34 (d, $J = 8.6\text{ Hz}$, 1H), 6.81 (d, $J = 8.2\text{ Hz}$, 1H), 5.95 (t, $J = 55.8\text{ Hz}$, 1H), 3.21 (s, 3H), 1.52 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ (126 MHz, CDCl_3) δ 174.4 (dd, $J = 9.3, 1.1\text{ Hz}$), 142.4, 129.2, 128.6, 128.5, 125.4 (d, $J = 1.4\text{ Hz}$), 116.4 (dd, $J = 248.1, 245.0\text{ Hz}$), 109.3, 52.1 (t, $J = 21.0\text{ Hz}$), 26.5, 17.8 (dd, $J = 5.2, 2.6\text{ Hz}$); ^{19}F NMR (377 MHz, CDCl_3) δ -121.9 (ddd, $J = 281.9, 55.6, 1.0\text{ Hz}$), -129.8 (dd, $J = 281.9, 56.0\text{ Hz}$) ppm; HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{11}\text{H}_{11}\text{ClF}_2\text{NO}$: 246.0492, found 246.0490.

Note: Each ^{19}F peak appears as a broad quartet and quintet (four peaks for each fluorine atom), but not distinctly enough for clear assignment. As a result, MestReNova software could not assign values to all peaks, so we have provided the ^{19}F values accordingly.

Enantiomeric excess = 82%, determined by HPLC (Daicel Chiralpak OJ-H Column, 1% $i\text{PrOH}$ in $n\text{-Hexane}$, flow rate 0.5 mL/min, $T = 25\text{ }^{\circ}\text{C}$, $\lambda = 254\text{ nm}$): $t_{\text{R}} = 33.92\text{ min}$ (minor), $t_{\text{R}} = 42.92\text{ min}$ (major). $[\alpha]_{\text{D}}^{28.3} = -22^{\circ}$ ($c = 5 \times 10^{-4}$, CHCl_3).





Figure S34. HPLC chromatograms for racemic **6f** and enantioenriched **6f**.

(*R*)-5-Bromo-3-(difluoromethyl)-1,3-dimethylindolin-2-one (6g**):**



According to **GP-IX**, the reaction of **5g** (41.6 mg, 0.1 mmol) using $\text{Pd}(\text{TFA})_2$ (2.33 mg, 7 mol%), (*R*)-SEGPHOS (**L5**, 12.2 mg, 20 mol%), HCOONa (17 mg, 0.25 mmol) and Ag_3PO_4 (21 mg, 0.05 mmol) at $100\text{ }^{\circ}\text{C}$ afforded **6g** (9.9 mg) in 34% yield and 87% *ee* as a white solid; $R_{\text{f}} = 0.33$ (3% EtOAc , 30% DCM in hexane); Melting point: $96\text{--}98\text{ }^{\circ}\text{C}$.

^1H NMR (400 MHz, CDCl_3) δ 7.51–7.47 (m, 2H), 6.76 (bd, $J = 8.9\text{ Hz}$, 1H), 5.95 (t, $J = 55.8\text{ Hz}$, 1H), 3.21 (s, 3H), 1.52 (bt, 3H); $^{13}\text{C}\{^1\text{H}\}$ (101 MHz, CDCl_3) δ 174.3 (bd, $J = 9.5\text{ Hz}$), 142.9, 132.1, 128.9, 128.1 (d, $J = 1.6\text{ Hz}$), 116.4 (dd, $J = 248.1, 245.1\text{ Hz}$), 115.7, 109.8, 52.1 (t, $J = 21.2\text{ Hz}$), 26.5, 17.8 (dd, $J = 5.1, 2.6\text{ Hz}$); ^{19}F NMR (377 MHz, CDCl_3) δ -121.8 (dd, $J = 281.9, 55.6\text{ Hz}$), -129.8 (dd, $J = 281.8, 56.0\text{ Hz}$) ppm; HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{11}\text{H}_{11}\text{BrF}_2\text{NO}$: 289.9987, found 289.9986.

Enantiomeric excess = 87%, determined by HPLC (Daicel Chiralpak OJ-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 25 °C, λ = 254 nm): t_R = 38.16 min (minor), t_R = 50.48 min (major). $[\alpha]_D^{28.3}$ = -4° (c = 5×10^{-4} , CHCl₃).





Figure S35. HPLC chromatograms for racemic **6g** and enantioenriched **6g**.

(*R*)-3-(Difluoromethyl)-1,3-dimethyl-2-oxoindoline-5-carbonitrile (6h**):**



According to **GP-IX**, the reaction of **5h** (36 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), (*R*)-SEGPHOS (**L5**, 12.2 mg, 20 mol%), HCOONa (17 mg, 0.25 mmol) and Ag₃PO₄ (21 mg, 0.05 mmol) at 100 °C afforded **6h** (18.8 mg) in 80% yield and 90% *ee* as a white solid; R_f = 0.11 (3% EtOAc, 30% DCM in hexane); Melting point: 143–145 °C.

¹H NMR (500 MHz, CDCl₃) δ 7.69 (d, J = 8.2 Hz, 1H), 7.63 (s, 1H), 6.96 (d, J = 8.1 Hz, 1H), 5.97 (t, J = 55.7 Hz, 1H), 3.26 (s, 3H), 1.54 (s, 3H); **¹³C{¹H} (126 MHz, CDCl₃)** δ 174.6 (dd, J = 9.6, 0.8 Hz), 147.7, 134.6, 128.3 (d, J = 1.5 Hz), 128.0, 118.7, 116.2 (dd, J = 248.7, 245.2 Hz), 108.9, 106.5, 51.8 (t, J = 21.2 Hz), 26.7, 17.8 (dd, J = 5.0, 2.4 Hz); **¹⁹F NMR (377 MHz, CDCl₃)** δ -121.7 (dd, J = 282.9, 55.5 Hz), -129.7 (dd, J = 282.8, 55.8 Hz) ppm; **HRMS (ESI-TOF) m/z :** $[M+H]^+$ calcd. for C₁₂H₁₁F₂N₂O: 237.0834, found 237.0832.

Enantiomeric excess = 90%, determined by HPLC (Daicel Chiralpak OD-H Column, 2.5% *i*PrOH in *n*-Hexane, flow rate 2.0 mL/min, T = 25 °C, λ = 254 nm): t_R = 14.87 min (major), t_R = 16.38 min (minor). $[\alpha]_D^{26.5}$ = -16° (c = 5×10^{-4} , CHCl₃).





Figure S36. HPLC chromatograms for racemic **6h** and enantioenriched **6h**.

(*R*)-3-(Difluoromethyl)-1,3-dimethyl-5-(trifluoromethyl)indolin-2-one (6i**):**



According to **GP-IX**, the reaction of **5i** (61 mg, 0.15 mmol) using Pd(TFA)₂ (3.5 mg, 7 mol%), (*R*)-SEGPLHOS (**L5**, 18.3 mg, 20 mol%), HCOONa (26 mg, 0.375 mmol) and Ag₃PO₄ (32 mg, 0.075 mmol) at 110 °C afforded **6i** (11.9 mg) in 29% yield and 94% *ee* as a yellow liquid; *R*_f = 0.33 (3% EtOAc, 30% DCM in hexane).

¹H NMR (500 MHz, CDCl₃) δ 7.65 (d, *J* = 8.1 Hz, 1H), 7.61 (s, 1H), 6.96 (d, *J* = 8.2 Hz, 1H), 5.98 (t, *J* = 55.8 Hz, 1H), 3.26 (s, 3H), 1.55 (s, 3H); **¹³C{¹H} (126 MHz, CDCl₃)** δ 174.8 (dd, *J* = 9.4, 1.4 Hz), 146.8 (q, *J* = 1.3 Hz), 127.6 (bq, *J* = 1.3 Hz), 127.1 (q, *J* = 4.1 Hz), 125.4 (q, *J* = 32.7 Hz), 124.2 (q, *J* = 271.4 Hz), 121.9 (q, *J* = 3.9, 1.7 Hz), 116.4 (dd, *J* = 248.1, 245.4 Hz), 108.2, 51.9 (t, *J* = 21.2 Hz), 26.6, 17.8 (dd, *J* = 5.0, 2.7 Hz); **¹⁹F NMR (377 MHz, CDCl₃)** δ -61.5 (d, *J* = 0.6 Hz), -CF₃), -121.8 (ddd, *J* = 282.3, 55.6, 1.1 Hz), -(129.3–130.3, m) ppm; **HRMS (ESI-TOF) *m/z***: [M+H]⁺ calcd. for C₁₂H₁₁F₅NO: 280.0755, found 280.0753.

Note: Each ¹⁹F peak appears as a broad quartet and quintet (four peaks for each fluorine atom), but not distinctly enough for clear assignment. As a result, MestReNova software could not assign values to all peaks, so we have provided the ¹⁹F values accordingly.

Enantiomeric excess = 94%, determined by HPLC (Daicel Chiralpak OJ-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 25 °C, λ = 254 nm): t_R = 27.19 min (minor), t_R = 37.81 min (major). $[\alpha]_D^{28.2}$ = -12° (c = 10⁻³, CHCl₃).





Figure S37. HPLC chromatograms for racemic **6i** and enantioenriched **6i**.

(*R*)-3-(Difluoromethyl)-1,3,6-trimethylindolin-2-one (6j**):**



According to **GP-IX**, the reaction of **5j** (35 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), (*R*)-SEGPPOS (**L5**, 9.2 mg, 15 mol%), HCOONa (17 mg, 0.25 mmol) and Ag₃PO₄ (21 mg, 0.05 mmol) at 90 °C afforded **6j** (13.2 mg) in 59% yield and 90% *ee* as a white solid; R_f = 0.30

(3% EtOAc, 30% DCM in hexane); Melting point: 120–122 °C.

¹H NMR (400 MHz, CDCl₃) δ 7.27–7.24 (m, 1H), 6.93 (dq, J = 7.6, 0.8 Hz, 1H), 6.71 (s, 1H), 5.93 (t, J = 56.1 Hz, 1H), 3.21 (s, 3H), 2.40 (s, 3H), 1.50 (bs, 3H, appears like triplet but not splitted clearly); **¹³C{¹H} (126 MHz, CDCl₃)** δ 175.2 (dd, J = 9.6, 1.4 Hz), 143.9, 139.5, 124.5 (d, J = 0.8 Hz), 124.0 (bd, J = 0.8 Hz), 123.5, 116.7 (dd, J = 247.6, 244.6 Hz), 109.3, 51.7 (t, J = 21.2 Hz), 26.3, 21.8, 17.8 (dd, J = 5.1, 2.6 Hz); **¹⁹F NMR (377 MHz, CDCl₃)** δ -122.1 (dd, J = 280.6, 56.0 Hz), -129.8 (dd, J = 280.6, 56.3 Hz) ppm; **HRMS (ESI-TOF) m/z** : $[M+H]^+$ calcd. for C₁₂H₁₄F₂NO: 226.1038, found 226.1035.

Enantiomeric excess = 90%, determined by HPLC (Daicel Chiralpak AD-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 25 °C, λ = 254 nm): t_R = 14.91 min (major), t_R = 16.08 min (minor). $[\alpha]_D^{28.4}$ = -2° (c = 10^{-3} , CHCl_3).





Figure S38. HPLC chromatograms for racemic **6j** and enantioenriched **6j**.

(*R*)-3-(Difluoromethyl)-6-fluoro-1,3-dimethylindolin-2-one (6k**):**



According to **GP-IX**, the reaction of **5k** (35.5 mg, 0.1 mmol) using $\text{Pd}(\text{TFA})_2$ (2.33 mg, 7 mol%), (*R*)-SEGPPOS (**L5**, 9.2 mg, 15 mol%), HCOONa (17 mg, 0.25mmol) and Ag_3PO_4 (21 mg, 0.05mmol) at 115 °C afforded **6k** (11 mg) in 48% yield and 84% *ee* as a yellow liquid; R_f = 0.37 (3% EtOAc, 30% DCM in hexane).

^1H NMR (500 MHz, CDCl_3) δ 7.31 (t, J = 6.6 Hz, 1H), 6.79 (t, J = 8.8 Hz, 1H), 6.62 (d, J = 8.7 Hz, 1H), 5.93 (t, J = 56.0 Hz, 1H), 3.21 (s, 3H), 1.50 (s, 3H); **$^{13}\text{C}\{^1\text{H}\}$ (126 MHz, CDCl_3)** δ 175.2 (dd, J = 9.5, 1.2 Hz), 163.8 (d, J = 246.5 Hz), 145.4 (d, J = 11.7 Hz), 125.9 (dd, J = 9.8, 1.2 Hz), 122.2 (bd, J = 1.7 Hz), 116.5 (dd, J = 247.7, 244.9 Hz), 109.1 (d, J = 22.4 Hz), 97.4 (d, J = 27.7 Hz), 51.6 (t, J = 21.2 Hz), 26.5, 17.8 (dd, J = 4.9, 2.4 Hz); **^{19}F NMR (377 MHz, CDCl_3)** δ -110.5 (td, J = 9.1, 5.3 Hz, 1F), -122.1 (dd, J = 281.4, 55.8 Hz, 1F), -129.9 (dd, J = 281.3, 56.2 Hz, 1F) ppm; **HRMS (ESI-TOF) m/z** : $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{11}\text{H}_{11}\text{F}_3\text{NO}$: 230.0787, found 230.0793.

Enantiomeric excess = 84%, determined by HPLC (Daicel Chiralpak AD-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 25 °C, λ = 254 nm): t_R = 16.24 min (major), t_R = 17.20 min (minor). $[\alpha]_D^{28}$ = -4° (c = 5×10^{-4} , CHCl₃).





Figure S39. HPLC chromatograms for racemic **6k** and enantioenriched **6k**.

(*R*)-6-Chloro-3-(difluoromethyl)-1,3-dimethylindolin-2-one (6l**):**



According to **GP-IX**, the reaction of **5l** (37 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), (*R*)-SEGPPOS (**L5**, 9.2 mg, 15 mol%), HCOONa (17 mg, 0.25 mmol) and Ag₃PO₄ (21 mg, 0.05 mmol) at 90 °C afforded **6l** (14.6 mg) in 59% yield and 96% *ee* as a white solid; R_f = 0.33 (3% EtOAc, 30% DCM in hexane); Melting point: 97–99 °C.

¹H NMR (500 MHz, CDCl₃) δ 7.29 (d, J = 7.8 Hz, 1H), 7.09 (dd, J = 7.9, 1.4 Hz, 1H), 6.88 (bd, J = 1.1 Hz, 1H), 5.94 (t, J = 55.9 Hz, 1H), 3.21 (s, 3H), 1.50 (s, 3H); **¹³C{¹H} (126 MHz, CDCl₃)** δ 174.8 (dd, J = 9.2, 1.2 Hz), 145.0, 135.2, 125.7 (bd, J = 0.6 Hz), 125.3, 122.9, 116.4 (dd, J = 248.0, 244.9 Hz), 109.2, 51.7 (t, J = 21.2 Hz), 26.5, 17.7 (dd, J = 5.0, 2.4 Hz); **¹⁹F NMR (377 MHz, CDCl₃)** δ -122.1 (dd, J = 280.6, 56.0 Hz, 1F), -129.8 (dd, J = 280.6, 56.3 Hz, 1F) ppm; **HRMS (ESI-TOF) m/z** : $[M+H]^+$ calcd. for C₁₁H₁₁ClF₂NO: 246.0492, found 246.0486.

Enantiomeric excess = 96%, determined by HPLC (Daicel Chiralpak OJ-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 25 °C, λ = 254 nm): t_R = 38.03 min (major), t_R = 45.16 min (minor). $[\alpha]_D^{28.6}$ = -6° (c = 5×10^{-4} , CHCl₃).





Figure S40. HPLC chromatograms for racemic **6l** and enantioenriched **6l**.

Tri-substituted Monofluoromethyl Acrylamides:

(*R*)-3-(Fluoromethyl)-1,3-dimethylindolin-2-one (**8a**):



According to **GP-X**, the reaction of **7a** (31.91 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), (*R*)-SEGPPOS (**L5**, 12.21 mg, 20 mol%), HCOONa (13.6 mg, 0.20 mmol) and Ag₃PO₄ (21 mg, 0.05 mmol) afforded **8a** (8.6 mg) in 45% yield and 78% *ee* as a white solid; *R*_f = 0.21 (3% EtOAc, 30% DCM in hexane);

Melting point: 50–52 °C.

¹H NMR (400 MHz, CDCl₃) δ 7.36–7.28 (m, 2H), 7.10 (t, *J* = 7.5 Hz, 1H), 6.88 (d, *J* = 7.7 Hz, 1H), 4.57 (d, *J* = 47.0 Hz, 2H), 3.23 (s, 3H), 1.40 (s, 3H); ¹³C{¹H} (126 MHz, CDCl₃) δ 177.4 (d, *J* = 6.2 Hz), 143.4, 131.0 (d, *J* = 0.8 Hz), 128.5, 123.2 122.8, 108.3, 86.3 (d, *J* = 177.4 Hz), 49.3 (d, *J* = 19.6 Hz), 26.3, 18.5 (d, *J* = 6.2 Hz); ¹⁹F NMR (377 MHz, CDCl₃) δ -223.6 (t, *J* = 47.0 Hz, 1F) ppm; HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. for C₁₁H₁₃FNO: 194.0976, found 194.0974.

Enantiomeric excess = 78%, determined by HPLC (Daicel Chiralpak AD-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 25 °C, λ = 254 nm): *t*_R = 26.58 min (minor), *t*_R = 29.56 min (major). [α]_D^{27.9} = -2° (c = 5*10⁻⁴, CHCl₃).





Figure S41. HPLC chromatograms for racemic **8a** and enantioenriched **8a**.

(*R*)-5-Fluoro-3-(fluoromethyl)-1,3-dimethylindolin-2-one (8b**):**



According to **GP-X**, the reaction of **7b** (33.71 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), (*R*)-SEGPHOS (**L5**, 12.21 mg, 20 mol%), HCOONa (13.6 mg, 0.20 mmol) and Ag₃PO₄ (21 mg, 0.05 mmol) afforded **8b** (12.8 mg) in 61% yield and >99% *ee* as a white solid; *R*_f = 0.20 (3% EtOAc, 30% DCM in hexane); Melting point: 88–90 °C.

¹H NMR (400 MHz, CDCl₃) δ 7.07–6.96 (m, 2H), 6.81 (dd, *J* = 8.4, 4.0 Hz, 1H), 4.55 (d, *J* = 47.0 Hz, 2H), 3.21 (s, 3H), 1.39 (s, 3H); ¹³C{¹H} (126 MHz, CDCl₃) δ 176.9 (d, *J* = 6.3 Hz), 159.4 (d, *J* = 241.1 Hz), 139.3 (d, *J* = 1.9 Hz), 132.6 (dd, *J* = 8.1, 0.6 Hz), 114.7 (d, *J* = 23.5 Hz), 111.6 (d, *J* = 24.8 Hz), 108.7 (d, *J* = 8.1 Hz), 86.0 (d, *J* = 177.8 Hz), 49.7 (dd, *J* = 19.5, 1.6 Hz), 26.4, 18.4 (d, *J* = 6.1 Hz); ¹⁹F NMR (377 MHz, CDCl₃) δ -(120.17–120.25) (m, 1F), -223.8 (t, *J* = 47.0 Hz, 1F) ppm; HRMS (ESI-TOF) *m/z*: [M+Na]⁺ calcd. for C₁₁H₁₁F₂NNaO: 234.0701, found 234.0702. Enantiomeric excess = >99%, determined by HPLC (Daicel Chiralpak AD-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 25 °C, λ = 254 nm): *t*_R = 28.03 min (major), *t*_R = 30.45 min (minor). [α]_D^{26.4} = -4° (c = 5·10⁻⁴, CHCl₃).





Figure S42. HPLC chromatograms for racemic **8b** and enantioenriched **8b**.

(*R*)-5-Bromo-3-(fluoromethyl)-1,3-dimethylindolin-2-one (8c**):**



According to **GP-X**, the reaction of **7c** (39.80 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), (*R*)-SEGPHOS (**L5**, 12.21 mg, 20 mol%), HCOONa (13.6 mg, 0.20 mmol) and Ag₃PO₄ (21 mg, 0.05 mmol) afforded **8c** (21.8 mg) in 80% yield and 77% *ee* as a white solid; *R*_f = 0.20 (3% EtOAc, 30% DCM in hexane); Melting point: 96–98 °C.

¹H NMR (400 MHz, CDCl₃) δ 7.44 (d, *J* = 8.2 Hz, 1H), 7.41 (s, 1H), 6.75 (d, *J* = 8.2 Hz, 1H), 4.55 (d, *J* = 46.9 Hz, 2H), 3.21 (s, 3H), 1.39 (s, 3H); ¹³C{¹H} (126 MHz, CDCl₃) δ 176.8 (d, *J* = 6.1 Hz), 142.5, 133.0, 131.4, 126.6, 115.5, 109.7, 86.0 (d, *J* = 177.9 Hz), 49.5 (d, *J* = 19.6 Hz), 26.4, 18.4 (d, *J* = 6.1 Hz); ¹⁹F NMR (377 MHz, CDCl₃) δ -223.5 (t, *J* = 46.9 Hz, 1F) ppm; HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. for C₁₁H₁₂BrFNO: 272.0081, found 272.0081.

Enantiomeric excess = 77%, determined by HPLC (Daicel Chiralpak AD-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 25 °C, λ = 254 nm): *t*_R = 26.99 min (minor), *t*_R = 42.82 min (major). [α]_D^{28.6} = -7° (c = 10⁻³, CHCl₃).





Figure S43. HPLC chromatograms for racemic **8c** and enantioenriched **8c**.

(*R*)-3-(Fluoromethyl)-1,3,6-trimethylindolin-2-one (8d**):**



According to **GP-X**, the reaction of **7d** (33.31 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), (*R*)-SEGPHOS (**L5**, 12.21 mg, 20 mol%), HCOONa (13.6 mg, 0.20 mmol) and Ag₃PO₄ (21 mg, 0.05 mmol) afforded **8d** (9.3 mg) in 45% yield and 83% *ee* as a white solid; *R*_f = 0.21 (3% EtOAc, 30% DCM in hexane); Melting point: 131–133 °C.

¹H NMR (400 MHz, CDCl₃) δ 7.17 (d, *J* = 7.5 Hz, 1H), 6.91 (d, *J* = 7.5 Hz, 1H), 6.70 (bs, 1H), 4.62–4.56 (m, 1H), 4.53–4.46 (m, 1H), 3.21 (s, 3H), 2.40 (s, 3H), 1.37 (bd, *J* = 1.2 Hz, 3H); **¹³C{¹H} (126 MHz, CDCl₃)** δ 177.7 (d, *J* = 6.0 Hz), 143.5, 138.7, 128.0 (d, *J* = 1.2 Hz), 123.2, 122.9, 109.2, 86.4 (d, *J* = 177.2 Hz), 49.1 (d, *J* = 19.4 Hz), 26.3, 21.8, 18.5 (d, *J* = 6.1 Hz); **¹⁹F NMR (377 MHz, CDCl₃)** δ -223.5 (t, *J* = 47.1 Hz, 1F) ppm; **HRMS (ESI-TOF) *m/z***: [M+Na]⁺ calcd. for C₁₂H₁₄FNNaO: 230.0952, found 230.0948.

Enantiomeric excess = 83%, determined by HPLC (Daicel Chiralpak AD-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 25 °C, λ = 254 nm): *t*_R = 23.57 min (minor), *t*_R = 27.89 min (major). [α]_D^{26.3} = -16° (c = 5·10⁻⁴, CHCl₃).





Figure S44. HPLC chromatograms for racemic **8d** and enantioenriched **8d**.

(R)-6-Chloro-3-(fluoromethyl)-1,3-dimethylindolin-2-one (8e**):**



According to **GP-X**, the reaction of **7e** (35.36 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), (*R*)-SEGPPOS (**L5**, 12.21 mg, 20 mol%), HCOONa (13.6 mg, 0.20 mmol) and Ag₃PO₄ (21 mg, 0.05 mmol) afforded **8e** (14.3 mg) in 63% yield and 84% *ee* as a white solid; *R*_f = 0.25 (3% EtOAc, 30% DCM in hexane); Melting point: 87–89 °C.

¹H NMR (400 MHz, CDCl₃) δ 7.20 (d, *J* = 7.9 Hz, 1H), 7.07 (d, *J* = 7.8 Hz, 1H), 6.87 (bs, 1H), 4.54 (d, *J* = 47.0 Hz, 2H), 3.21 (s, 3H), 1.38 (s, 3H); ¹³C{¹H} (126 MHz, CDCl₃) δ 177.2 (d, *J* = 6.1 Hz), 144.6, 134.4, 129.3 (d, *J* = 0.7 Hz), 124.1, 122.6, 109.1, 86.0 (d, *J* = 177.8 Hz), 49.1 (d, *J* = 19.5 Hz), 26.4, 18.4 (d, *J* = 6.0 Hz); ¹⁹F NMR (377 MHz, CDCl₃) δ -223.5 (t, *J* = 47.0 Hz, 1F) ppm; HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd. for C₁₁H₁₂ClFNO: 228.0586, found 228.0581.

Enantiomeric excess = 84%, determined by HPLC (Daicel Chiralpak AD-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 25 °C, λ = 254 nm): *t*_R = 22.02 min (minor), *t*_R = 25.90 min (major). [α]_D^{28.4} = -2° (c = 5*10⁻⁴, CHCl₃).





Figure S45. HPLC chromatograms for racemic **8e** and enantioenriched **8e**.

6. Synthetic Applications:

Halogenation Reactions: Chlorination using NCS and Bromination using NBS:



Scheme S11. Chlorination of **2a** using NCS provides **2f** and Bromination of **2a** using NBS provides **2g**.

Chlorination using NCS: Compound **2a** (22.92 mg, 0.1 mmol) and *N*-chlorosuccinimide (40 mg, 0.3 mmol) were taken in a 7.0 ml reaction vial equipped with a magnetic stir bar. Then, *t*BuOH (0.1 M) was added to the reaction mixture, vial was sealed and purged with N₂ gas. Afterwards, the reaction was kept for stirring at 50 °C for 48 h. The reaction mixture was concentrated under reduced pressure, and the crude mixture was purified on silica gel column chromatography to afford the desired chlorinated product **2f** (16 mg, 61%, >99% ee) as yellow liquid; R_f = 0.54 (3.0%, EtOAc, 30% DCM in hexane).

(S)-5-Chloro-1,3-dimethyl-3-(trifluoromethyl)indolin-2-one (2f)

Enantiomeric excess = >99%, determined by HPLC (Daicel Chiralpak OD-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 15 °C, λ = 254 nm): t_R = 22.51 min (major), t_R = 30.25 min (minor). $[\alpha]_D^{28.6}$ = +38° (c = 5*10⁻⁴, CHCl₃).




Figure S46. HPLC chromatography of the enantioenriched **2f**.

Bromination using NBS: Compound **2a** (22.92 mg, 0.1 mmol) and *N*-bromosuccinimide (19.5 mg, 0.11 mmol) were taken in a 7.0 ml reaction vial equipped with a magnetic stir bar. Then the reaction vial was taken under the glove box to add acetonitrile solvent (MeCN, 0.1 M). The reaction mixture was allowed to stir at room temperature for 36 hours. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure, and the crude mixture was purified on silica gel column chromatography to afford the desired brominated product **2g** (27.7 mg, 91%, 98% *ee*) as white solid; R_f = 0.26 (3.0%, EtOAc, 30% DCM in hexane).

(S)-5-Bromo-1,3-dimethyl-3-(trifluoromethyl)indolin-2-one (2g)

Enantiomeric excess = 98%, determined by HPLC (Daicel Chiralpak OJ-H Column, 2.5% *i*PrOH in *n*-Hexane, flow rate 1.0 mL/min, T = 25 °C, λ = 254 nm): t_R = 14.18 min (major), t_R = 27.14 min (minor). $[\alpha]_D^{29.1}$ = +38° (c = 10⁻³, CHCl₃).





Figure S47. HPLC chromatography of the enantioenriched **2g**.


7. Stereo-divergent reactions:

(S)-1,3-Dimethyl-3-(trifluoromethyl)indolin-2-one (**2a**) and **(R)**-1,3-Dimethyl-3-(trifluoromethyl)indolin-2-one (**2a'**):



Scheme S12. Stereo-divergent products with ligands *S*-L₄ and *R*-L₄.

(R)-1,3-Dimethyl-3-(trifluoromethyl)indolin-2-one (**2a'**):



According to **GP-V**, the reaction of *N*-(2-bromophenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1a**, 46.2 mg, 0.15 mmol) using $\text{Pd}(\text{TFA})_2$ (3.5 mg, 7 mol%), (*R*)-PHOX (**L**₄, 8.4 mg, 15 mol%), HCOONa (26 mg, 0.375 mmol) and K_3PO_4 (18 mg, 0.06 mmol) afforded the desired amide **2a'** (26.5 mg) in 77% yield and 91% ee as a white solid; R_f = 0.50 (3% EtOAc, 30%

DCM in hexane).

Enantiomeric excess = 91%, determined by HPLC (Daicel Chiralpak OJ-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 25 °C, λ = 254 nm): t_R = 21.45 min (minor), t_R = 22.67 min (major). $[\alpha]_D^{28.3} = -17^\circ$ ($c = 10^{-3}$, CHCl₃).






Figure S48. HPLC chromatography of the racemic **2a** and enantioenriched **2a** and **2a'**.

(*R*)-3-(Difluoromethyl)-1,3-dimethylindolin-2-one (6a) and (*S*)-3-(Difluoromethyl)-1,3-dimethylindolin-2-one (6a'):



Scheme S13. Stereo-divergent products with ligands *R*-L₅ and *S*-L₅.

(*S*)-3-(Difluoromethyl)-1,3-dimethylindolin-2-one (6a'):



According to **GP-IX**, the reaction of **5a** (33.71 mg, 0.1 mmol) using Pd(TFA)₂ (2.33 mg, 7 mol%), (*R*)-SEGPPOS (**L**₅, 9.2 mg, 15 mol%), HCOONa (17 mg, 0.25 mmol) and Ag₃PO₄ (21 mg, 0.05 mmol) afforded **6a'** (11.8 mg) in 56% yield and 92% *ee* as a colorless liquid; *R*_f = 0.32 (3% EtOAc, 30% DCM in hexane).

Enantiomeric excess = 92%, determined by HPLC (Daicel Chiralpak OJ-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 25 °C, λ = 254 nm): *t*_R = 23.39 min (major), *t*_R = 24.94 min (minor). [α]_D^{28.5} = +6° (c = 5*10⁻⁴, CHCl₃).







Figure S49. HPLC chromatography of the racemic **6a** and enantioenriched **6a** and **6a'**.

8. Mechanistic Studies:

Control Experiments:


Deuterium Incorporation Experiment:

An oven-dried reaction vial (7.0 mL) equipped with a magnetic bead was charged with *o*-bromo trifluoromethyl acryl amide (**1a**, 1.0 equiv., 0.1 mmol), Pd(TFA)₂ (2.33 mg, 7 mol%), DCOONa (18 mg, 0.25 mmol) and Ag₂CO₃ (11 mg, 0.04 mmol). Then the reaction vial was introduced inside the glove box and acetonitrile solvent (MeCN, 0.1 M) was added. The reaction vial was capped, taken outside, and stirred at 90 °C (oil bath/heating block) for 48 hours. After completion of the reaction (monitored by TLC), the vial was cooled to room temperature, the reaction mixture was diluted with DCM (10 mL) and filtered through a celite pad, and the filtrate was concentrated under vacuum. The crude mixture was purified on silica gel column chromatography to afford the desired product **Rac 2a-D** (20.7 mg, 90%) as a white solid; R_f = 0.22 (3.0%, EtOAc, 30% DCM in hexane).



Scheme S14. The racemic reductive Heck reaction of **1a** with DCOONa as hydride source.

An oven-dried reaction vial (7.0 mL) equipped with a magnetic bead was charged with *o*-bromo trifluoromethyl acryl amide (**1a**, 1.0 equiv., 0.05 mmol), Pd(TFA)₂ (1.2 mg, 7 mol%), L₄ (2.8 mg, 15 mol%), DCOONa (8.63 mg, 0.125 mmol) and K₃PO₄ (4.25 mg, 0.02 mmol). Then the reaction vial was introduced inside the glove box and acetonitrile solvent (MeCN, 0.05 M) was added. The reaction vial was capped, taken outside, and stirred at 60 °C (oil bath/heating block) for 48 hours. After completion of the reaction (monitored by TLC), the vial was cooled to room temperature, the reaction mixture was diluted with DCM (10 mL) and filtered through a celite pad, and the filtrate was concentrated under vacuum. The crude mixture was purified on silica gel column chromatography to afford the desired product **2a-D** (11 mg, 95%) and 96% *ee* a white solid; R_f = 0.22 (3.0%, EtOAc, 30% DCM in hexane).



Scheme S15. The asymmetric reductive Heck reaction of **1a** with DCOONa as hydride source.

(S)-1-Methyl-3-(methyl-D)-3-(trifluoromethyl)indolin-2-one (2a-D)

^1H NMR (400 MHz, CDCl_3) δ 7.43–7.35 (m, 2H), 7.12 (t, $J = 7.5$ Hz, 1H), 6.89 (d, $J = 7.8$ Hz, 1H), 3.24 (s, 3H), 1.63 (s, 2H); ^{13}C NMR (101 MHz, CDCl_3) δ 172.2 (q, $J = 2.8$ Hz), 143.6, 129.8, 126.2, 124.9 (q, $J = 281.7$ Hz), 124.5, 123.1, 108.6, 52.0 (q, $J = 27.7$ Hz), 26.5, 17.5 (tq, $J = 20.2$, 2.6 Hz); ^{19}F NMR (377 MHz, CDCl_3) δ -73.5 ppm; HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{11}\text{H}_{10}\text{DF}_3\text{NO}$: 231.0851, found 231.0860.

Enantiomeric excess = 96%, determined by HPLC (Daicel Chiralpak OJ-H Column, 1% $i\text{PrOH}$ in $n\text{-Hexane}$, flow rate 0.5 mL/min, $T = 25$ °C, $\lambda = 254$ nm): $t_R = 25.36$ min (major), $t_R = 27.50$ min (minor). $[\alpha]_D^{27.8} = +17^\circ$ ($c = 3 \times 10^{-4}$, CHCl_3).





Figure S50. HPLC chromatography of the enantioenriched **2a-D**.

Reactivity Profile without Hydride Source and Ligand:

According to **GP-IX**, the reaction of *N*-(2-bromophenyl)-*N*-methyl-2-(trifluoromethyl)acrylamide (**1a**, 0.025 mmol) was conducted under two conditions: (i) without a hydride source and (ii) without a ligand. *Without a hydride source, the reaction did not yield the desired product, leaving only the starting material. However, when the reaction was carried out without a ligand, 90% of the racemic product was obtained (by crude ¹⁹F NMR analysis), suggesting the presence of a rapid background reaction.*




Scheme S16. Role of hydride source and ligand in the reaction medium.

Asymmetric reductive Heck cyclization of monosubstituted terminal alkenes (**1a''**):

Following the general procedure (**GP-V**), the reaction of **1a''** afforded **2a''** in 19% yield and 5% *ee*. The NMR data matched with the reported data.^{7a}


Enantiomeric excess = 5%, determined by HPLC (Daicel Chiralpak OJ-H Column, 1% *i*PrOH in *n*-Hexane, flow rate 0.5 mL/min, T = 25 °C, λ = 254 nm): *t*_R = 25.26 min (minor), *t*_R = 30.59 min (major).



Scheme S17. Asymmetric Reductive Heck cyclization of *o*-bromo-acrylamides.

Asymmetric reductive Heck cyclization of terminally disubstituted (**3a'''**) acrylamides:

Following the general procedure (**GP-VII**), the reaction of **3a'''** afforded **4a'''** in 60% yield. The NMR data matched with the reported data.^{7b}



Scheme S18. Asymmetric Reductive Heck cyclization of *o*-iodo- β , β -methy, phenyl acrylamides.

9. Computational Studies:

The reaction mechanisms were studied through Density Functional Theory (DFT) using the B3LYP functional.⁸ Mixed basis sets were used to account for the relativistic effects from the heavy elements such as Pd. Lanl2DZ basis set⁹ was used for Pd, Br and I and for lighter atoms H, C, N, P, F and O the basis set 6-31G(D,P)¹⁰ was used. The Gaussian Program Package was used for all the calculations.¹¹ All the structures were optimized and stable geometries were found on the account of positive frequencies. We have located the species **A**, **TSs**, **TS_R**, **S-B** and **R-B** pertinent to the enantio-selectivity in the migratory insertion step.

For the reaction involving substrate **1a** with **S-L₄**, the energies with respect to the energy of **A** is given in Table S7. The location of possible transition state points (TS_R, TS_S) for both the *re* and *si* face based on interaction of ligand is done. The pictorial representation of optimized geometries can be seen in Figure S51.

Table S7: The energies (in kcal/mol) with respect to the energy of **A** for both the pathways **R** and **S** respectively for the reaction involving substrate **1a** and ligand **S-L₄**.

Pathway	E _A	E _{TS}	E _B
R	0.0	25.79	-15.83
S		21.27	-16.96




Figure S51. The pictorial representation of A, TS_R , TS_S , R-B , S-B for the reaction involving **1a** with ligand **S-L4**. The values in the parenthesis are the first vibrational frequency in cm^{-1} units.

The enantioselectivity is determined by the interaction between the isopropyl group of the ligand (**L4**) and the *Re* or *Si*-face of alkene (**1a**) during the migratory insertion step. Two intermediates (**R-B** and **S-B**) can be formed through the transition states (**TS_R** and **TS_S**). We have calculated the energies of the oxidative addition intermediate **A**, the two transition states (**TS_R**, **TS_S**), and two intermediates (**R-B** and **S-B**). The activation energies computed are ~21 kcal/mol for **TS_S** and ~26 kcal/mol for **TS_R**, corresponding to the *Si* and *Re* attack of the alkene, respectively (Scheme 17). The steric interactions between the isopropyl group and the alkene destabilize **TS_R** more than **TS_S**. For instance, the distance between these two carbons is 3.47 Å in **TS_R** and 4.62 Å in **TS_S**. Additionally, we identified a dihedral angle (52-54-71-76) that governs the positioning of the isopropyl and alkene groups. This dihedral angle is 18° for **TS_R** and -11° for **TS_S**, which results in the alkene being pushed toward the isopropyl group in **TS_R**, while it is pushed away in **TS_S**. Furthermore, the reaction Gibbs free energy (ΔG) was calculated at the reaction temperature of 60 °C for both processes. The formation of **S-B** (21.68 kcal/mol) was found to be more favorable than the formation of **R-B** (27.97 kcal/mol), supporting the preferential formation of **S-2a** under the given conditions.




Figure S52. Transition states for enantio-induction step.

Optimized cartesian coordinates (in XYZ format):

Substrate 1a with ligand S-L4

A (E = -2394.42243645 au)

P	-1.84375	-1.08355	-0.10486
C	-2.77010	-0.55590	-1.61220
C	-3.14001	0.79931	-1.79333
C	-3.15699	-1.49141	-2.58087
C	-3.90450	1.16262	-2.91387
C	-3.89347	-1.11165	-3.70446
H	-2.88330	-2.53249	-2.45455
C	-4.27259	0.21810	-3.86878
H	-4.19501	2.19926	-3.03383
H	-4.17405	-1.85907	-4.44056
H	-4.85133	0.52400	-4.73469
C	-1.50120	-2.86974	-0.36354
C	-2.20580	-3.87684	0.31169
C	-0.47033	-3.23192	-1.24716
C	-1.89219	-5.22057	0.09632
H	-2.99492	-3.61876	1.00883
C	-0.16709	-4.57402	-1.46543
H	0.10551	-2.46586	-1.75420
C	-0.87704	-5.57181	-0.79298
H	-2.44273	-5.99078	0.62857
H	0.63389	-4.83892	-2.14887
H	-0.63288	-6.61740	-0.95616
C	-3.14021	-1.01372	1.20635
C	-2.78635	-0.60024	2.50011
C	-4.47514	-1.36191	0.94009
C	-3.74792	-0.54972	3.51118
H	-1.76390	-0.29904	2.70897
C	-5.43296	-1.30773	1.95278
H	-4.76957	-1.67008	-0.05853
C	-5.07031	-0.90348	3.23981
H	-3.46125	-0.22608	4.50729
H	-6.46239	-1.57698	1.73481
H	-5.81831	-0.85875	4.02608

C	-2.74526	1.89743	-0.88261
C	-3.06612	3.89819	0.08732
C	-1.63506	3.40245	0.35384
H	-3.12735	4.90431	-0.32880
H	-3.72011	3.82284	0.96214
H	-1.39371	3.38514	1.41830
N	-1.69722	1.99800	-0.13780
O	-3.56761	2.97150	-0.91524
C	-0.52531	4.20401	-0.37474
C	-0.34733	5.57348	0.29843
H	-0.11600	5.46188	1.36234
H	0.47915	6.11978	-0.16626
H	-1.24326	6.20075	0.20489
C	-0.74523	4.34126	-1.88790
H	-0.83411	3.36618	-2.37697
H	-1.63876	4.92927	-2.13098
H	0.10945	4.85329	-2.34082
H	0.39534	3.63611	-0.21030
Pd	-0.19361	0.44217	0.47615
Br	1.16886	2.03325	1.99959
C	1.18913	-0.98941	0.83198
C	1.00603	-1.89166	1.88756
C	2.34188	-1.12909	0.02944
C	1.91108	-2.92518	2.13961
H	0.14288	-1.78659	2.53762
C	3.22341	-2.19915	0.26028
C	3.02108	-3.08686	1.31305
H	1.73959	-3.60135	2.97293
H	4.09012	-2.30951	-0.38347
H	3.72587	-3.89583	1.48144
N	2.65238	-0.22137	-1.04366
C	1.74285	-0.15699	-2.18877
H	1.99465	0.71719	-2.78695
H	1.84254	-1.04834	-2.82388

H	0.71376	-0.07780	-1.83141
C	3.90095	0.33425	-1.24958
O	4.21716	0.83643	-2.32495
C	4.89670	0.36263	-0.11744
C	6.28139	-0.09775	-0.50125
F	6.22842	-1.30177	-1.13512
F	7.07514	-0.26048	0.58163
F	6.91345	0.75170	-1.32939
C	4.65983	0.87592	1.09017
H	3.67359	1.22631	1.37812
H	5.45859	0.95471	1.82021

TS_R (E = -2394.38132934 au)

P	1.08540	1.36762	0.06175
C	1.86193	1.40873	-1.62589
C	2.43341	0.22325	-2.14479
C	1.93974	2.57202	-2.40266
C	3.06087	0.22964	-3.39731
C	2.54093	2.56350	-3.66344
H	1.53529	3.50105	-2.01917
C	3.09956	1.39054	-4.16618
H	3.51632	-0.68495	-3.76100
H	2.58033	3.48103	-4.24333
H	3.57306	1.37889	-5.14287
C	0.46405	3.07721	0.34225
C	0.87629	3.82769	1.45448
C	-0.49268	3.62782	-0.52705
C	0.35773	5.10395	1.67841
H	1.60371	3.41809	2.14605
C	-0.99549	4.90992	-0.30990
H	-0.84051	3.05508	-1.38034
C	-0.57222	5.65164	0.79451
H	0.68744	5.67067	2.54427
H	-1.72643	5.32469	-0.99798

H	-0.96880	6.64798	0.96677
C	2.55580	1.23625	1.16482
C	2.47398	0.45019	2.32317
C	3.74551	1.92850	0.87649
C	3.57235	0.36607	3.18423
H	1.57360	-0.12138	2.54372
C	4.83582	1.83730	1.73957
H	3.82201	2.53515	-0.02101
C	4.74953	1.05633	2.89646
H	3.49887	-0.25068	4.07506
H	5.75248	2.37264	1.50874
H	5.60166	0.98508	3.56683
C	2.47140	-1.03826	-1.37339
C	3.56670	-2.77378	-0.46122
C	2.06956	-2.84023	-0.08597
H	3.95194	-3.67538	-0.93994
H	4.20941	-2.50593	0.38199
H	1.90913	-2.78629	0.99461
N	1.53790	-1.57170	-0.66541
O	3.65112	-1.68898	-1.42857
C	1.33475	-4.09781	-0.60272
C	1.85972	-5.34294	0.13018
H	1.76180	-5.22714	1.21392
H	1.28835	-6.22811	-0.16663
H	2.91277	-5.54608	-0.10157
C	1.38769	-4.26531	-2.12729
H	0.98661	-3.38916	-2.64722
H	2.41025	-4.43062	-2.48849
H	0.79521	-5.13258	-2.43582
H	0.29226	-3.97493	-0.30098
Pd	-0.35911	-0.57049	-0.02593
Br	-0.11077	-2.15456	2.63537
C	-2.16296	0.46687	0.44602
C	-2.26295	0.69787	1.82755

C	-2.94809	1.24460	-0.43128
C	-2.98617	1.79347	2.30012
H	-1.72850	0.04427	2.51148
C	-3.67193	2.34500	0.04483
C	-3.66550	2.62924	1.40783
H	-3.01142	1.99713	3.36652
H	-4.27398	2.93818	-0.63581
H	-4.22599	3.48249	1.77858
N	-3.08765	0.77664	-1.75237
C	-3.52216	1.61586	-2.85775
H	-4.57725	1.89551	-2.75632
H	-2.91710	2.52583	-2.90627
H	-3.39503	1.03899	-3.77358
C	-2.91205	-0.57429	-1.94373
O	-2.93843	-1.13013	-3.03129
C	-2.65413	-1.32339	-0.64165
C	-3.89577	-1.69833	0.17244
F	-4.82136	-0.72165	0.23072
F	-3.59872	-2.07684	1.41806
F	-4.48358	-2.74778	-0.45135
C	-1.60217	-2.24997	-0.62444
H	-1.10574	-2.46499	-1.56542
H	-1.57536	-2.99659	0.16023

TSs(E=-2394.38852991 au)

P	-1.41432	-0.80034	0.21925
C	-2.99350	-0.14443	-0.51929
C	-3.34898	1.22937	-0.48844
C	-3.88503	-1.03815	-1.12653
C	-4.56059	1.64722	-1.05936
C	-5.08487	-0.60809	-1.69593
H	-3.64379	-2.09264	-1.16328
C	-5.42480	0.74051	-1.66530
H	-4.81136	2.70030	-1.02364

H	-5.74609	-1.33374	-2.16052
H	-6.35376	1.08821	-2.10688
C	-1.54011	-2.63451	-0.04193
C	-1.83655	-3.54307	0.98463
C	-1.23236	-3.13685	-1.32144
C	-1.83191	-4.91898	0.73872
H	-2.06852	-3.18327	1.98077
C	-1.23964	-4.51014	-1.56477
H	-0.99512	-2.44661	-2.12704
C	-1.53585	-5.40625	-0.53403
H	-2.06157	-5.60811	1.54675
H	-1.00789	-4.87880	-2.55999
H	-1.53321	-6.47604	-0.72284
C	-1.74617	-0.61383	2.02890
C	-0.69373	-0.36265	2.91725
C	-3.04795	-0.74212	2.54080
C	-0.93314	-0.24741	4.28746
H	0.31213	-0.24733	2.53646
C	-3.28622	-0.62394	3.91096
H	-3.87983	-0.93110	1.86997
C	-2.22903	-0.37685	4.78865
H	-0.10351	-0.05349	4.96169
H	-4.29933	-0.72381	4.29031
H	-2.41539	-0.28412	5.85490
C	-2.50225	2.26241	0.13014
C	-2.09597	4.33247	0.91286
C	-0.86596	3.40299	1.11318
H	-1.89017	5.22086	0.31052
H	-2.55764	4.64190	1.85566
H	-0.64052	3.29719	2.18258
N	-1.33186	2.09916	0.61563
O	-3.04789	3.51453	0.19620
C	0.43565	3.85705	0.41039
C	1.00840	5.11331	1.08328

H	1.15274	4.96722	2.16052
H	1.97717	5.37365	0.64575
H	0.34835	5.97961	0.95113
C	0.28179	4.04968	-1.10414
H	-0.12524	3.15616	-1.58621
H	-0.37135	4.89697	-1.34570
H	1.25912	4.25912	-1.55125
H	1.14723	3.03723	0.56650
Pd	0.67534	-0.14419	-0.92246
C	2.04597	-0.89362	0.59468
C	1.84925	-2.27310	0.75400
C	2.71223	-0.19328	1.61957
C	2.11743	-2.88990	1.97730
H	1.42092	-2.85801	-0.05261
C	2.98556	-0.80601	2.85003
C	2.65779	-2.14807	3.03158
H	1.89030	-3.94342	2.10783
H	3.48991	-0.25483	3.63667
H	2.86586	-2.62569	3.98433
N	3.20063	1.08335	1.29881
C	3.60845	2.05433	2.30346
H	3.80628	2.99365	1.78848
H	2.81020	2.19233	3.03776
H	4.52030	1.73256	2.81962
C	3.41793	1.34065	-0.03357
O	3.81787	2.40744	-0.47325
C	3.07262	0.16248	-0.94504
C	4.17231	-0.88382	-1.13853
F	3.69887	-2.00498	-1.71253
F	4.81051	-1.22685	-0.00511
F	5.10563	-0.36588	-1.96592
C	2.33865	0.47915	-2.10927
Br	-0.66750	0.35296	-3.08807
H	2.09530	1.51902	-2.29648

H 2.40721 -0.16370 -2.97912

R-B(E=-2394.44767058 au)

P	1.11015	-1.26892	0.18849
C	1.18470	-1.03360	2.02915
C	1.83066	0.07054	2.65011
C	0.51901	-1.95357	2.85188
C	1.81208	0.19043	4.04740
C	0.49769	-1.81375	4.24111
H	0.01378	-2.80155	2.40580
C	1.14954	-0.74101	4.84247
H	2.32111	1.03414	4.49810
H	-0.02729	-2.54822	4.84461
H	1.14122	-0.62398	5.92173
C	0.35839	-2.94301	-0.04501
C	1.06817	-4.11940	0.25427
C	-0.93738	-3.04874	-0.56991
C	0.48268	-5.36779	0.04948
H	2.08217	-4.06286	0.63610
C	-1.52108	-4.30058	-0.77469
H	-1.48351	-2.14945	-0.83511
C	-0.81374	-5.46138	-0.46386
H	1.04340	-6.26839	0.28264
H	-2.52429	-4.36075	-1.18602
H	-1.26410	-6.43603	-0.62879
C	2.85930	-1.54474	-0.32504
C	3.22496	-1.42489	-1.67196
C	3.81577	-1.96561	0.61428
C	4.53004	-1.72114	-2.06929
H	2.50307	-1.07586	-2.40373
C	5.11804	-2.25988	0.20834
H	3.55409	-2.05872	1.66320
C	5.47858	-2.13834	-1.13475
H	4.80170	-1.61707	-3.11566

H	5.84901	-2.58126	0.94499
H	6.49345	-2.36504	-1.44908
C	2.53234	1.11304	1.88110
C	3.85765	2.91090	1.63347
C	3.37756	2.37210	0.25565
H	3.44751	3.89485	1.87938
H	4.94365	2.93635	1.74496
H	4.21880	1.91797	-0.28627
N	2.46392	1.27583	0.61816
O	3.33432	1.95621	2.59478
C	2.73014	3.40171	-0.69552
C	3.78076	4.40747	-1.19101
H	4.63178	3.90310	-1.66244
H	3.34459	5.08543	-1.93115
H	4.16820	5.02700	-0.37173
C	1.51358	4.11525	-0.09299
H	0.77357	3.40497	0.28205
H	1.79037	4.78608	0.72983
H	1.02488	4.72881	-0.85637
H	2.38004	2.81753	-1.55540
Pd	-0.14719	0.30399	-0.87866
Br	0.69170	0.58143	-3.32436
C	-3.60758	0.17380	-0.47107
C	-3.45599	-0.28018	-1.77502
C	-4.75969	-0.16470	0.25709
C	-4.45895	-1.08795	-2.33412
H	-2.58253	-0.01513	-2.36402
C	-5.76121	-0.96615	-0.28008
C	-5.59157	-1.42580	-1.59285
H	-4.35041	-1.44415	-3.35356
H	-6.64696	-1.22384	0.29111
H	-6.36050	-2.05061	-2.03800
N	-4.71259	0.41368	1.53434
C	-5.73955	0.29164	2.54901

H	-5.40791	0.86209	3.41731
H	-6.69219	0.69657	2.19019
H	-5.88403	-0.75657	2.83321
C	-3.56744	1.16546	1.71378
O	-3.27581	1.79154	2.71388
C	-2.70504	1.01607	0.41579
C	-2.45479	2.40029	-0.17664
F	-3.59172	3.03457	-0.50649
F	-1.71310	2.27961	-1.32791
F	-1.75897	3.19992	0.64590
C	-1.36571	0.35016	0.80271
H	-1.57486	-0.64009	1.21117
H	-0.86305	0.94971	1.56515

***S*-B(E=-2394.44946953 au)**


P	1.66434	1.05601	0.14072
C	3.26077	0.68628	-0.74086
C	3.89632	-0.58265	-0.70540
C	3.86252	1.69676	-1.50397
C	5.09553	-0.78098	-1.40723
C	5.04737	1.48199	-2.20947
H	3.40201	2.67523	-1.55238
C	5.66953	0.23840	-2.16045
H	5.56704	-1.75486	-1.35649
H	5.47809	2.29239	-2.79043
H	6.59314	0.05879	-2.70247
C	1.46035	2.88545	-0.10978
C	1.88052	3.85276	0.81550
C	0.79821	3.30962	-1.27691
C	1.64651	5.20956	0.58000
H	2.38792	3.54962	1.72503
C	0.57670	4.66652	-1.51495
H	0.46391	2.57141	-2.00126
C	0.99666	5.62014	-0.58476

H	1.97513	5.94533	1.30902
H	0.07133	4.97649	-2.42539
H	0.81738	6.67628	-0.76636
C	2.11357	0.94628	1.92939
C	1.09670	0.71566	2.86822
C	3.43071	1.11530	2.38280
C	1.39418	0.65576	4.23073
H	0.07383	0.58234	2.53265
C	3.72526	1.05101	3.74602
H	4.23069	1.29158	1.67062
C	2.70783	0.82074	4.67351
H	0.59728	0.47320	4.94653
H	4.75069	1.18027	4.08129
H	2.93791	0.76894	5.73406
C	3.35886	-1.72958	0.04713
C	3.51835	-3.75130	1.01701
C	2.09065	-3.15861	1.18014
H	3.54342	-4.72346	0.51861
H	4.06327	-3.82331	1.96390
H	1.84513	-3.03742	2.24265
N	2.20221	-1.81949	0.57876
O	4.20596	-2.79787	0.17635
C	0.95623	-3.98929	0.53189
C	0.76643	-5.31746	1.28129
H	0.59483	-5.15706	2.35217
H	-0.09519	-5.86315	0.88347
H	1.63932	-5.97425	1.17753
C	1.14966	-4.20648	-0.97471
H	1.20867	-3.25471	-1.50952
H	2.05334	-4.78842	-1.19491
H	0.30153	-4.76511	-1.38502
H	0.04577	-3.39589	0.66434
Pd	-0.48473	0.11815	-0.65616
C	-4.77736	-0.22015	-0.34876

C	-5.73370	-0.85827	-1.12242
C	-5.13449	0.89326	0.42802
C	-7.04551	-0.36042	-1.11971
H	-5.47051	-1.72515	-1.71950
C	-6.42584	1.39976	0.44786
C	-7.38312	0.74970	-0.34478
H	-7.80415	-0.84476	-1.72631
H	-6.69232	2.26139	1.05102
H	-8.40321	1.12151	-0.35249
N	-3.99239	1.38729	1.10941
C	-3.94677	2.61129	1.89003
H	-2.90952	2.78585	2.17642
H	-4.30680	3.45585	1.29393
H	-4.56443	2.51581	2.78831
C	-2.89889	0.65676	0.78042
O	-1.72181	0.92586	1.07745
C	-3.29999	-0.50402	-0.12956
C	-3.14805	-1.82505	0.64211
F	-3.52430	-2.86779	-0.12500
F	-3.91857	-1.83792	1.75430
F	-1.88152	-2.05127	1.04518
C	-2.35223	-0.45926	-1.35151
H	-2.67074	0.32503	-2.04226
H	-2.32027	-1.41289	-1.87792
Br	0.41098	-0.53042	-2.93587

10. X-ray Structural Analysis:

Crystal Growth of Compound 7b:



A saturated solution of **7b** in DCM was kept at room temperature to obtain crystals. Colorless crystals were observed after DCM evaporation. A suitable crystal was selected and visualized on a Bruker APEX-II CCD diffractometer. The crystal was kept at 298.00 K during data collection.

Using Olex2, the structure was solved with the olex2.solve structure solution program using Charge Flipping and refined with the olex2.refine refinement package using Gauss–Newton minimization. The crystal structure was drawn on diamond-3 software.

Crystal Structure of Compound 7b:





Figure S53. Crystal Structure of compound **7b**. The ellipsoid contour has been drawn at 25% probability levels.

Table S8: Crystal data and structure refinement for **7b**:

Empirical formula	C₁₁H₁₀F₂INO
CCDC	2384466
Formula weight	337.11
Temperature/K	298.00
Crystal system	monoclinic
Space group	C2/c
a/Å	20.4768(11)
b/Å	11.5083(6)
c/Å	14.1850(8)

$\alpha/^{\circ}$	90
$\beta/^{\circ}$	132.601(1)
$\gamma/^{\circ}$	90
Volume/ $\text{\AA}^3$	2460.5(2)
Z	8
$\rho_{\text{calc}}(\text{g}/\text{cm}^3)$	1.820
μ/mm^{-1}	2.607
F(000)	1293.7
Crystal size/ mm^3	$0.015 \times 0.014 \times 0.012$
Radiation	Mo K α ($\lambda = 0.71073$)
2 Θ range for data collection/ $^{\circ}$	4.46 to 55.42
Index ranges	$-26 \leq h \leq 26, -15 \leq k \leq 15, -18 \leq l \leq 18$
Reflections collected	25756
Independent reflections	2895 [$R_{\text{int}} = 0.0368, R_{\text{sigma}} = 0.0192$]
Data/restraints/parameters	2895/0/147
Goodness-of-fit on F^2	1.038
Final R indexes [$I \geq 2\sigma(I)$]	$R_1 = 0.0285, wR_2 = 0.0622$
Final R indexes [all data]	$R_1 = 0.0398, wR_2 = 0.0682$
Largest diff. peak/hole/ $e \text{\AA}^{-3}$	0.77/-0.83

Crystal Growth of Compound 2g:



A saturated solution of **2g** in DCM was kept at room temperature to obtain crystals. Colorless crystals were observed after DCM evaporation. A suitable crystal was selected and visualized on a Bruker APEX-II CCD diffractometer. The crystal was kept at 295.00 K during data collection.

Using Olex2, the structure was solved with the olex2.solve structure solution program using Charge Flipping and refined with the olex2.refine refinement package using Gauss-Newton minimization. The crystal structure was drawn on diamond-3 software.

Crystal Structure of Compound 2g:





Figure S54. Crystal Structure of compound **2g**. The ellipsoid contour has been drawn at 25% probability levels.

Table S9: Crystal data and structure refinement for 2g:

Empirical formula	C₁₁H₉BrF₃NO
CCDC	2384458
Formula weight	308.10
Temperature/K	295.00
Crystal system	orthorhombic
Space group	P2 ₁ /ac
a/Å	7.084(3)
b/Å	10.507(5)
c/Å	16.180(8)
α /°	90
β /°	90
γ /°	90
Volume/Å ³	1204.3(10)
Z	4
ρ_{calc} (g/cm ³)	1.699
μ /mm ⁻¹	0.063
F(000)	608
Crystal size/mm ³	0.22 × 0.14 × 0.102
Radiation	Mo K α (λ = 0.71073)
2 Θ range for data collection/°	4.62 to 52.90
Index ranges	-8 ≤ h ≤ 8, -13 ≤ k ≤ 13, -20 ≤ l ≤ 20
Reflections collected	17814
Independent reflections	2419 [R _{int} = 0.0476, R _{sigma} = 0.0364]

Data/restraints/parameters	2419/0/156
Goodness-of-fit on F^2	1.028
Final R indexes [$I \geq 2\sigma(I)$]	$R_1 = 0.0265$, $wR_2 = 0.0589$
Final R indexes [all data]	$R_1 = 0.0388$, $wR_2 = 0.0630$
Largest diff. peak/hole/ $e \text{ \AA}^{-3}$	0.25/−0.32
Flack parameter	0.048(6)

Crystal Growth of Compound **6g**:



A saturated solution of **6g** in DCM was kept at room temperature to obtain crystals. Colorless crystals were observed after DCM evaporation. A suitable crystal was selected and visualized on a Rigaku XtaLab Synergy Custom, X-Ray Diffractometer with RA-MicroMax 007HF Generator and HyPix 6000 Detector. The crystal was kept at 100.00 K during data collection. Using CrysAlisPro, the structure was solved and refined with the olex2.refine refinement package using Gauss–Newton minimization. The crystal structure was drawn on diamond–3 software.

Crystal Structure of compound **6g**:




Figure S55. Crystal Structure of compound **6g**. The ellipsoid contour has been drawn at 50% probability levels.

Table S10: Crystal data and structure refinement for **6g:**

Empirical formula	C₁₁H₁₀BrF₂NO
CCDC	2407321
Formula weight	290.11
Temperature/K	100.00
Crystal system	orthorhombic
Space group	P2 ₁ 2 ₁ 2 ₁

a/Å	7.2114(5)
b/Å	8.6463(5)
c/Å	17.6697(11)
$\alpha/^\circ$	90
$\beta/^\circ$	90
$\gamma/^\circ$	90
Volume/Å ³	1101.74(12)
Z	4
$\rho_{\text{calc}}(\text{g}/\text{cm}^3)$	1.749
μ/mm^{-1}	5.180
F(000)	576.0
Crystal size/mm ³	$0.192 \times 0.134 \times 0.094$
Radiation	Cu K α ($\lambda = 1.54184$)
2 Θ range for data collection/ $^\circ$	5.006 to 81.420
Index ranges	$-8 \leq h \leq 9, -10 \leq k \leq 4, -22 \leq l \leq 22$
Reflections collected	4283
Independent reflections	2105 [Rint = 0.0800, Rsigma = 0.0658]
Data/restraints/parameters	2105/0/129
Goodness-of-fit on F ²	1.171
Final R indexes [$I > 4\sigma(I)$]	$R_1 = 0.0649, wR_2 = 0.1874$
Final R indexes [all data]	$R_1 = 0.0680, wR_2 = 0.1857$
Largest diff. peak/hole/ e Å ⁻³	1.366/-1.443
Flack parameter	0.02(5)

11. References:

1. Bai, X.; Wu, C.; Ge, S.; Lu, Y. *Angew. Chem. Int. Ed.* **2020**, *59*, 2764–2768.
2. (a) Sharma, R.; Sihag, N.; Bhartiya, H.; Saini, S.; Kumar, A.; Yadav, M. R. *Org. Chem. Front.* **2024**, *11*, 1736–1741. (b) Dong, W.; Liu, Y.; Hu, B.; Ren, K.; Li, Y.; Xie, X.; Jiang, Y.; Zhang, Z. *Chem. Commun.* **2015**, *51*, 4587–4590. (c) Seashore-Ludlow, B.; Somfai, P. *Org. Lett.* **2012**, *14*, 3858–3861.
3. Xiao, P.; Pannecoucke, X.; Bouillon, J.P.; Couve-Bonnaire, S. *Adv. Synth. Catal.* **2020**, *362*, 949–954.
4. Li, Y.; Sun, G.; He, X.; Lv, H.; Gao, B. *J. Fluor. Chem.* **2023**, *268*, 110115.

5. (a) Kilaru, P.; Acharya, S.P.; Zhao, P. *Chem. Commun.* **2018**, *54*, 924–927. (b) Liu, Z.; Zhong, S.; Ji, X.; Deng, G.J.; Huang, H. *ACS Catal.* **2021**, *11*, 4422–4429.
6. Shaw, R.; Sihag, N.; Jain, S.; Sharma, R.; Yadav, M. R. *J. Org. Chem.* **2023**, *88*, 5652–5660.
7. (a) Giraldo, J. J. A.; Lindsay, A. C.; Seo, R. C.-Y.; Kilmartina, P. A.; Sperry, J. *Org. Biomol. Chem.* **2023**, *21*, 5609–5615. (b) Tang, S.; Peng, P.; Zhong, P.; Li, J.-H. *J. Org. Chem.* **2008**, *73*, 5476–5480.
8. Becke A. D. *J. Chem. Phys.* **1993**, *98*, 5648.
9. Dunning Jr., T. H; Hay, P. J. in *Modern Theoretical Chemistry*, Ed. H. F. Schaefer III, Vol. 3 (Plenum, New York, 1977) 1–28.
10. Ditchfield, R.; Hehre, W. J.; Pople J. A. *J. Chem. Phys.* **1971**, *54*, 724.
11. Gaussian 09, Revision E. 01, Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A. ; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Petersson, G. A.; Nakatsuji, H.; Li, X.; Caricato, M.; Marenich, A.; Bloino, J.; Janesko, B. G.; Gomperts, R.; Mennucci, B.; Hratchian, H. P.; Ortiz, J. V.; Izmaylov, A. F.; Sonnenberg, J. L.; Williams-Young D.; Ding, F.; Lipparini, F.; Egidi, F.; Goings, J.; Peng, B.; Petrone, A.; Henderson, T.; Ranasinghe, D.; Zakrzewski, V. G.; Gao, J.; Rega, N.; Zheng, G.; Liang, W.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Throssell, K.; Montgomery, Jr. J. A.; Peralta, J. E.; Ogliaro, F.; Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, K. N.; Staroverov, V. N.; Keith, T.; Kobayashi, R.; Normand, J.; 57 Raghavachari, K.; Rendell, A.; Burant, J. C.; Iyengar, A. S.; Tomasi, J.; Cossi, M.; Millam, J. M.; Klene, M.; Adamo, C.; Cammi, R.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Farkas, O.; Foresman, J. B.; Fox, D.-J.; Gaussian, Inc., Wallingford CT, 2016.

Jul24-2024
4-ester cf3 aa liquid


8.327
8.020
8.004

7.271
7.260


5.805
5.629

3.946

3.321



¹H-NMR (500 MHz, CDCl₃)



30.01.24
ns-4ester sm


164.69
163.41

146.17
135.18
134.32
134.07
133.82
133.56
131.69
130.04
129.98
124.94
124.91
124.87
124.42
122.50
122.25
120.07
117.89


77.25
77.00
76.75

52.66


36.31





¹³C{¹H}-NMR (126 MHz, CDCl₃)







NS-4-ester SM
19F




¹⁹F-NMR (377 MHz, CDCl₃)











November 2023 all
NS-ibf amide P



$^{19}\text{F}\{^1\text{H}\}$ -NMR (471 MHz, CDCl_3)



^1H -NMR (500 MHz, CDCl_3)



14.02.24
ns-chlo sm

— 173.48

— 163.63

— 153.76

139.98

134.12

133.97

133.86

133.61

133.35

131.42

130.23

129.03

128.67

124.52

124.48

124.44

124.40

122.64

122.22

120.58

120.04

117.86

79.33

77.25

77.00


76.74

— 61.94


— 46.84

25.17


24.80




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)



NS-CHLOFIBRIC SM
 ^{19}F




^{19}F -NMR (377 MHz, CDCl_3)




May17-2024
ns-n-et cf3 aa

7.917
7.906
7.387
7.374
7.360
7.260
7.114
7.100
7.068
7.054
7.039
5.737
5.645
4.370
4.357
4.343
4.330
4.317
3.251
3.242
3.230
3.216
1.163
1.152




$^1\text{H-NMR}$ (500 MHz, CDCl_3)




May17-2024
ns-n-et cf3 aa


163.10
143.60
140.50
134.67
134.42
134.16
133.92
131.00
129.88
124.71
124.19
124.15
124.11
122.53
120.35
118.18
99.55
77.25
77.00
76.75
43.92
11.87




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)



NS-N-ET
19F




^{19}F -NMR (377 MHz, CDCl_3)




May30-2024
ns-nbnz solid cf3 aa


7.918
7.902
7.260
7.253
7.247
7.188
6.896
6.891
6.591
5.802
5.772
5.763
5.715
4.157
4.129




^1H -NMR (500 MHz, CDCl_3)




May30-2024
ns-nbnz solid cf3 aa




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)



NS-BNZ O-I AMIDE
19F



^{19}F -NMR (377 MHz, CDCl_3)




Apr22-2024
ns-4-me iodo cf3 aa

7.707
7.260
7.164
7.148
7.039
7.023


5.776
5.679

3.256

2.316



¹H-NMR (500 MHz, CDCl₃)



Apr22-2024
ns-4-me iodo cf3 aa

163.73

143.05
140.67
140.36
134.35
134.10
133.85
133.60
130.55


128.86
124.66
124.62
124.58
124.54
122.47
120.29
118.11

98.31


77.25
77.00
76.75

36.93


20.43




¹³C{¹H}-NMR (126 MHz, CDCl₃)




4-Me




¹⁹F-NMR (377 MHz, CDCl₃)




Apr22-2024
4F-cf3 aa iodo



¹H-NMR (500 MHz, CDCl₃)



Apr22-2024
4F-cf3 aa iodo




163.52
162.08
160.06

141.93
141.90
134.05
130.17
130.10
127.19
126.99
124.65
124.61
122.30
120.13
116.86
116.56
98.49


77.25
77.00
76.74

36.86

¹³C{¹H}-NMR (126 MHz, CDCl₃)




NS-4-F-CF₃ AA
19F




-64.11
-64.78

-110.62
-110.63
-110.65


¹⁹F-NMR (377 MHz, CDCl₃)




May31-2024
ns-4-cl cf3 aa




¹H-NMR (500 MHz, CDCl₃)




May31-2024
ns-4-cl cf3 aa




¹³C{¹H}-NMR (126 MHz, CDCl₃)




NS-4-CL CF3 AA
19F




¹⁹F-NMR (377 MHz, CDCl₃)




Apr26-2024
rs-4br-o-i-cf3 aa




¹H-NMR (500 MHz, CDCl₃)




Apr26-2024
RS-4BR-OI-CF3-AA




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)



RS-4-Br AA
19F




^{19}F -NMR (377 MHz, CDCl_3)




May30-2024
NS 4 CN CF3

8.185
7.701
7.686
7.277
7.260
5.847
5.669
3.287




¹H-NMR (500 MHz, CDCl₃)




May30-2024
NS 4cn cf3


163.18
149.85
143.66
134.00
133.75
133.45
130.01
125.45
125.43
124.37
122.20
120.02
117.84
115.95
113.90
98.83
77.25
77.00
76.75
36.76




¹³C{¹H}-NMR (126 MHz, CDCl₃)



NS 4 CN



¹⁹F-NMR (377 MHz, CDCl₃)




May30-2024
ns-4-cf3 amide


8.134
7.656
7.641
7.288
7.273
7.260

5.828
5.678


3.285




¹H-NMR (500 MHz, CDCl₃)




May30-2024
ns-4-cf3 amide




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)




4 CF3 OI AA




^{19}F -NMR (377 MHz, CDCl_3)



10. 5-Me




¹H-NMR (500 MHz, CDCl₃)




Apr24-2024


RS-5Me O-I-CF₃ AA




¹³C{¹H}-NMR (126 MHz, CDCl₃)




RS-5-Me o-I CF3 AA
19F




¹⁹F-NMR (377 MHz, CDCl₃)




Apr24-2024
rs-5f-o-i-cf3 aa




¹H-NMR (500 MHz, CDCl₃)




Apr24-2024
rs-5f-o-i-cf3 aa




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)



RS-5F-o-I CF3 AA
19F



^{19}F -NMR (377 MHz, CDCl_3)




Apr22-2024
ns-5-cl cf3 aa


7.817
7.800
7.260
7.184
7.074
7.070
7.057
7.053

5.839
5.694

3.277



¹H-NMR (500 MHz, CDCl₃)



Apr22-2024
ns-5-cl cf3 aa


163.40

146.72
141.05
135.63
134.34
134.09
133.84
133.58
130.24
129.80
125.02
124.98
124.55
122.34
120.16
117.97


95.95

77.25
77.00
76.75


36.83




¹³C{¹H}-NMR (126 MHz, CDCl₃)




NS 5 CL
19F




¹⁹F-NMR (377 MHz, CDCl₃)



07.02.24
beta ph sn




¹H-NMR (500 MHz, CDCl₃)




07.02.24
ns-beta phh s

165.41
165.39
145.77
140.40
140.10
140.07
140.04
140.01
132.29
129.95
129.94
129.75
129.38
128.75
128.73
128.25
126.00
122.66
98.42
77.25
77.00
76.74
36.74




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)




July 2023
NS-o-iodo Ph

-56.720




$^{19}\text{F}\{^1\text{H}\}$ -NMR (471 MHz, CDCl_3)




23.01.2024 2
ns-bnz-beta ph sm

7.968
7.952
7.265
7.252
7.239
7.183
7.143
7.073
7.060
6.988
6.668
5.837
5.809
4.222
4.194




¹H-NMR (500 MHz, CDCl₃)




01.02.24
NS-N-Bn BETA


165.03
165.01
142.87
140.24
139.46
139.43
135.80
132.16
131.84
129.94
129.34
129.32
129.16
128.69
128.68
128.39
128.22
127.78
126.22
95.106
95.106
77.25
77.00
76.74
51.60




¹³C{¹H}-NMR (126 MHz, CDCl₃)




NS-NBNZ BETA
19F




¹⁹F-NMR (377 MHz, CDCl₃)





28.02.24
NS-4 Me Beta SM




¹H-NMR (500 MHz, CDCl₃)







14.03.2024
ns-4-f-beta sm




¹H-NMR (500 MHz, CDCl₃)




¹³C{¹H}-NMR (126 MHz, CDCl₃)


NS 4F BETA PH SM




^{19}F -NMR (377 MHz, CDCl_3)




14.02.24
ns-4-cf3 sm beta




^1H -NMR (500 MHz, CDCl_3)






NS-4-CF3 BETA SM
19F



^{19}F -NMR (377 MHz, CDCl_3)




13.06.24
ns-gdf sm hxn wash


7.912
7.896
7.404
7.389
7.374
7.264
7.254
7.080
7.065
7.050

3.302
3.253
3.248

1.653
1.647



¹H-NMR (500 MHz, CDCl₃)



13.06.24
ns-gdf sm hxn wash


166.10
166.07
166.03
166.00
155.54
153.22
150.91
145.35
144.89
140.17
140.03
129.84
129.58
129.38
129.08
129.06
128.51

98.26
97.58


86.06
86.03
85.89
85.85
77.00
76.74

38.53
36.87


11.24
10.69




¹³C{¹H}-NMR (126 MHz, CDCl₃)




NS-STD GDF HXN WASH
19F




¹⁹F-NMR (377 MHz, CDCl₃)





29.05.24
NS-NET GDF




¹H-NMR (500 MHz, CDCl₃)







13.06.24
ns-bnz-gdf




$^1\text{H-NMR}$ (500 MHz, CDCl_3)




13.06.24
ns-bnz-gdf




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)




NS-BNZ-SM-2 1
19F




¹⁹F-NMR (377 MHz, CDCl₃)



RS-4ME GDF P2




¹H-NMR (400 MHz, CDCl₃)




Sep12-2024
ns-4-me gdf sm


166.27
166.24
166.19
166.17
155.44
153.13
150.82
142.72
140.45
140.23
130.13
128.48
128.46




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)




RS-4ME GDF P2
19F




^{19}F -NMR (377 MHz, CDCl_3)




RS-4F GDF 1




$^1\text{H-NMR}$ (400 MHz, CDCl_3)




RS-4F GDF



$^{13}\text{C}\{^1\text{H}\}$ -NMR (101 MHz, CDCl_3)




RS-4-F GDF P2
19F




-78.866
-78.873
-78.951
-78.958
-81.499
-81.595
-89.313
-89.319
-89.404
-89.411
-89.934
-90.030

-110.915
-110.935
-110.950
-110.970
-111.900
-111.919
-111.935
-111.953

¹⁹F-NMR (377 MHz, CDCl₃)



RS-4-CL GDF P1




7.867
7.861
7.361
7.355
7.340
7.334
7.260
7.178
7.171
7.157
7.150

3.257
3.197

1.907
1.661
1.653
1.645

¹H-NMR (400 MHz, CDCl₃)




May27-2024
RS-4CL GDF P1

165.88
165.85
165.80
165.78
155.41
153.10
153.08
150.77
144.04
139.39
134.60
129.53
129.47
129.45


98.52
85.98
85.84
85.80
85.66
77.25
77.00
76.75

36.78

11.25




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)




RS-4-CL GDF P1
19F


78.51
78.52
78.52
78.53
78.54
78.59
78.60
78.61
78.61
78.62
81.23
81.33
88.74
88.75
88.75
88.76
88.83
88.84
88.85
88.85
89.64
89.64
89.74
89.74




^{19}F -NMR (377 MHz, CDCl_3)




May21-2024
RS 4 br GDF




$^1\text{H-NMR}$ (500 MHz, CDCl_3)




May27-2024
rs-4br gdf




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)




RS-4BR GDF P3
19F




¹⁹F-NMR (377 MHz, CDCl₃)



16.07.24 2
NS-4-CN GDF SM




¹H-NMR (500 MHz, CDCl₃)




16.07.24 2
NS-4-CN GDF SM

165.61
165.53
155.73
153.42
153.40
151.08
149.69
143.53
132.94
129.60
116.17
113.75
98.57
86.02
85.88
85.84
85.71




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)




NS-4-CN GDF
19F


-77.29
-77.37
-80.39
-80.48
-87.18
-87.25
-88.65
-88.74




^{19}F -NMR (377 MHz, CDCl_3)




May30-2024
ns-4-cf3 gdf




$^1\text{H-NMR}$ (500 MHz, CDCl_3)




29.05.24
ns-4-cf3 gdf




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)




NS 4 CF3




^{19}F -NMR (377 MHz, CDCl_3)



Jun10-2024
RS-5ME GDF FINAL



^1H -NMR (500 MHz, CDCl_3)



Jun10-2024
RS-5ME GDF FINAL


166.04
166.02
165.97
165.95
155.45
153.14
150.83
145.07
139.80
139.67
130.85
129.75
129.73

93.88
86.22
86.08
85.90
85.75
77.00
76.75


36.80

20.74

11.24




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)




RS-5ME GDF P3
19F

-79.44
-79.44
-79.45
-79.46
-79.47
-79.53
-79.53
-79.53
-79.54
-79.55
-81.79
-81.89


-89.65
-89.66
-89.66
-89.67
-89.73
-89.74
-89.75
-89.76
-90.33
-90.34
-90.43
-90.44





^{19}F -NMR (377 MHz, CDCl_3)




May01-2024
rs-5f gdf p2




^1H -NMR (500 MHz, CDCl_3)




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)




RS-5F-GDF P2
19F




¹⁹F-NMR (377 MHz, CDCl₃)



RS-5-CL GDF P2



¹H-NMR (400 MHz, CDCl₃)



RS-5-CL GDF P2

165.78
165.75
165.69
165.66
156.09
153.19
150.28
146.38
140.74
135.00
130.06
129.28
129.25

95.58

85.98

85.81


85.59

77.32


77.00

36.77

11.28




$^{13}\text{C}\{^1\text{H}\}$ -NMR (101 MHz, CDCl_3)




RS-5-CL GDF P2
19F

-78.289
-78.296
-78.370
-78.376
-80.983
-81.077
-88.357
-88.363
-88.438
-88.445
-89.427
-89.522



^{19}F -NMR (377 MHz, CDCl_3)




18.07.24
ns mf sm


7.905
7.891
7.381
7.369
7.259
7.170
7.157
7.048
7.035
6.834
6.669

3.227

1.644



¹H-NMR (500 MHz, CDCl₃)



18.07.24
ns mf sm

168.79
168.67

153.73
151.61
146.48
140.42


129.73
129.49
129.14

116.72
116.64


98.96

37.43

10.74
10.70



¹³C{¹H}-NMR (126 MHz, CDCl₃)




NS STD MF SM


NS STD MF SM

-123.48
-123.70

-123.48
-123.70



¹⁹F-NMR (377 MHz, CDCl₃)




Aug07-2024
ns-4f mf sm


7.591
7.577
7.123
7.113
7.101
7.085
6.818
6.653

3.182

1.620



¹H-NMR (500 MHz, CDCl₃)



Aug07-2024
ns-4f mf sm


168.66
168.54
161.79
159.77
153.51
151.38
142.73
129.69
129.62
127.15
126.95
116.76
116.58
116.53
116.45

98.81
98.74


77.25
77.00
76.75

37.43


10.67
10.62




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)



NS-4F-MF SM
19F



^{19}F -NMR (377 MHz, CDCl_3)




01.08.24
NS-4-BR MF SM


8.042
7.520
7.503
7.260
7.036
7.019
6.845
6.680

3.202

1.657




¹H-NMR (500 MHz, CDCl₃)




Aug07-2024
ns-4-br mf sm


168.63
168.51
153.75
151.60
145.68
142.42
132.90
129.97
122.13
116.59
116.52
99.68
77.25
77.00
76.75
37.40
10.76
10.71




¹³C{¹H}-NMR (126 MHz, CDCl₃)



4-br



¹⁹F-NMR (377 MHz, CDCl₃)




01.08.24
NS-5ME SOLIDE MF SM

7.731
7.715
7.261
6.967
6.851
6.834
6.660


3.195

2.300

1.642



¹H-NMR (500 MHz, CDCl₃)



01.08.24
NS-5-ME MF SM

168.65
168.53

153.61
151.47
146.19
140.12
139.87

130.45
129.71

116.62
116.55


94.59

77.25
77.00
76.74


37.32

20.76


10.70
10.66




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)



NS 5Me MF SM
19F



^{19}F -NMR (377 MHz, CDCl_3)




01.08.24
NS-5-CL MF SM


7.820
7.803
7.260
7.170
7.058
7.041
6.859
6.694

3.216

1.688



¹H-NMR (500 MHz, CDCl₃)



01.08.24
NS-5-CL MF SM

168.56
168.44
153.77
151.65
147.59
141.04
135.45
129.77
129.28


116.53
116.46

96.27


77.25
77.00
76.74

37.46


10.76
10.72




¹³C{¹H}-NMR (126 MHz, CDCl₃)




NS-5-Cl-MF




^{19}F -NMR (377 MHz, CDCl_3)



June 2023
NS-115



^1H -NMR (500 MHz, CDCl_3)



19.03.24
NS-505


172.31
172.30
172.28
172.26

143.66
129.87
128.27
126.22
126.03
124.53
123.79
123.16
121.55
108.58


77.25
77.00
76.75

52.43
52.21
51.99
51.78


26.58
17.77
17.75
17.74
17.72




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)




June 2023
NS-115




$^{19}\text{F}\{^1\text{H}\}$ -NMR (471 MHz, CDCl_3)




July 2023
NS-178




¹H-NMR (500 MHz, CDCl₃)




NS-147




¹³C{¹H}-NMR (126 MHz, CDCl₃)




July 2023
NS-178




$^{19}\text{F}\{^1\text{H}\}$ -NMR (471 MHz, CDCl_3)





June 2023
NS-133




^1H -NMR (500 MHz, CDCl_3)



NS-4-OME FP CF3




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)




June 2023
NS-133


— 73.63




$^{19}\text{F}\{^1\text{H}\}$ -NMR (471 MHz, CDCl_3)




July 2023
NS-135 chiral




$^1\text{H-NMR}$ (500 MHz, CDCl_3)




July 2023
NS-116




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)




July 2023
NS-135 chiral




$^{19}\text{F}\{^1\text{H}\}$ -NMR (471 MHz, CDCl_3)




July 2023
NS-195



^1H -NMR (500 MHz, CDCl_3)



May 2023
NS-74 re



171.86
171.85
160.26
158.34

139.63
127.99
127.57
127.50
125.75
123.51
121.27
116.33
116.14
112.96
112.76
109.22
109.15


77.25
77.00
76.75

52.80
52.79
52.58
52.57
52.36
52.34
52.12


26.69

17.69
17.67

$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)




July 2023
NS-195




-73.64

-119.32



$^{19}\text{F}\{^1\text{H}\}$ -NMR (471 MHz, CDCl_3)




July 2023
NS-223(1)




$^1\text{H-NMR}$ (500 MHz, CDCl_3)




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)




July 2023
NS-223(1)




$^{19}\text{F}\{^1\text{H}\}$ -NMR (471 MHz, CDCl_3)





24.08.24
NS-728



^1H -NMR (500 MHz, CDCl_3)






July 2023
NS-157


7.689
7.673
7.604
7.261
6.985
6.969

3.286

1.680



$^1\text{H-NMR}$ (500 MHz, CDCl_3)




NS-117

172.12
172.11
172.09
172.07
146.65
127.88
127.78
127.75
127.72
127.69
127.24
126.72
126.00
125.74
125.63
125.48
125.21
125.08
123.39
122.92
121.72
121.69
121.66
121.63
121.28
120.77
108.51


77.25
77.00
76.74

52.43
52.20
51.98
51.76


26.79
17.65
17.63
17.62
17.60




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)




July 2023
NS-157




$^{19}\text{F}\{^1\text{H}\}$ -NMR (471 MHz, CDCl_3)





July 2023
NS-204-1




^1H -NMR (500 MHz, CDCl_3)






July 2023
NS-158-1 (4-CN)

7.731
7.728
7.715
7.712
7.628
7.259
6.986
6.970



$^1\text{H-NMR}$ (500 MHz, CDCl_3)



NS-203

171.77
171.75
171.74
171.72


147.43

135.07
127.96
127.63
127.10
125.39
123.15
120.91
118.39
109.17
106.58


77.25
77.00
76.74

52.22
51.99
51.77
51.54


26.81
17.54
17.52
17.51
17.49




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)




July 2023
NS-158-1 (4-CN)




$^{19}\text{F}\{^1\text{H}\}$ -NMR (471 MHz, CDCl_3)





30.01.24 (2)
NS-4-ester FP C1




^1H -NMR (500 MHz, CDCl_3)







01.02.24
NS-136




^1H -NMR (500 MHz, CDCl_3)




NS-5-ME CF3 FP




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)




June 2023
NS-5Me-1




¹⁹F{¹H}-NMR (471 MHz, CDCl₃)



August
NS-230



¹H-NMR (500 MHz, CDCl₃)



August
NS-230

— 172.88

— 161.43

— 144.98

128.38

126.11

125.26

123.87

121.64

118.07

— 106.89

— 96.62

77.25

77.00

76.74

55.57

52.06

51.83


51.61

51.38


— 26.58

17.85


17.84




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)




August
NS-230





$^{19}\text{F}\{^1\text{H}\}$ -NMR (471 MHz, CDCl_3)



June 2023
NS-5-Cl chiral




^1H -NMR (500 MHz, CDCl_3)




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)


June 2023
NS-5-Cl chiral




$^{19}\text{F}\{^1\text{H}\}$ -NMR (471 MHz, CDCl_3)




July 2023
NS-180




^1H -NMR (500 MHz, CDCl_3)





Jan24-2024
NS-181




July 2023
NS-160


8.326
8.316
7.304
7.291
7.279
7.260
7.153
7.137

3.263


1.709




¹H-NMR (500 MHz, CDCl₃)




ns 160






¹³C{¹H}-NMR (126 MHz, CDCl₃)




July 2023
NS-160




$^{19}\text{F}\{^1\text{H}\}$ -NMR (471 MHz, CDCl_3)






^1H -NMR (500 MHz, CDCl_3)






NS-FLV FP
19F







NS-IBF FP
19F




¹⁹F-NMR (377 MHz, CDCl₃)




05.03.24
ns-482




¹H-NMR (500 MHz, CDCl₃)







NSS-482
19F




September 2023
NS-Ph Final S1




¹H-NMR (500 MHz, CDCl₃)




September 2023
NS-Ph Final S1




¹⁹F{¹H}-NMR (471 MHz, CDCl₃)




NS-487
single_pulse




¹H-NMR (400 MHz, CDCl₃)



NS-487
19F




¹⁹F-NMR (377 MHz, CDCl₃)




20.03.24
ns-438

7.281
7.260
7.079
7.065
7.051
7.036
7.021
7.007
6.834
6.820
6.481
6.465

3.602
3.576
3.304
3.278
2.909
2.387



¹H-NMR (500 MHz, CDCl₃)




20.03.24
ns-472

170.77
170.76
170.74
170.72


141.79
132.95
132.34
130.13
129.99
127.67
127.04
125.92
125.86
123.56
108.00

58.48
58.27
58.06
57.85


37.28
37.26
26.12
21.17




¹³C{¹H}-NMR (126 MHz, CDCl₃)




NS-438P
19F




¹⁹F-NMR (377 MHz, CDCl₃)




23-01-2024
ns-439




¹H-NMR (500 MHz, CDCl₃)




ns 439
19F




¹⁹F-NMR (377 MHz, CDCl₃)




NS-427
single_pulse






¹H-NMR (400 MHz, CDCl₃)






dec 2023
NS-392






NS-STD GDF FP
19F



30.05.24 2
ns-n-et fp



31.05.24
ns-629

174.57
174.56
174.50
174.48

142.89


129.15
127.29
124.98
122.76
118.75
116.81
116.78
114.84
108.51

77.25
77.00
76.75


51.96
51.79
51.62

34.84

17.75
17.73
17.71
17.69
12.51




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)




NS 700-2

-121.92
-122.06
-122.66
-122.81
-129.47
-129.62
-130.22
-130.37



^{19}F -NMR (377 MHz, CDCl_3)




21.06.24
ns-bnz gdf fp


7.403
7.388
7.329
7.314
7.299
7.272
7.260
7.245
7.227
7.211
7.094
7.079
7.063
6.743
6.728
6.159
6.047
5.935

5.052
5.020
4.845
4.813

1.590



¹H-NMR (500 MHz, CDCl₃)



08.07.24 2
ns-bnz fp gdf

175.15
175.14
175.07
175.06


142.87
135.24
129.13
128.83
127.68
127.00
126.99
126.95
124.84
124.84
123.02
118.81
116.87
116.84
114.90
109.47

77.25
77.00
76.74


52.10
51.93
51.76

43.73




18.03
18.01
17.99
17.97




¹³C{¹H}-NMR (126 MHz, CDCl₃)




NS 692

Jul24-2024
ns-4me gdf fp**¹H-NMR (500 MHz, CDCl₃)**


Jul24-2024
ns-4me gdf fp




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)




NS-4-ME GDF FP




^{19}F -NMR (377 MHz, CDCl_3)




Jul12-2024
ns-4-f pentane fp




¹H-NMR (500 MHz, CDCl₃)




12.07.24
ns-4-f pentane fp




¹³C{¹H}-NMR (126 MHz, CDCl₃)




NS-4-F GDF FP




^{19}F -NMR (377 MHz, CDCl_3)




694




^1H -NMR (500 MHz, CDCl_3)




Jul24-2024
ns-650




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)



NS-650



^{19}F -NMR (377 MHz, CDCl_3)




NS-722
single_pulse

7.501
7.498
7.493
7.483
7.478
7.260
6.772
6.749


6.086
5.947
5.807

3.209

1.516



¹H-NMR (400 MHz, CDCl₃)



NS-722
single pulse decoupled gated NOE


177.35
177.26

142.89
132.13
128.93
128.10
128.08
118.88
116.44
116.41
115.71
113.98
109.80


77.32
77.00
76.68

52.29
52.08
51.87


26.50
17.83
17.81
17.78
17.75




¹³C{¹H}-NMR (101 MHz, CDCl₃)




NS-722
19F




¹⁹F-NMR (377 MHz, CDCl₃)




4-cn




¹H-NMR (500 MHz, CDCl₃)




Jul12-2024
ns-652




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)



NS-4-CN HXN
19F



^{19}F -NMR (377 MHz, CDCl_3)




08.07.24 2
ns-4-cf3 gdf fp

7.660
7.643
7.610
7.260
6.968
6.951


6.089
5.978
5.866

3.261

1.553



¹H-NMR (500 MHz, CDCl₃)



08.07.24 2
ns-4-cf3 gdf fp

174.84
174.83
174.77
174.76


146.79
146.78
146.77

127.56
127.55
127.15
127.12
127.09
127.06
125.55
125.29
123.08
121.94
121.93
121.91
121.90


118.32
116.36
116.34
114.39
109.23
77.00
76.75

52.08
51.92
51.75


26.60
17.78
17.76
17.74
17.72




¹³C{¹H}-NMR (126 MHz, CDCl₃)




NS-627




^{19}F -NMR (377 MHz, CDCl_3)



5-ME AK FP



^1H -NMR (400 MHz, CDCl_3)




12.07.24 2
5 ME AK
175.25
175.24
175.18
175.16

143.86
139.54
124.50
124.49
124.06
124.05
123.52
118.68
116.73
116.71
114.76
109.34


77.25
77.00
76.75

51.86
51.69
51.52

26.34
21.83
17.81
17.79
17.77
17.75




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)




5-Me

-121.70
-121.85
-122.44
-122.59
-129.33
-129.48
-130.08
-130.23




^{19}F -NMR (377 MHz, CDCl_3)




08.07.24 2
NS-5F GDF FP

7.325
7.311
7.298
7.260
6.807
6.790
6.630
6.613
5.931
5.819



$^1\text{H-NMR}$ (500 MHz, CDCl_3)



08.07.24 2
NS-5F GDF FP


175.23
175.22
175.15
175.14
164.73
162.78

145.42
145.33


125.98
125.97
125.91
125.90
122.25
122.24
118.46
116.51
116.49
114.54
109.21
109.04
97.47
97.25

51.76
51.59
51.42


26.51
17.84
17.82
17.80
17.78




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)




NS-5-F GDF FP
19F




¹⁹F-NMR (377 MHz, CDCl₃)




12.07.24
ns-5-cl pentane FP




¹H-NMR (500 MHz, CDCl₃)




12.07.24
ns-5-cl pentane FP




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)







5-Cl





^{19}F -NMR (377 MHz, CDCl_3)




std


 ^1H -NMR (400 MHz, CDCl_3)Jul24-2024
ns-431 $^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)




22-01-2024
ns-448




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)



NS-448
19F



^{19}F -NMR (377 MHz, CDCl_3)




Sep19-2024
NS 756

7.453
7.437
7.412
7.260
6.758
6.742


4.595
4.501

3.210

1.388



$^1\text{H-NMR}$ (400 MHz, CDCl_3)



Sep19-2024
NS 756

176.77
176.72

142.50

133.04

131.40

126.62

115.47

109.70


86.66
85.25

49.60
49.45


26.45

18.41


18.36




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)




NS-756
19F




¹⁹F-NMR (377 MHz, CDCl₃)




5-me




¹H-NMR (400 MHz, CDCl₃)




05.03.24 2
NS 450 solid




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)




5-me




^{19}F -NMR (377 MHz, CDCl_3)




5-Cl




$^1\text{H-NMR}$ (400 MHz, CDCl_3)




23-01-2024
ns 451




$^{13}\text{C}\{^1\text{H}\}$ -NMR (126 MHz, CDCl_3)




5-Cl




¹⁹F-NMR (377 MHz, CDCl₃)




NSD
single_pulse



¹H-NMR (400 MHz, CDCl₃)





NS-719
19F

